Immunomodulating polynucleotides and their antibody conjugates and use methods thereof

Modified immunomodulatory polynucleotides with targeted delivery improve the therapeutic potential of CpG ODNs by reducing toxicity and enhancing specificity, effectively treating cancers through enhanced immune stimulation or suppression.

JP2024167198AActive Publication Date: 2024-12-03TALLAC THERAPEUTICS INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024124259
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-07-27
Filing Date
2024-07-31
Publication Date
2024-12-03
Estimated Expiration
2038-04-13

AI Technical Summary

Technical Problem

CpG ODNs, commonly used for immune stimulation, face challenges such as heterogeneous tissue distribution, off-target activity, and local toxicity due to their pharmacokinetic and pharmacodynamic properties, limiting their therapeutic potential in treatments like anti-cancer therapy.

Method used

Development of immunomodulatory polynucleotides with specific modifications, including 5-modified uridine and cytidine, internucleoside phosphotriesters, and conjugation with targeting moieties like antibodies, to enhance specificity and reduce off-target effects.

Benefits of technology

The modified polynucleotides demonstrate improved targeting and reduced toxicity, effectively stimulating or suppressing immune responses, thereby enhancing therapeutic efficacy in treating cancers like non-Hodgkin B cell lymphoma and solid tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167198000307
    Figure 2024167198000307
  • Figure 2024167198000308
    Figure 2024167198000308
  • Figure 2024167198000309
    Figure 2024167198000309
Patent Text Reader

Abstract

To provide immunomodulating polynucleotides and conjugates thereof comprising a targeting moiety and one or more immunomodulating polynucleotides.SOLUTION: The immunomodulating polynucleotide may comprise 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and / or one or more abased spacers and / or inter-nucleoside phosphotriesters. The conjugate comprises a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotide and conjugate may further comprise one or more auxiliary moieties. Also disclosed is a composition comprising an immunomodulating polynucleotide or conjugate comprising one or more stereochemically enriched internucleoside phophorothioates. Still further disclosed is a pharmaceutical composition comprising the immunomodulating polynucleotide or conjugate and use methods thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application is a continuation of U.S. Provisional Application No. 62 / 485,707, filed April 14 and July 27, 2017, respectively. 48 and 62 / 537,925; the disclosures of each of which are incorporated herein by reference. The entire contents of which are incorporated herein by reference.

[0002] FIELD OF THE INVENTION The present invention relates to compositions and methods for modulating immune system responses. Also provided herein are immunomodulatory polynucleotides containing 5-modified uridine or The immunomodulatory polypeptide contains a 5-modified cytidine and has a length ranging from about 6 to about 16 nucleotides. Further provided herein are targeting moieties and one or more immunoglobulins. Provided herein are conjugates comprising a regulatory polynucleotide. Conjugates containing a targeting moiety or a targeting moiety and one or more immunomodulatory polynucleotides. Provided herein are pharmaceutical compositions containing benzodiazepines for treating diseases such as cancer. This is how they are used. [Background technology]

[0003] (background) Pathogen-associated molecular patterns (PAMPs) are molecules associated with various pathogens and are expressed by toll-like receptors (TLRs). They are recognized by TLRs and other pattern recognition receptors (PRRs) that activate the innate immune response. The ability of PAMPs to mobilize the immune system in the absence of pathogens may contribute to the development of natural immunity to various diseases involving cell destruction. Strategies for treating (e.g., anti-cancer therapy) through the use of immune system responses are provided. One class of PAMPs being considered for application is CpG ODNs (e.g., agatolimod). CpG ODNs are immunostimulatory polynucleotides that stimulate immune cells (e.g., B cells, monocytes, and Mediates TLR9 dimerization in plasmacytoid dendritic cells (pDCs) to promote cytokine (e.g., type I) expression. upregulating natural killer hormones (interferons and interleukins) It is thought to activate cells.

[0004] CpG ODNs are generally classified into three classes: class A, class B, and class C. A CpG ODN usually has a phosphorothioate backbone and poly-G tails at the 3'- and 5'-ends. Class A CpG ODNs contain a central palindromic sequence containing a phosphate backbone. , usually contains a CpG in the central palindromic sequence. Class B CpG ODNs usually The 5' end sequence of class B CpG ODNs often contains a complete phosphorothioate backbone. Class C CpG ODNs are crucial for TLR9 activation. CpG ODNs often contain a complete phosphorothioate backbone with end sequences. Therefore, the pharmacokinetics of CpG ODNs is crucial for their development as therapeutic agents. Furthermore, CpG ODNs exhibit heterogeneous tissue distribution in vivo. The main sites of accumulation are in the liver, kidneys, and spleen. It can induce off-target activity and local toxicity associated with PAMPs. Therapeutic applications of G ODNs may be achieved by addressing the pharmacokinetic / pharmacodynamic challenges described herein. This can be promoted.

[0005] Thus, there is a need for novel immunomodulatory polynucleotides. Summary of the Invention

[0006] (Summary of the Invention) In general, the present invention relates to immunomodulatory (e.g., immunostimulatory) polynucleotides, as well as targeting moieties. and a conjugate comprising one or more immunomodulatory (e.g., immunostimulatory) polynucleotides. Regarding.

[0007] In one aspect, disclosed is an immunomodulatory polynucleotide. The nucleotide can be an immunostimulatory polynucleotide. The nucleotide may be an immunosuppressive polynucleotide.

[0008] In some embodiments, the immunomodulatory polynucleotide comprises one or more (e.g., one or two) In certain embodiments, the phosphotriester comprises one or more of: The immunomodulatory polynucleotide may contain one or more (e.g., 1 to 5) internucleoside phosphotriesters. In a further embodiment, the internucleoside phosphotriester At least one of the immunomodulators contains a conjugate group. The polynucleotide may have a terminal phosphate (e.g., a 5'-terminal phosphate or a 3'-terminal phosphate). In still further embodiments, the terminal phosphate ester is The ester contains a conjugate group. In other embodiments, the immunomodulatory polynucleotide comprises In yet another embodiment, the immunomodulatory polynucleotide comprises a 5'-cap or a 3'-cap. The leutide contains a 5'-cap, which is a 5'-5' cap. The 5'-5' cap may be an internucleoside phosphate, an internucleoside phosphorothioate, or or containing a conjugated group covalently linked to the internucleoside phosphorodithioate. In some embodiments, the immunomodulatory polynucleotide comprises an internucleoside phosphate, Covalently bonded to internucleoside phosphorothioate or internucleoside phosphorodithioate The 3'-cap contains a conjugated group.

[0009] In a further embodiment, the immunomodulatory polynucleotide is a monophosphate, diphosphate Sulfate, triphosphate, auxiliary moiety, terminal phosphodiester, terminal phosphotriester a tert-, 5'-5'-cap, or group -OR' (where R' is a bioreversible group, a non-bioreversible group, or In still further embodiments, the 5'-capping group is a 5'-protecting group, The 5'-capping group may be a phosphate, phosphorothioate, or phosphorodithioate. Optionally substituted C bonded to 1-6 Alkyl-containing monophosphate or terminal phosphodiester In still further embodiments, the immunomodulatory polynucleotide is a monovalent ester. phosphate, diphosphate, triphosphate, auxiliary moiety, terminal phosphodiester, terminal terminal phosphotriesters, and a group -OR', where R' is a bioreversible group, a non-bioreversible group, or is an O-protecting group). The 3'-capping group may be a phosphate, phosphorothioate, or phosphorodithioate. Optionally substituted C bonded to 1-6 Alkyl-containing monophosphate or terminal phosphodiester It's Steal.

[0010] In certain embodiments, the immunomodulatory polynucleotides comprise one or more (e.g., one or two) In a further embodiment, the abasic spacer In still further embodiments, at least one of the nucleoside groups is an abasic internucleoside spacer. At least one of the abasic spacers is a 3'-terminal abasic spacer. In some embodiments, at least one of the abasic spacers comprises a conjugate group.

[0011] In certain embodiments, the immunomodulatory polynucleotide comprises a 5-modified uridine (e.g., 5- Haloridine (e.g., 5-bromouridine or 5-iodouridine) or 5-modified cytidine In further embodiments, the 5-modified uridine (e.g., 5-halouridine ( For example, 5-bromouridine or 5-iodouridine) is one of the two 5'-terminal nucleosides. or in an immunostimulatory sequence (ISS) in the immunomodulatory polynucleotide. In still further embodiments, the 5-modified uridine (e.g., 5-halouridine) contains a 3'-position attached to the internucleoside phosphodiester phosphate. In a similar manner, the 5-modified uridine (e.g., 5-halouridine) is an internucleoside phosphodiester. In yet a further embodiment, the 5'-position is linked to a steric phosphorothioate. The modified uridine (e.g., 5-halouridine) is at the 5'-terminus. In certain embodiments, the 5-modified uridine is 5-bromouridine. The immunomodulatory polynucleotides contain cytidine and guanosine as the second and third nucleosides. as the 3rd and 4th nucleosides.

[0012] In certain embodiments, the immunomodulatory polynucleotide comprises a 5'-terminal immunostimulatory sequence. In certain embodiments, at least one of the internucleoside phosphotriesters The other is the 3'-carbon atom of a nucleoside with a 5'-carbon atom attached to a 5'-terminal immunostimulatory sequence. It is bonded to elementary atoms.

[0013] In further embodiments, the immunomodulatory polynucleotides comprise a total of 6 to 16 (e.g., 6, 7 , 8, 9, 10, 11, 12, 13, 14, 15, or 16) nucleotides. In such a manner, at least 10% ( For example, at least 20%, at least 30%, at least 40%, at least 50%, at least At least 60%, at least 70%, at least 80%, or at least 90% are phosphorothioates In still further embodiments, the nucleotides in the immunomodulatory polynucleotide At least 50% of the interosidic bridging groups contain phosphorothioate.

[0014] In some embodiments, the immunomodulatory polynucleotide is It comprises a conjugated group covalently attached to the nucleobase in the nucleotide.

[0015] In certain embodiments, the immunomodulatory polynucleotide comprises one or more auxiliary moieties. In certain embodiments, the immunomodulatory polynucleotide comprises at least one of the auxiliary moieties In some embodiments, the conjugate moiety comprises one of the auxiliary moieties. At least one of them is poly(ethylene glycol) (PE) having a molecular weight of 100 Da to 2,500 Da. In a further embodiment, each PEG independently contains a total of at least three In still further embodiments, each PEG contains ethylene glycol repeating units. , independently, contain a total of at least 20 ethylene glycol repeat units. In embodiments, each PEG independently contains a total of 50 or fewer ethylene glycol repeat units. In other embodiments, the immunomodulatory polynucleotide contains 1 to 8 PEGs. do.

[0016] In certain embodiments, the immunomodulatory polynucleotide is a polynucleotide described herein (e.g., in Table 2). ) is a polynucleotide disclosed.

[0017] In another aspect, disclosed is an immunoglobulin hybridized to a complementary polynucleotide. A hybridized immunomodulatory polynucleotide containing an immunomodulatory polynucleotide. .

[0018] In yet another aspect, disclosed are compositions containing immunomodulatory polynucleotides. wherein the immunomodulatory polynucleotide has at least one stereochemically enriched It contains internucleoside phosphorothioates.

[0019] In some embodiments, at least one stereochemically enriched nucleoside The intervening phosphorothioate is a 5'-terminal nucleotide in the immunostimulatory sequence of the immunomodulatory polynucleotide. In a further embodiment, one of the amino acids is located between the nucleotide and the cytidine of the CpG. The biochemically enriched internucleoside phosphorothioates are used to prepare the immunomodulatory polynucleotides. In yet a further embodiment, the first nucleoside is linked to the second nucleoside in the In this case, one stereochemically enriched internucleoside phosphorothioate is used in the immunomodulation It is attached to the 5'-carbon atom of the cytidine of the CpG in the immunostimulatory sequence in the polynucleotide. In yet further embodiments, one stereochemically enriched internucleoside phosphoro The thioate is located at the fourth nucleoside and the fifth nucleoside in the immunomodulatory polynucleotide. In some embodiments, the stereochemically enriched internucleoside phosphonates The holothioate is S-stereogenic. In certain embodiments, the stereochemistry The specifically enriched internucleoside phosphorothioates are R-stereogenic.

[0020] In yet another aspect, disclosed is a method for detecting a targeting moiety and one or more immunomodulatory polynucleotides. It is a conjugate containing an oxide.

[0021] In some embodiments, the targeting moiety is an antigen-binding moiety, a polypeptide, an aptamer, or a polypeptide. In some embodiments, the targeting moiety is an antibody. In a further embodiment, the antigen-binding moiety is an antibody or antigen-binding fragment thereof. The antibody or antibody fragment thereof may comprise an N-terminal or C-terminal Q-tag, wherein the immunomodulatory polynucleotide The oxidase is independently covalently attached to the N-terminal or C-terminal Q-tag. In some embodiments, the Q-tag is located in the heavy or light chain of the antibody or antibody fragment.

[0022] In certain embodiments, the immunomodulatory polynucleotide is a polynucleotide as disclosed in other embodiments. This is exactly what is happening.

[0023] In certain embodiments, at least one of the immunomodulatory polynucleotides comprises a 5-modified uridine dinucleotide. In a further embodiment, the immunomodulatory polynucleotide comprises a 5-amino acid residue or a 5-modified cytidine. At least one of the oxidases is a 5-halouridine, a 5-alkynyluridine, or a 5-heterocyclidine. In still further embodiments, the 5-modified uridine is methyluridine. The lysine is a 5-halouridine (e.g., 5-bromouridine or 5-iodouridine). In some embodiments, the 5-modified uridine is present in at least one of the immunomodulatory polynucleotides. In another embodiment, the 5'-modified nucleotide is one of the two 5'-terminal nucleotides. Modified uridines contain a 3'-position linked to the internucleoside phosphate. In yet other embodiments, the 5-modified uridine is an internucleoside phosphate phospho In yet another embodiment, the immunomodulatory polynucleotide comprises a 3'-position linked to a thiolate. At least one of the nucleotides has a cytidine and a guanosine as the second and third nucleosides. In certain embodiments, the immunomodulatory polynucleotide comprises at least One contains cytidine and guanosine as the third and fourth nucleosides.

[0024] In some embodiments, at least one of the immunomodulatory polynucleotides comprises a total of 6 Contains up to 16 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) nucleotides .

[0025] In further embodiments, at least one of the immunomodulatory polynucleotides comprises one or more It contains an abasic spacer or an internucleoside phosphotriester. In embodiments, at least one abasic spacer or at least one phosphotriester The chain contains a linker.

[0026] In certain embodiments, at least one of the immunomodulatory polynucleotides comprises one or more (e.g., In other embodiments, the abasic spacer At least one of the spacers is an abasic internucleoside spacer. In some embodiments, at least one of the abasic spacers is a 3'-terminal abasic spacer.

[0027] In certain embodiments, at least one of the immunomodulatory polynucleotides comprises one or more It contains 1 to 5 internucleoside phosphotriesters.

[0028] In some embodiments, the conjugate comprises one or more auxiliary groups attached to a linker. In a further embodiment, at least one of the auxiliary moieties further comprises 100 Poly(ethylene glycol) (PEG) having a molecular weight of 2,500 Da. In embodiments, each PEG independently has a total of at least 3 (e.g., at least 5, At least 6, at least 7, at least 8, at least 9, at least 10, at least at least 12, at least 14, at least 16, at least 18, or at least 20) In yet further embodiments, each PEG independently comprises: A total of 50 or fewer (e.g., 45 or fewer, 40 or fewer, 35 or fewer, or 30 or fewer) ethylene glycol repeats In some embodiments, the conjugate contains 1 to 8 PEG units. .

[0029] In certain embodiments, the 5'-amino acid residue in at least one of the immunomodulatory polynucleotides Capping groups include monophosphates, diphosphates, triphosphates, auxiliary moieties, terminal terminal phosphodiester, terminal phosphotriester, or group -OR' (where R' is a bioreversible In a further embodiment, the 5 The '-capping group may be a monophosphate or phosphate, phosphorothioate, or is an optionally substituted C linked to a phosphorodithioate 1-6 Alkyl-containing terminal phosphonate In yet further embodiments, at least one of the immunomodulatory polynucleotides is a diester. The 3'-capping group in at least one of a phosphate, an auxiliary moiety, a terminal phosphodiester, a terminal phosphotriester, or a group -OR'( where R' is a bioreversible group, a non-bioreversible group, or an O-protecting group. In embodiments, the 3'-capping group is a monophosphate or a phosphate, phospho optionally substituted C linked to phosphorothioate or phosphorodithioate 1-6 Alkyl It is a terminal phosphodiester containing

[0030] In certain embodiments, at least one of the immunomodulatory polynucleotides is linked to a linker. It contains linked nucleobases.

[0031] In further embodiments, the conjugate comprises one to six (e.g., one to four) immunomodulatory In yet a further embodiment, the conjugate comprises a polynucleotide. In still further embodiments, the construct contains only one immunomodulatory polynucleotide. In another embodiment, the immunomodulatory polynucleotide comprises only two immunomodulatory polynucleotides. , the conjugate contains one targeting moiety.

[0032] In some embodiments, the immunomodulatory polynucleotide comprises the 4 nucleotides at the 5'-terminus. In some embodiments, the immunomodulatory polynucleotide contains a human immunostimulatory sequence within the The human immunostimulatory sequence within four nucleotides of the 5'-end of the peptide is a nucleotide substituted with a lysine. It contains a cytidine containing a 5'-carbon atom bonded to a phosphate ester.

[0033] In certain embodiments, at least one of the immunomodulatory polynucleotides is a 5-modified ribonucleotide. Contains lysine or 5-modified cytidine.

[0034] In certain embodiments, at least one of the immunomodulatory polynucleotides is It is hybridized to.

[0035] In a further embodiment, at least one of the immunomodulatory polynucleotides comprises at least Both contain one stereochemically condensed internucleoside phosphorothioate.

[0036] In a further aspect, disclosed is a method for administering a targeting moiety and one or more immunomodulatory polynucleotides to a mammal. a composition comprising a conjugate comprising a nucleotide of the immunomodulatory polynucleotide; Each independently comprises a linker, wherein the targeting moiety is covalently attached to the linker. and at least one of the immunomodulatory polynucleotides is at least one sterically enriched. A composition containing condensed internucleoside phosphorothioates.

[0037] In some embodiments, at least one stereochemically enriched nucleoside The intervening phosphorothioate is a 5'-terminal nucleotide in the immunostimulatory sequence of the immunomodulatory polynucleotide. It is located between the nucleotide and the cytidine of the CpG. The two stereochemically enriched internucleoside phosphorothioates are The cytidine is attached to the 5'-carbon atom of the CpG in the immunostimulatory sequence of the peptide. In embodiments, at least one stereochemically enriched internucleoside phosphorothioate The nucleotide is a nucleotide that cleaves the first and second nucleosides in the immunomodulatory polynucleotide. In a further embodiment, at least one stereochemically enriched nucleotide is The interosidic phosphorothioate is the fourth nucleoside in the immunomodulatory polynucleotide. and the fifth nucleoside. The condensed internucleoside phosphorothioate is S-stereogenic. In one embodiment, the stereochemically enriched internucleoside phosphorothioate is , R-stereogenic.

[0038] In yet a further aspect, disclosed is a method for treating a skin ulcer comprising administering to a subject the method of the present invention a pharmaceutically acceptable carrier and a method for treating a skin ulcer comprising administering to a subject the method of the present invention. Immunomodulatory polynucleotides, stereochemically enriched compositions of the invention, or compositions of the invention A pharmaceutical composition containing the adjugate.

[0039] In yet a further aspect, disclosed is a cell comprising an endosomal toll-like receptor. the immunomodulatory polynucleotide of the present invention, the composition of the present invention, the conjugate of the present invention, or The pharmaceutical composition of the present invention and a method for delivering the immunomodulatory polynucleotide to the cells are provided. By contacting the cells under conditions that allow the endosomal toll-like receptor to bind to the endosomal toll-like receptor, a method of modulating an endosomal toll-like receptor, the method comprising: The activity of the receptor is modulated.

[0040] In some embodiments, the immunomodulatory polynucleotide is an immunostimulatory polynucleotide. The method is for stimulating endosomal toll-like receptors.

[0041] In certain embodiments, the immunomodulatory polynucleotide is an immunosuppressive polynucleotide. wherein the method is for inhibiting endosomal toll-like receptors.

[0042] In another embodiment, disclosed is an antigen-presenting antibody comprising an endosomal toll-like receptor. The cells are treated with an immunomodulatory polynucleotide of the invention, a composition of the invention, a conjugate of the invention, or a combination thereof. or a pharmaceutical composition of the present invention and one or more immunomodulatory polynucleotides delivered into said cells. contacting the antigen-presenting cells under conditions that allow the antigen-presenting cells to express one or more subunits; a method for inducing cytokines, the method comprising: after said contacting, inducing at least one cytokine in said cell; the level of the targeting moiety is increased, the targeting moiety targets the antigen-presenting cells, and the immunomodulatory polynucleotide The method wherein the nucleotide is an immunostimulatory polynucleotide.

[0043] In some embodiments, the antigen-presenting cells are B cells. At least one of the one or more cytokines is a pro-inflammatory cytokine. In one embodiment, the antigen-presenting cells are plasmacytoid dendritic cells, wherein the targeting The moiety targets the plasmacytoid dendritic cells. In one embodiment, the antigen-presenting cells In a further embodiment, at least one of the cytokines is a macrophage. Another is a type I interferon. In still further embodiments, the toll-like receptor is TLR9.

[0044] In yet another aspect, disclosed is a method for administering to a patient an immunomodulatory polynucleotide of the invention. administering an effective amount of the composition of the present invention, the conjugate of the present invention, or the pharmaceutical composition of the present invention wherein the targeting moiety is a B-cell targeting moiety. and the immunostimulatory polynucleotide is a TLR9 agonist. It is a reotide, a method.

[0045] In certain embodiments, the liquid tumor is a hematological tumor (e.g., the hematological tumor is a lymphoma). In certain embodiments, the lymphoma is a non-Hodgkin's B-cell lymphoma. In further embodiments, the lymphoma is mantle cell lymphoma, diffuse large intestinal lymphoma, or diffuse large intestinal lymphoma. Large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, or multiple myeloma be.

[0046] In yet another aspect, disclosed is a method for administering to a patient an immunomodulatory polynucleotide of the invention. By administering the composition of the present invention, the conjugate of the present invention, or the pharmaceutical composition of the present invention, a method of treating a solid tumor in a patient by targeting a plasmacytoid dendritic cell line comprising administering to said patient a therapeutically effective amount of a targeting moiety to said patient. and an immunostimulatory polynucleotide that targets TLR9 cells and is a TLR9 agonist. In some embodiments, the solid tumor in the patient is The method of treatment comprises administering to the patient an immunomodulatory polynucleotide as disclosed herein. wherein the immunomodulatory polynucleotide targets B cells in the patient. do.

[0047] The present invention provides a method for treating a tumor in a patient for the purposes described herein (e.g., treating a patient with a liquid or solid tumor). The use of immunomodulatory polynucleotides of the invention in the manufacture of a product (e.g., a pharmaceutical product) for treating a tumor The present invention provides a method for the treatment of a rheumatoid arthritis, ... It should be understood that the present invention provides a method for the production of a medicament for the purposes described herein (e.g., Immunomodulatory polynucleoside analogs of the invention (e.g., for treating liquid or solid tumors in a patient) are also useful. The present invention also provides a use of a medicament, a conjugate of the present invention, a composition of the present invention, or a pharmaceutical composition of the present invention. It should also be understood that the present invention is not limited to the above-described embodiments. Immunomodulatory Agents of the Invention for Use (e.g., for Treating Liquid or Solid Tumors in a Patient) Polynucleotide of the Invention, Conjugate of the Invention, Composition of the Invention, or Pharmaceutical Composition of the Invention It should be understood that the provision of

[0048] In any embodiment of the invention, the linker is as disclosed herein (e.g., For example, it can be according to any one of formulas (II), (V), and (VI) to (XV). In any embodiment of the invention, the conjugate group can be as disclosed herein. Cut.

[0049] Provided herein are oligonucleotides of formula (A): or stereoisomers thereof, two or more a mixture of diastereomers, tautomers, or mixtures of two or more tautomers of Pharmaceutically acceptable salts, solvates, or hydrates thereof; X 5' -(X N ) b -Y P -(X N ) c -X 3' (A) (In the formula: Each X N are independently nucleotides; X 3' is the 3' terminal nucleotide; X 5' is the 5' terminal nucleotide; Y P is an internucleoside phosphotriester; and b and c are each an integer ranging from about 0 to about 25; provided that their sum is 5 or greater; wherein the oligonucleotide comprises nucleotides having modified nucleobases).

[0050] Also provided herein are N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 An oligonucleotide with the sequence T A nucleotide, or a stereoisomer thereof, a mixture of two or more diastereomers, a tautomer, or or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, or or a hydrate; (where: x is an integer ranging from 1 to 4; N 1 is absent or 2'-deoxythymidine; N 2 is a 2'-deoxyribonucleotide having a modified nucleobase; N 3is 2'-deoxyadenosine or 2'-deoxyadenosine, each optionally containing a 3'-phosphotriester. is oxythymidine; N 4 is 2'-deoxyadenosine or 2'-deoxythymidine; and N 5 is 2'-deoxythymidine optionally containing a 3'-phosphotriester).

[0051] Further provided herein is a compound of formula (B): or a stereoisomer thereof, two or more diastereoisomers thereof A mixture of stereomers, tautomers, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, or hydrate of R X -L N -(Q) e (B) (In the formula: R x is a conjugated group; L N is a linker; each Q is independently a phosphotriester-containing oligonucleotide; and and e is an integer of 1, 2, 3, or 4.

[0052] Further provided herein is a compound of formula (C): or a stereoisomer thereof, two or more diastereoisomers thereof A mixture of stereomers, tautomers, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, or hydrate of [ka] (In the formula: Ab is antibody; Each L N are independently linkers; each Q is independently a phosphotriester-containing oligonucleotide; each e is independently an integer of 1, 2, 3, or 4; and and f is an integer of 1, 2, 3, or 4.

[0053] In one aspect, provided herein is a method for treating cancer in a subject having cancer. administering to said subject a therapeutically effective amount of a CpG-Ab immunoconjugate, In this method, the CpG-Ab immunoconjugate does not bind to a tumor-associated antigen (TAA). In some embodiments, the CpG-Ab immunoconjugate binds to at least one toll-like receptor. In some embodiments, the antibody specifically binds to a target antigen associated with a normal immune cell that expresses the receptor. In some embodiments, the normal immune cells express TLR9. The immune cell is an antigen-presenting cell (APC). In some embodiments, the APC is a B cell. In some embodiments, the target antigen is a dendritic cell, a macrophage, or a dendritic cell. MHC molecules, T cell costimulatory molecules, immune checkpoint molecules, B cell specific antigens, dendritic cell characteristics In some embodiments, the antigen is selected from the group consisting of a macrophage-specific antigen, a heterologous antigen, and a macrophage-specific antigen. In some embodiments, the MHC molecule is selected from MHC class I and MHC class II molecules. In embodiments, the T cell costimulatory molecule is OX40, CD2, CD27, CDS, ICAM-1, LFA-1 / CD11a / CD18, ICOS / CD278, 4-1BB / CD137, GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C , SLAMF7, NKp80, CD160, B7-H3, and CD83. In embodiments, the immune checkpoint molecule is PD-1, PD-L1, PD-L2, TIM-1, or TIM-3. , LAG-3, CEACAM-1, CEACAM-5, CLTA-4, VISTA, BTLA, TIGIT, LAIR1, CD47, CD160, 2B4 In some embodiments, the target is selected from the list consisting of CD172a, CD172b, and TGFR. Antigens include CD1, CD2, CD3, CD5, CD6, CD9, CD11, CD14, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD30, CD32, CD37, CD38, CD39, CD40, CD44, CD 45R (B220), CD49, CD52, CD55, CD56, CD64, CD66 (carcinoembryonic antigen, CEA), CD68, CD70, CD 74, CD79b, CD80, CD93, CD115, CD123, CD126, CD127, CD137, CD138, CD163, CD196, C D197, CD200R, CD205, CD206, CD207, CD208, CD209, CD267, CD269, CD274, CD300a, CD 301, CD303, CD304, CD319, CD336, CLEC5a, CLEC6, CLEC9a, CXCL16, CX3CR1, and DC-S In some embodiments, the CpG-Ab immunoconjugate is selected from the group consisting of TAMPs. In some embodiments, the immunostimulatory polynucleotide comprises an immunostimulatory polynucleotide selected from Table 2. The CpG-Ab immunoconjugates are selected from the group consisting of p236, p238, p243, p246, p275, p276, p308, p3 13, p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479 p480, p481, p482, p483, p484, p485, p486, p487, p488, and p489. In some embodiments, the CpG-Ab immunostimulatory polynucleotide comprises an immunostimulatory polynucleotide selected from the group consisting of: The conjugate is not conjugated to a T cell epitope. In some cases, the T cell epitope is an epitope of ovalbumin (OVA). In some embodiments, the cancer is a solid tumor. In some embodiments of the methods provided herein, the cancer is a recurrent or recurrent liquid tumor. In some embodiments of the methods provided herein, the administration or co-administration In some embodiments of the methods provided herein, administration is by systemic administration. wherein a therapeutically effective amount of the CpG-Ab immunoconjugate activates the complement pathway in a subject. In some embodiments of the methods provided herein, the amount is It is not effective in activating complement C3 in a subject.

[0054] In some embodiments, provided herein are methods for treating cancer in a subject with cancer. 1. A method for treating a subject comprising administering to said subject a therapeutically effective amount of a CpG-Ab immunoconjugate. wherein the CpG-Ab immunoconjugate specifically binds to a tumor-associated antigen (TAA). wherein the TAA is selected from the group consisting of CD19, CD20, CD22, exportin 7, Her2, Src, EGFR, CD52, CXC The antigen is not selected from the group consisting of R-4, Muc-1, and DNA. In embodiments, the binding of the CpG-Ab immunoconjugate to a TAA inhibits the expression of the TAA in cancer cells expressing the TAA. In some embodiments, the CpG-Ab immunoconjugate is internalized into the host. Binding of the CpG-Ab immunoconjugate to a TAA induces its transport to the endosomes of cancer cells expressing the TAA. In some embodiments, the CpG-Ab immunoconjugate is delivered to a recipient site. The binding of the immunoconjugate to a TAA inhibits TLR9 signaling in cancer cells expressing the TAA. In some embodiments, a TAA and TLR9 promote activation of the pathway. In some embodiments, both the TAA and TLR9 are located on the same cell membrane of the cell. It is located on the cell membrane of cancer cells that express the TAA. In some embodiments, the TAA and TLR9 Both are located on the endosomal membrane of cancer cells that express the TAA. In this manner, the binding of a CpG-Ab immunoconjugate to a TAA induces apoptosis in cancer cells expressing the TAA. In some embodiments, the TAA induces mitosis. In some embodiments, the TAA is not expressed by normal immune cells. In some embodiments, the normal immune cells are antigen-presenting cells (APCs). In some embodiments, the TAA is CD8, CD11b, CD11c, CD14, CD33, CD40, CD123, CD157 , CD168, CD169, CD172a, CD200, CD204, CD205, CD301, CD302, CD303, CD304, and CD2 In some embodiments, the CpG-Ab immunoconjugate is selected from the group consisting of: The compound is not conjugated to a TAA or any other TAA expressed by the cancer. In some embodiments, the CpG-Ab immunoconjugate comprises an immunostimulatory polypeptide selected from Table 2. In some embodiments, the CpG-Ab immunoconjugate comprises: p236, p238, p243, p246, p275, p276, p308, p313, p347, p361, p362, p425, p433, p4 34, p435, p436, p437, p438, p477, p478, p479, p480, p481, p482, p483, p484, p485 p486, p487, p488, and p489. In some embodiments, the CpG-Ab immunoconjugate is directed to a T cell epitope. In some embodiments, the T cell epitope is In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is a liquid tumor. In some embodiments, the cancer is a recurrent cancer. In some embodiments, the administration or co-administration is by systemic administration. In some embodiments of the method, the therapeutically effective amount of the CpG-Ab immunoconjugate is However, any of the methods provided herein is not effective in activating the complement pathway in a subject. In some embodiments, the amount is not effective to activate complement C3 in the subject. .

[0055] In some embodiments, provided herein are immunotherapy-resistant or refractory A method of treating immunotherapy-resistant or refractory cancer in a subject with cancer, comprising administering a CpG-Ab immunotherapy administering to the subject a therapeutically effective amount of an immunoconjugate. In an embodiment, the CpG-Ab immunoconjugate does not bind to a tumor-associated antigen. In some embodiments, the CpG-Ab immunoconjugate binds to at least one toll-like receptor. In some embodiments, the antibody specifically binds to a target antigen associated with a normal immune cell that expresses the antibody. In some embodiments, the CpG-Ab immunoconjugate specifically binds to a tumor-associated antigen. In an embodiment, the cancer is resistant to treatment with an immune checkpoint modulator. In some embodiments, the method comprises administering to the subject an immune checkpoint module. In some embodiments, the immunosuppressant further comprises co-administering a CpG-Ab immunoconjugate. The conjugate comprises an immunostimulatory polynucleotide selected from Table 2. In embodiments, the CpG-Ab immunoconjugate comprises any of p236, p238, p243, p246 as shown in Table 2. , p275, p276, p308, p313, p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479, p480, p481, p482, p483, p484, p485, p486, p487, p488, and In some embodiments, the immunostimulatory polynucleotide is selected from the group consisting of p489 and p489. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is a liquid tumor. In some embodiments of the methods provided herein, the cancer is a recurrent cancer. In some embodiments of the methods provided herein, the administration or co-administration is systemic. In some embodiments of the methods provided herein, the Cp A therapeutically effective amount of a G-Ab immunoconjugate is effective to activate the complement pathway in a subject. In some embodiments of the methods provided herein, the amount is It is not effective in activating the complement component C3.

[0056] In some embodiments, provided herein is a method for treating a subject in need thereof. 1. A method for preventing cancer in a subject, comprising administering to said subject a therapeutically effective amount of a CpG-Ab immunoconjugate. wherein the CpG-Ab immunoconjugate binds to at least one toll-like receptor. The method specifically binds to a target antigen associated with normal immune cells expressing the receptor. In some embodiments, such methods involve binding a tumor-associated antigen to the CpG-Ab immunoconjugate. In some embodiments, the CpG-Ab immunoconjugate further comprises co-administering the CpG-Ab immunoconjugate with a The gate is not conjugated to the tumor-associated antigen. In some embodiments, the normal immune cells express TLR9. In some embodiments, the CpG-Ab immunoconjugate is an antigen-presenting cell (APC). The antibody comprises an immunostimulatory polynucleotide selected from Table 2. In some embodiments, The CpG-Ab immunoconjugates are selected from the group consisting of p236, p238, p243, p246, p275, and p277 shown in Table 2. 6, p308, p313, p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477 , p478, p479, p480, p481, p482, p483, p484, p485, p486, p487, p488, and p489 In some embodiments, the immunostimulatory polynucleotide comprises an immunostimulatory polynucleotide selected from the group consisting of: The cancer is a solid tumor. In some embodiments, the cancer is a liquid tumor. In some embodiments of the methods provided herein, the cancer is a recurrent cancer. In some embodiments of the methods provided herein, the administering or co-administering is by systemic administration. In some embodiments of the methods provided herein, the CpG-Ab immunoconjugate A therapeutically effective amount of a conjugate is not effective to activate the complement pathway in a subject. In some embodiments of the methods provided herein, the amount comprises increasing complement C3 in the subject. It is not effective for activation.

[0057] In some embodiments, provided herein is a method for treating a subject in need thereof. A method for preventing cancer in a patient, comprising administering a therapeutically effective amount of a CpG-Ab immunoconjugate to a patient in need thereof. and co-administering the CpG-Ab immunoconjugate with at least one tol This method specifically binds to target antigens associated with normal immune cells that express I-like receptors. In some embodiments, the CpG-Ab immunoconjugate is used as an adjuvant for a cancer vaccine. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is a liquid tumor. In some embodiments, the cancer is a recurrent cancer. In an embodiment, the administration or co-administration is by systemic administration. In some embodiments of the method, the therapeutically effective amount of the CpG-Ab immunoconjugate is Some of the methods provided herein are not effective in activating the complement pathway in humans. In some embodiments, the amount is not effective to activate complement C3 in the subject.

[0058] In some embodiments, provided herein are methods for detecting an adaptive immune response in a subject. 1. A method for inducing a leukemia comprising administering to a subject a therapeutically effective amount of a CpG-Ab immunoconjugate. wherein the CpG-Ab immunoconjugate expresses at least one toll-like receptor. In some embodiments, the method specifically binds to a target antigen associated with a normal immune cell. In some embodiments, the subject has cancer. In some embodiments, the target antigen is a TA In some embodiments, the target antigen is not CD19, CD20, CD22, STAT3, ERK1, ERK2, ERK3, ERK4, ERK5, ERK6, ERK7, ERK8, ERK9, ERK10, ERK11, ERK22, ERK3, ERK4, ERK5, ERK6, ERK7, ERK8, ERK9, ERK12, ERK13, ERK14, ERK15, ERK1 exportin 7, Her2, Src, EGFR, CD52, CXCR-4, Muc-1, and DNA. In some embodiments, the subject has an infectious disease. In some embodiments, the normal immune cells express TLR9. In some embodiments, the normal immune cells are antigen-presenting cells (APCs). In some embodiments, the adaptive immune response is CD8+ T cell dependent. The CpG-Ab immunoconjugate comprises an immunostimulatory polynucleotide selected from Table 2. In some embodiments, the CpG-Ab immunoconjugate comprises a CpG-Ab immunoconjugate selected from the group consisting of p236, p238, p239 ... , p243, p246, p275, p276, p308, p313, p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479, p480, p481, p482, p483, p484, p485, p486, p4 87, p488, and p489. In some embodiments, the cancer is a solid tumor. In some embodiments of the methods provided herein, the cancer is: In some embodiments of the methods provided herein, the administration or coadministration Administration is by systemic administration. In some embodiments of the methods provided herein, wherein a therapeutically effective amount of the CpG-Ab immunoconjugate activates the complement pathway in a subject. In some embodiments of the methods provided herein, the amount is , is not effective in activating complement C3 in a subject.

[0059] In some embodiments, provided herein are methods for treating cancer in a subject with cancer. 1. A method of treating a subject with a CpG-Ab immunoconjugate selected from Table 6. In some embodiments, the method comprises administering a therapeutically effective amount of the CpG-Ab immunoglobulin to a subject. The immunoconjugate binds to a tumor-associated antigen (TAA). In some embodiments, the The pG-Ab immunoconjugate binds to a target antigen other than a TAA. The CpG-Ab immunoconjugates target targets associated with normal immune cells expressing TLR receptors. In some embodiments, the CpG-Ab immunoconjugate binds to an antigen. Shown are p236, p238, p243, p246, p275, p276, p308, p313, p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479, p480, p481, p482, p483, p4 84, p485, p486, p487, p488, and p489. In some embodiments, the therapeutic effect of at least one additional cancer therapeutic agent is In some embodiments, the method further comprises co-administering an effective amount of at least one The cancer therapeutic agent comprises a second TAA, a T cell costimulatory molecule, and an immune checkpoint modulator. In some embodiments, the second TAA is the same as the TAA. In some embodiments, the second TAA is different from the TAA. wherein the T cell costimulatory molecule is OX40, CD2, CD27, CDS, ICAM-1, LFA-1 / CD11a / CD18, I COS / CD278, 4-1BB / CD137, GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7 , NKp80, CD160, B7-H3, and CD83, or their ligands. In some embodiments, the T cell costimulatory molecule is an anti-OX40 antibody, an anti-ICOS / CD278 antibody, or an anti- In some embodiments, the antibody is an anti-4-1BB / CD137 antibody, or an antigen-binding fragment thereof. In the above, wherein the immune checkpoint modulator is PD-1, PD-L1, PD-L2, TIM-3, LAG-3, CEACAM-1, CEACAM-5, CLTA-4, VISTA, BTLA, TIGIT, LAIR1, CD47, CD160 an immunoglobulin A (IgA) antibody selected from the list consisting of 2B4, CD172a, and TGFR; In some embodiments, the immune checkpoint modulator is an inhibitor. The antibody is an anti-CD47 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, or an antigen-binding fragment thereof. In some embodiments, the cancer is a solid tumor. In some embodiments of the methods provided herein, the cancer is a liquid tumor. In some embodiments of the methods provided herein, the administration or The co-administration is by systemic administration. wherein a therapeutically effective amount of the CpG-Ab immunoconjugate activates the complement pathway in a subject. In some embodiments of the methods provided herein, the amount is not effective in activating complement C3 in a subject.

[0060] In some embodiments of any of the methods provided herein, wherein the CpG- The Ab immunoconjugate comprises an oligonucleotide of formula (A) as defined above. In some embodiments of any of the methods provided herein, wherein the CpG-Ab immunization The conjugate comprises a compound of formula (B) as defined above. In some embodiments of any of the methods, wherein the CpG-Ab immunoconjugate comprises: A compound of formula (C) as defined above. [Brief explanation of the drawings]

[0061] BRIEF DESCRIPTION OF THE DRAWINGS The application file contains at least one drawing executed in color. Copies of such patents or patent applications will be provided by the Patent Office upon request and payment of the necessary fee. can be.

[0062] [Figure 1] Figure 1A is a series of structures showing abbreviations with corresponding structures. These abbreviations are those used in Table 2.

[0063] Figure 1B is a series of structures showing abbreviations with corresponding structures. These abbreviations are listed in Table 2. These are the abbreviations used.

[0064] [Figure 2] FIG. 2 is an image of an ethidium bromide-stained denaturing gel of single-stranded CpG ODN (lanes A (p145) and D (p88)) and annealed double-stranded CpG ODN (lanes B (p88 / p144) and C (p88 / p145)).

[0065] [Figure 3] Figure 3A is an image of an ethidium bromide-stained reducing gel of Q-tagged anti-CD38 antibody before (lane A) and after mouse transglutaminase-mediated conjugation with polynucleotides (p76, p77, p78, p79, p80, p81, and p82), corresponding to lanes B, C, D, E, F, G, and H, respectively. HC+1 indicates the band of the Q-tagged anti-CD38 antibody heavy chain conjugated to the polynucleotide. HC indicates the band of the Q-tagged anti-CD38 antibody heavy chain. LC indicates the band of the anti-CD38 antibody light chain.

[0066] FIG. 3B shows polynucleotides p83 and p84 corresponding to lanes B, C, D, E, F, and G, respectively. , p85, p86, p87, and p88. 1 is an image of an ethidium bromide stained reducing gel of Q-tagged anti-CD38 antibody before (lane A) and after (lane B). HC+1 shows the band of the Q-tagged anti-CD38 antibody heavy chain conjugated to the polynucleotide. HC indicates the band of the Q-tagged anti-CD38 antibody heavy chain. LC indicates the band of the anti-CD38 antibody light chain. This shows:

[0067] [Figure 4]Figure 4A shows an ethidium bromide-stained denaturing gel image of Q-tagged anti-CD38 conjugated to an azido linker before (lane A) and after conjugation with a single-stranded polynucleotide (lane B, Dar1 conjugate with p88) or a double-stranded polynucleotide (lanes C, D, E, and F) via dipolar cycloaddition. Lane C corresponds to the resolved first AEX peak of the conjugate of a Q-tagged anti-CD38 antibody and a p88 / p145 CpG double-stranded linked by metal-free 1,3-dipolar cycloaddition. Lane D corresponds to the resolved second AEX peak of the conjugate of a Q-tagged anti-CD38 antibody and a p88 / p145 CpG double-stranded linked by metal-free 1,3-dipolar cycloaddition. Lane E corresponds to the resolved first AEX peak of the conjugate of a Q-tagged anti-CD38 antibody and a p88 / p144 double-stranded CpG linked by metal-free 1,3-dipolar cycloaddition. Lane F corresponds to the resolved second AEX peak of the conjugate of a Q-tagged anti-CD38 antibody and a p88 / p144 double-stranded CpG linked by metal-free 1,3-dipolar cycloaddition.

[0068] Figure 4B shows the rituximab-p19 conjugates showing absorbance signals at 280 nm and 260 nm. 1 is a graph showing the AEX-HPLC trace of the crude mixture containing the gate. There are three peaks corresponding to the conjugates.

[0069] Figure 4C shows the crude mixture, p19, and rituximab-p19 AEX peak 1, listed in Figure 4B. 1 is a graph showing the synthesis of AEX-HPLC traces of 2 and 3:

[0070] Figure 4D shows rituximab-PEG. 24 -N3 (lane A) and crude conjugation reaction mixture (lane B) ) and separated rituximab-p19 AEX peaks 1 (lane C), 2 (lane D), and 3 (lane E). Comparative image of a denaturing SDS PAGE 6% Tris-glycine gel.

[0071] [Figure 5] Figure 5 is a graph showing the efficacy of mouse immunostimulatory polynucleotides in inducing IL-6 in mouse spleen cells in a dose-dependent manner. The data shown indicate that for the mouse immunostimulatory polynucleotide sequence p18, at least 15 phosphorothioates are preferred for achieving immunostimulatory activity. In the absence of a conjugated targeting moiety, the phosphorothioate backbone is a key feature controlling the efficacy of immunostimulatory polynucleotides in inducing IL-6.

[0072] [Figure 6] 6 is a graph showing the efficacy of immunoconjugates of the invention and CpG 7909 in dose-dependent activation of NFκB in Ramos Blue cells as measured by alkaline phosphatase levels 5.5 hours after treatment. The x-axis provides the concentration of the conjugate (nM) on a logarithmic scale.

[0073] [Figure 7] 7 is a graph showing the efficacy of immunoconjugates and CpG 7909 in dose-dependent activation of NFκB in Ramos Blue cells as measured by alkaline phosphatase levels 24 hours after treatment and 2.5 hours after QB incubation. The x-axis provides the logarithm of the concentration (M) of the conjugate on a linear scale.

[0074] [Figure 8] 8 is a graph showing the efficacy of immunoconjugates in dose-dependent activation of NFκB in Ramos Blue cells as measured by alkaline phosphatase levels 48 hours after treatment and 2.5 hours after QB incubation. The x-axis provides the logarithm of the conjugate concentration (M) on a linear scale.

[0075] [Figure 9] FIG. 9 is a graph comparing the potency of p1 and p6 polynucleotides in dose-dependent activation of NFκB in Ramos Blue cells as measured by alkaline phosphatase levels.

[0076] [Figure 10] FIG. 10 is a graph depicting the efficacy of immunoconjugates in dose-dependent activation of NFκB in Ramos Blue cells as measured by alkaline phosphatase levels.

[0077] [Figure 11] FIG. 11 is a graph depicting the efficacy of immunoconjugates in dose-dependent activation of NFκB in Ramos Blue cells as measured by alkaline phosphatase levels.

[0078] [Figure 12] FIG. 12 is a graph depicting the efficacy of immunoconjugates in dose-dependent activation of NFκB in Ramos Blue cells as measured by alkaline phosphatase levels.

[0079] [Figure 13] FIG. 13 is a graph depicting the efficacy of immunoconjugates in dose-dependent activation of NFκB in Ramos Blue cells as measured by alkaline phosphatase levels.

[0080] [Figure 14] FIG. 14 is a graph depicting the efficacy of immunoconjugates in dose-dependent activation of NFκB in Ramos Blue cells as measured by alkaline phosphatase levels.

[0081] [Figure 15]15 is a graph showing the efficacy of immunoconjugates in dose-dependently inducing IL-6 in DB cells. The y-axis shows the multiplicative increase in IL-6 secretion normalized to PPIB levels.

[0082] [Figure 16] Figure 16 is a graph showing the efficacy of immunoconjugates in dose-dependent induction of NFκB in Ramos Blue cells, comparing conjugates with one polynucleotide (Dar1) or two polynucleotides (Dar2) that activate NFκB.

[0083] [Figure 17] Figure 17 is a graph showing the efficacy of immunoconjugates in dose-dependently inducing IL-6 in DB cells. The figure compares conjugates with one polynucleotide (Dar1) or two polynucleotides (Dar2) that induce IL-6. The y-axis shows the multiplicative increase in IL-6 secretion normalized to PPIB levels.

[0084] [Figure 18] FIG. 18 is a graph depicting the efficacy of immunoconjugates containing immunostimulatory polynucleotides of various lengths in activating NFκB in Ramos-Blue cells as measured by alkaline phosphatase readout.

[0085] [Figure 19] FIG. 19 is a graph depicting the efficacy of immunoconjugates containing immunostimulatory polynucleotides of various lengths in activating NFκB in Ramos-Blue cells as measured by alkaline phosphatase readout.

[0086] [Figure 20]20 is a graph showing a comparison of the immunostimulatory activity of conjugates containing polynucleotides with 5'-terminal 5-iodo-2-deoxyuridines linked to internucleoside phosphodiester phosphates with that of conjugates containing polynucleotides with 5'-terminal 5-iodo-2-deoxyuridines linked to internucleoside phosphodiester phosphorothioates, as assessed by measuring NFκB activation in Ramos-Blue cells, as measured by alkaline phosphatase readout.

[0087] [Figure 21] 21 is a graph showing a comparison of the immunostimulatory activity of conjugates containing polynucleotides with 5'-terminal 5-iodo-2-deoxyuridines linked to internucleoside phosphodiester phosphates with that of conjugates containing polynucleotides with 5'-terminal 5-iodo-2-deoxyuridines linked to internucleoside phosphodiester phosphorothioates, as assessed by measuring NFκB activation in Ramos-Blue cells, as measured by alkaline phosphatase readout.

[0088] [Figure 22] 22 is a graph showing a comparison of the immunostimulatory activity of conjugates containing one or more 5-iodo-2-deoxyuridines, as assessed by measuring NFκB activation in Ramos-Blue cells, as measured by alkaline phosphatase readout.

[0089] [Figure 23] 23 is a graph showing a comparison of the immunostimulatory activity of conjugates containing or lacking 5-iodo-2-deoxyuridine, as assessed by measuring NFκB activation in Ramos-Blue cells, as measured by alkaline phosphatase readout.

[0090] [Figure 24] 24 is a graph showing a comparison of the immunostimulatory activity of conjugates containing phosphate-based or phosphorothioate-based internucleoside phosphotriesters, as assessed by measuring NFκB activation in Ramos-Blue cells, as measured by alkaline phosphatase readout.

[0091] [Figure 25] 25 is a graph showing a comparison of the immunostimulatory activity of conjugates containing phosphate-based or phosphorothioate-based internucleoside phosphotriesters, as assessed by measuring NFκB activation in Ramos-Blue cells, as measured by alkaline phosphatase readout.

[0092] [Figure 26] Figure 26A is a graph showing a comparison of the immunostimulatory activity of conjugates containing one or more phosphorothioate-based internucleoside phosphotriesters, as assessed by measuring NFκB activation in Ramos-Blue cells, as measured by alkaline phosphatase readout.

[0093] Figure 26B shows a nucleotide sequence containing one or more phosphorothioate-based internucleoside phosphotriesters. 1 is a graph showing a comparison of the immunostimulatory activity of conjugates having of NFκB activation in Ramos-Blue cells as measured by alkaline phosphatase readout It was evaluated by measurement.

[0094] [Figure 27] 27 is a graph showing a comparison of the immunostimulatory activity of conjugates containing an antibody and one or more immunostimulatory polynucleotides, as assessed by measuring NFκB activation in Ramos-Blue cells, as measured by alkaline phosphatase readout.

[0095] [Figure 28] Figure 28 is a graph showing a comparison of cell-dependent cytotoxicity (CDC) of immunostimulatory polynucleotides conjugated via heavy chain Q-tags or light chain Q-tags in antibodies. CDC assays were performed on Daudi cells incubated with the conjugates in human serum, and cytotoxicity was measured by fluorescence.

[0096] [Figure 29] Figure 29 is a graph showing a comparison of the immunostimulatory activity of conjugates with auxiliary moieties. The immunostimulatory activity was assessed by measuring NFκB activation in Ramos-Blue cells, measured by alkaline phosphatase readout. The reference name in parentheses indicates the linker / auxiliary moiety structure used in the conjugate, and no AM indicates that the conjugate SB-189 does not contain an auxiliary moiety.

[0097] [Figure 30] Figure 30 is a graph showing a comparison of CDC activity of conjugates with auxiliary moieties. CDC assays were performed on Daudi cells incubated with the conjugates in human serum, and cytotoxicity was measured by fluorescence.

[0098] [Figure 31] FIG. 31 is a graph showing the induction of IL6 in A20 murine B-cell lymphoma cells using a conjugate containing a truncated mouse-cross-reactive human immunostimulatory polynucleotide (p275) linked to a murine anti-CD22 antibody via a Q-tag.

[0099] [Figure 32] Figure 32 is a graph showing the induction of IL6 in A20 murine B cell lymphoma cells using a conjugate containing a truncated mouse cross-reactive human immunostimulatory polynucleotide (p275) linked to a murine anti-CD22 antibody via a Q-tag.

[0100] [Figure 33] FIG. 33A is a graph showing induction of IL6 in A20 murine B cell lymphoma cells with conjugates containing immunostimulatory polynucleotides or with unconjugated immunostimulatory polynucleotides.

[0101] Figure 33B shows the results of the anti-mouse CD22 antibody and immunoglobulin in the presence of various concentrations of free anti-mouse CD22 antibody. in A20 murine B-cell lymphoma cells by conjugates containing immunostimulatory polynucleotides. 1 is a graph showing the induction of IL6 in the IL-11 cells.

[0102] [Figure 34] FIG. 34A is a graph showing the induction of interferon-α in human PBMCs by the class A CpG ODN CpG-2336.

[0103] Figure 34B shows the induction of interferon-α in human PBMCs using conjugate SB-340. The anti-BDCA2 antibodies SB-341 and p246 were used as controls in this experiment. The axis gives the optical density in arbitrary units at a wavelength of 450 nm.

[0104] Figure 34C shows the interaction of purified plasmacytoid cells with conjugated SB-342. 1 is a graph showing the induction of BDCA2 antibody, anti-BDCA4 antibody, and anti-SB-343 antibody in this experiment. was used as a control.

[0105] [Figure 35] FIG. 35 is a graph showing a comparison of the immunostimulatory activity of polynucleotides having various 5′-end modifications and internucleoside triesters.

[0106] [Figure 36]FIG. 36 is a graph showing a comparison of the immunostimulatory activity of polynucleotides having various 5′-end modifications and internucleoside triesters.

[0107] [Figure 37] Figure 37A is a graph showing the progression of tumor volume increase after inoculation of mice with A20 murine B-cell lymphoma cells and three subsequent intratumoral administrations of vehicle (saline) or an immunostimulatory polynucleotide of the invention (p326) and a control (p18). The time of administration is indicated by the arrow on the X-axis.

[0108] Figure 37B shows the results of inoculation of mice with A20 murine B-cell lymphoma cells followed by three doses of vehicle ( saline), immunostimulatory polynucleotide (p3), anti-CD22 antibody (CD22), or conjugate S 1 is a graph showing the progression of tumor volume increase after intravenous administration of B-338, SB-339, or SB-344. The time of administration is indicated by an arrow on the X-axis.

[0109] [Figure 38] FIG. 38A is a graph showing the progression of tumor volume increase following inoculation of mice with A20 murine B cell lymphoma cells followed by three intratumoral administrations of vehicle (saline) or immunostimulatory polynucleotides.

[0110] Figure 38B shows the results of inoculation of mice with A20 murine B-cell lymphoma cells followed by three doses of vehicle ( Tumor volume values ​​20 days after intratumoral administration of saline or immunostimulatory polynucleotides are shown. This is a graph.

[0111] [Figure 39]FIG. 39A is a graph showing the progression of tumor volume increase after inoculation of mice with A20 murine B-cell lymphoma cells and (i) one subsequent intravenous administration of a conjugate of the invention (SB-337), or (ii) three subsequent intratumoral administrations of vehicle (saline) or an immunostimulatory polynucleotide.

[0112] Figure 39B shows inoculation of mice with A20 murine B-cell lymphoma cells and (i) subsequent administration of one dose of the present invention. or (ii) three subsequent intravenous doses of vehicle (saline). or a graph showing tumor volume values ​​20 days after intratumoral administration of an immunostimulatory polynucleotide. do.

[0113] [Figure 40] Figure 40 is a graph showing the percent survival of Balb / c mice inoculated with A20 mouse lymphoma cells and subsequently treated with saline, free antibody, antibody-immunostimulatory polynucleotide conjugate, or free immunostimulatory polynucleotide. The control group consisted of uninoculated, untreated Balb / c mice. Lines identified as CD22-10 and CD22-3 provide the percent survival of mice for the following treatment regimens: 10 mg / kg free anti-mouse CD22 antibody and 3 mg / kg free anti-mouse CD22 antibody, respectively. Lines identified as SB-337-10 and SB-337-3 provide the percent survival of mice for the following treatment regimens: 10 mg / kg SB-337 and 3 mg / kg SB-337, respectively.

[0114] [Figure 41] FIG. 41A is an image of a denaturing gel of polynucleotide samples incubated in mouse serum at 37° C. for up to 24 hours.

[0115] Figure 41B shows the activity of polynucleotides incubated in mouse serum at 37°C for up to 24 hours. 1 is an image of a denaturing gel of a sample.

[0116] Figure 41C shows the activity of polynucleotides incubated in rat serum at 37°C for up to 24 hours. 1 is an image of a denaturing gel of a sample.

[0117] Figure 41D shows the results of polynucleotide assays incubated in monkey serum at 37°C for up to 24 hours. 1 is an image of a denaturing gel of the material.

[0118] Figure 41E shows the results of a test of polynucleotides incubated in human serum at 37°C for up to 24 hours. 1 is an image of a denaturing gel of the material.

[0119] [Figure 42] FIG. 42 is a graph showing the effect of phosphate-based and phosphorothioate-based internucleoside phosphodiesters at the 5′-terminus of immunostimulatory polynucleotides on the stability of the polynucleotide in 80% mouse serum.

[0120] [Figure 43] FIG. 43 is a graph showing the percentage of degraded and intact p246 in a degradation experiment in 80% mouse serum.

[0121] [Figure 44] FIG. 44 is a graph showing the effect of 5′-terminal nucleotide structure on polynucleotide stability in 80% mouse serum.

[0122] [Figure 45] Figure 45 is a graph showing the effect of 5'-terminal nucleotide structure on polynucleotide stability in 80% mouse serum, 80% non-human primate (NHP) serum, and 80% human serum. Mouse serum data were obtained in separate experiments, so these data are marked with an asterisk.

[0123] [Figure 46]Figure 46A shows the experimental scheme described in Example 6. In this experimental scheme, mice bearing disseminated B-cell lymphoma were given an intravenous administration of CpG-Ab (CpG ODN conjugated to a murine anti-CD22 mAb).

[0124] Figure 46B shows the effect of (i) 3 mg / kg CpG(p313)-mAb(CD22) conjugate (black dots) on days 1, 3, and 5. (ii) 10 mg / kg CpG-mAb(CD22) (filled triangle); (iii) naked CpG ODN (open triangle) (iv) 10 mg / kg CD22 mAb (filled squares); (v) 10 mg / kg GpC-mAb control conjugate (open squares) or (vi) patients with disseminated B-cell lymphoma treated with saline solution (filled circle). The survival rate of mice treated with IFN-γ is shown.

[0125] Figure 46C shows a mouse that survived the first tumor implantation and then underwent a second tumor implantation on day 47. Survival rates of mice are shown. Survivors after the second tumor implantation received no treatment. Survivors treated with 10 mg / kg CpG-mAb (CD22) on days 1, 3, and 5 (downward-pointing triangles); and survivors (diamonds) treated with 3 mg / kg CpG-mAb (CD22) on day 5; tumor cells were transferred on day 47. A second control group (upward-pointing triangles) was implanted and treated with saline solution.

[0126] Figure 46D shows the survival of survivors from the first and second tumor implants, followed by a third tumor implant at 90 days. The experiment shows that mice were subjected to tumor implantation. Survivors after the second or third tumor implantation were not treated. A third control group was implanted with tumor cells on day 90 and treated with saline solution. The tumor volumes of survivors (squares) and control groups (circles) were monitored from day 90 to day 120. Ta.

[0127] [Figure 47] Figure 47A shows the experimental scheme described in Example 7. In this experimental scheme, mice bearing solid B-cell lymphoma were given an intravenous administration of CpG-Ab (CpG ODN conjugated to a murine anti-CD22 mAb).

[0128] Figure 47B shows the results of treatment with (i) 3 mg / kg CpG-mAb(CD22) (open diamonds); (ii) 10 mg / kg CpG-mAb(CD22) (large filled triangle); (iii) naked CpG ODN (open triangle); (iv) 10 mg / kg (v) 10 mg / kg GpC-mAb control conjugate (small filled squares) (vi) mice bearing solid B-cell lymphoma treated with saline solution (filled circles); The figures show the tumor volume of each patient.

[0129] Figure 47C shows the effect of 10 mg / kg SB-337 DAR1 or 10 mg / kg SB-337 DAR1 compared to controls (saline and SB-339). 1 shows tumor volumes in mice bearing solid B-cell lymphoma treated with SB-337 DAR2.

[0130] Figure 47D shows the effect of 10 mg / kg SB-337 PEG compared to controls (saline and SB-339). 24 Bis DAR1mata 10 mg / kg SB-337 PEG 24 Tumors in solid B-cell lymphoma-bearing mice treated with Bis DAR2 It shows the volume.

[0131] Figure 47E shows the effect of 10 mg / kg PD-1, 10 mg / kg PD-1 + 3 mg / kg SB-33 compared to saline control. 7 DAR1; or 10 mg / kg PD-1 + 3 mg / kg SB-337 DAR2 Figure 1 shows the tumor volumes of mice treated with IFN-γ.

[0132] Figure 47F shows the effect of p347, SB-337 on mouse body weight compared to controls (saline and mCD22). The effects of SB-337 DAR1 and SB-337 DAR2 are shown.

[0133] [Figure 48] Figure 48A shows the experimental scheme described in Example 8. In this experimental scheme, mice bearing solid colon cancer were given intravenous administration of B cell-targeting CpG-Ab (CpG ODN conjugated to a murine anti-CD22 mAb) alone or in combination with an anti-PD-1 antibody.

[0134] Figure 48B shows (i) 3 mg / kg CpG-mAb(CD22) (upward pointing triangle); (ii) anti-PD-1 antibody (closed square); ( iii) 3 mg / kg CpG-mAb (CD22) in combination with anti-PD-1 antibody (downward-pointing triangle); and (iv) saline. Tumor volume in mice bearing a solid B-cell lymphoma model after receiving an aqueous solution (filled circles) This shows:

[0135] [Figure 49] Figure 49A shows (i) tumor volume in immunocompetent Balb / C mice bearing solid B-cell lymphoma after receiving 10 mg / kg of CpG-mAb(CD22) (triangles) or saline solution (circles).

[0136] Figure 49B shows the results of the treatment with (i) 10 mg / kg CpG-mAb(CD22) (squares), (ii) naked CpG ODN (triangles), or (iii) physiological In immunodeficient Nu / Nu mice bearing solid B-cell lymphoma after receiving saline solution (circles) Tumor volumes are shown.

[0137] Figure 49C shows the results of (i) 10 mg / kg CpG-mAb(CD22) (squares), (ii) naked CpG ODN (triangles), or (iii) physiological In immunodeficient SCID mice bearing solid B-cell lymphoma after receiving saline solution (circles) Tumor volumes are shown.

[0138] [Figure 50] Figure 50A shows the survival rate of mice bearing soluble B cell lymphoma after receiving (i) CpG-mAb(CD22) alone (open circles); (ii) CpG-mAb(CD22) and CD4+ T cell depleting treatment (open squares); (iii) CD4+ T cell depleting treatment (filled squares); or (iv) saline solution (filled circles).

[0139] Figure 50B shows (i) CpG-mAb(CD22) alone (open circle); (ii) CpG-mAb(CD22) and natural (natural re) killer (NK) cell-depleting treatment (open squares); (iii) NK cell-depleting treatment (filled squares); or (i v) Survival of mice bearing soluble B-cell lymphoma after receiving saline solution (filled circles). The survival rate is shown.

[0140] Figure 50C shows: (i) CpG-mAb(CD22) alone (open circles); (ii) CpG-mAb(CD22) and CD8+ T cell depletion. treatment (open squares); (iii) CD8+ T cell depletion treatment (filled squares); or (iv) saline solution ( 1 shows the survival rate of mice bearing soluble B cell lymphoma after receiving IgG1 (filled circles).

[0141] [Figure 51]Figure 51A shows tumor volume in mice bearing solid B-cell lymphoma after receiving CpG-mAb (CD22) (squares) or saline solution (circles). Mice were sacrificed on day 17 for digestion, and tumors were harvested.

[0142] Figure 51B shows solid B cell lymphomas treated with (i) CpG-Ab (squares) or (ii) saline solution (circles). Percentage of viable CD4+ or CD8+ gated cells in tumors harvested from tumor-bearing mice This page shows the

[0143] Figure 51C shows CD in mice treated with (i) CpG-Ab (squares) or (ii) saline solution (circles). Correlation between percentage of 8+ tumor cells and tumor volume is shown.

[0144] [Figure 52] Figure 52A shows tumor volume in mice bearing solid B-cell lymphoma after receiving (i) CpG-mAb(CD22) alone (open circles); (ii) anti-PD-1 antibody alone (filled squares); (iii) CpG-mAb(CD22) in combination with anti-PD-1 antibody (open squares); or (iv) saline solution (filled circles).

[0145] Figure 52B shows the results of (i) CpG-mAb (CD22) alone (open circles); (ii) anti-PD-L1 antibody alone (closed triangles); (i ii) CpG-mAb (CD22) in combination with anti-PD-L1 antibody (open triangle); or (iv) saline solution ( Figure 1 shows tumor volume in mice bearing solid B-cell lymphoma after receiving 100 mg / kg of IgG4 (filled circles). There are.

[0146] Figure 52C shows the results of (i) CpG-mAb (CD22) alone (open circles); (ii) anti-PD-1 antibody alone (filled squares); i) CpG-mAb(CD22) in combination with anti-PD-1 antibody (open square); (iv) in combination with anti-PD-1 antibody or (v) received saline solution (filled circle). 1 shows tumor volume in mice bearing solid B-cell lymphoma after administration of 100 mg / kg of erythrocyte mononuclear cell lymphoma.

[0147] [Figure 53] Figure 53A shows the mean tumor volume in mice bearing solid B-cell lymphoma after receiving (i) anti-PD-1 antibody alone (squares); (ii) CpG-mAb(CD22) in combination with anti-PD-1 antibody (diamonds); or (iii) saline solution (circles).

[0148] Figure 53B shows the results of the PD-1 antibody-induced leukemia in individual mice bearing solid B-cell lymphoma after receiving only the anti-PD-1 antibody. The tumor volume in each group is shown.

[0149] Figure 53C shows a patient with solid B-cell lymphoma after receiving CpG-mAb (CD22) / anti-PD-1 antibody combination treatment. Tumor volumes in individual mice are shown.

[0150] Figure 53D shows the survival of the first tumor implant (upward pointing triangles) and the survival of the second tumor implant (upward pointing triangles). Tumor volumes in the treatment control group (downward pointing triangles) are shown.

[0151] [Figure 54] Figure 54A shows tumor volume in mice bearing solid B-cell lymphoma after receiving (i) anti-OX40 antibody alone (triangles); (ii) CpG-mAb (CD22) in combination with anti-OX40 antibody (diamonds); or (iii) saline solution (circles).

[0152] Figure 54B shows the results of (i) anti-ICOS antibody alone (squares); (ii) CpG-mAb(CD22) in combination with anti-ICOS antibody ( (iii) in mice bearing solid B-cell lymphoma after receiving saline solution (circles) The tumor volumes in the 100% WT and 100% WT groups are shown.

[0153] Figure 54C shows the results of (i) anti-4-1BB antibody alone (diamonds); (ii) CpG-mAb (CD22) in combination with anti-4-1BB antibody ( (iii) in mice bearing solid B-cell lymphoma after receiving saline solution (circles) The tumor volumes in the 100% WT and 100% WT groups are shown.

[0154] [Figure 55] FIG. 55A shows tumor volumes in colon cancer-bearing mice after receiving (i) 10 mg / kg CpG-mAb(CD22) or (i) saline solution on days 10, 13, and 16, respectively.

[0155] Figure 55B shows the IgG1-associated IgG1 expression vector isolated from mice treated with (i) CpG-mAb (CD22) or (ii) saline solution. 10 6 IFN-γ secretion in individual spleen cells before or after stimulation with AH1 antigen. The number of cells is shown.

[0156] [Figure 56] Figure 56A shows the mean tumor volume in mice bearing solid B-cell lymphoma after receiving intravenous administration of (i) 10 mg / kg CpG-Ab(PD-L1) (diamonds); (i) 10 mg / kg CpG-Ab(CD205) (triangles); or (iii) saline solution on days 10, 12, and 14, respectively.

[0157] Figure 56B shows the B cells after receiving intravenous administration of 10 mg / kg CpG-Ab (CD205) on days 10, 12, and 14. Tumor volumes in individual mice bearing cell lymphoma are shown.

[0158] Figure 56C shows B after receiving intravenous administration of 10 mg / kg CpG-Ab (PD-L1) on days 10, 12, and 14. Tumor volumes in individual mice bearing cell lymphoma are shown.

[0159] Figure 56D shows a single dose of CpG-Ab (CD205) treated mice after the second tumor implantation given on day 38. Survivors from tumor implantation (squares) or from the first tumor administration treated with CpG-Ab (PD-L1) The tumor volumes of the surviving (triangles) and untreated controls (circles) are shown.

[0160] [Figure 57] Figure 57A shows the mean tumor volume in mice bearing solid B-cell lymphoma after receiving intravenous administration of (i) 10 mg / kg CpG-Ab (CD205) (triangles); (ii) 10 mg / kg anti-CD205 antibody (squares); (iii) 10 mg / kg mouse IgG (open circles); or (iv) saline solution (filled circles) on days 10, 12, and 14, respectively.

[0161] Figure 57B shows mice receiving 10 mg / kg of anti-CD205 antibody intravenously on days 10, 12, and 14, respectively. Tumor volumes in individual mice with subsequent solid B-cell lymphoma are shown.

[0162] Figure 57C shows mice receiving intravenous administration of 10 mg / kg of CpG-Ab (CD205) on days 10, 12, and 14, respectively. Figure 1 shows the tumor volume in individual mice bearing solid B-cell lymphoma after transfection.

[0163] Figure 57D shows the results of a rat IgG2a antibody administered intravenously at 10 mg / kg on days 10, 12, and 14. Figure 1 shows tumor volumes in individual mice bearing solid B-cell lymphoma after administration of 100 mg / kg of IgG.

[0164] [Figure 58]Figure 58 shows NFκB activation in human Ramos cells after treatment with anti-CD38 antibody conjugated to p246 (filled squares), anti-CD38 antibody conjugated to p4 (filled circles), unconjugated p246 (open squares), or unconjugated p4 (open circles).

[0165] [Figure 59] Figure 59 shows complement activation (measured by C3 release) after incubation of monkey serum with zymosan (inverted triangle; positive control), p1 (filled circle), or two CpG-containing immunostimulatory polynucleotides provided herein (filled square and filled triangle).

[0166] [Figure 60] Figure 60A shows (i) saline solution (filled circle); (ii) 3 mg / kg CpG-Ab (4523-CD22; SB-337) (square); (iii) 3 mg / kg CD19-mAb (filled downward triangle); (iv) 3 mg / kg CpG-Ab (4523-CD19; SB-388) (filled diamond); (v) 1.9 μg / mouse naked CpG (P347) (upward triangle); (vi) 19 μg / mouse naked CpG (p347) (open downward triangle); (vii) 190 μg / mouse naked CpG (P347) (open diamond); 1 shows the progression of mean tumor volume increase in mice bearing A20 murine B-cell lymphoma cell xenografts after intravenous administration on days 10, 12, and 14, respectively.

[0167] Figure 60B shows (i) saline solution (solid line); (ii) 3 mg / kg CpG-Ab (SB-337) (checkered pattern); (iii) 3 mg / kg CD19-mAb (horizontal); (iv) 3 mg / kg CpG-Ab (SB-388) (vertical); (v) 1.9 μg / mouse naked CpG (P347) (downward diagonal line); A20 mouse B cells after intravenous administration on days 10, 12, and 14, respectively. 1 shows the mean tumor volume at day 20 in mice bearing follicular lymphoma cell xenografts.

[0168] Figure 60C shows (i) saline solution (black); (ii) 3 mg / kg CpG-Ab (SB-337) (checkered); (iii) 3 mg (iv) 3 mg / kg CD19-mAb (horizontal); (iv) 3 mg / kg CpG-Ab (SB-388) (vertical); (v) 1.9 μg / mouse naked CpG (P (vi) 19 μg / mouse naked CpG(P347) (grid); (vii) 190 μg / mouse naked CpG (P347) (upward diagonal line); A20 mice after intravenous administration on days 10, 12, and 14, respectively. Mean day 20 excluding tumor weight changes in mice bearing human B-cell lymphoma xenografts Shows weight change.

[0169] [Figure 61] Figure 61A shows the progression of mean tumor volume increase in mice following B16F10 melanoma re-implantation after intratumoral administration of (i) saline solution (filled circles); or (ii) p347 (filled squares); on days 7, 9, 11, and 13, respectively, and after re-implantation on day 14.

[0170] Figure 61B shows saline solution (upper panel) or p347 (lower panel); Mice reimplanted with B16F10 melanoma after intratumoral administration in each eye and after reimplantation on day 14 This shows lung metastasis from the tumor.

[0171] Figure 61C shows the results of the treatment with (i) saline solution (upward triangles); or (ii) p347 (downward triangles); of mice inoculated with CT26 colorectal xenografts after intratumoral administration on days 12 and 14, respectively. The progression of mean tumor volume increase is shown.

[0172] [Figure 62] Figure 62A shows the progression of mean tumor volume increase in genetically B cell-deficient mice using the CT26 colorectal model after intravenous administration of (i) saline solution (circles); or (ii) 10 mg / kg of CpG-mAb (SB-337) (squares) on days 10, 12, and 14, respectively.

[0173] Figure 62B shows the results of the treatment with (i) saline solution (circles); or (ii) 10 mg / kg CpG-mAb (SB-337) (squares); Anti-CD20 mAb was administered intravenously to B cells in the CT26 colorectal model on days 2 and 14, respectively. The progression of mean tumor volume increase in mice from which the tumors were removed is shown.

[0174] [Figure 63] Figure 63A shows the progression of mean tumor volume growth in mice using the MC38 colorectal syngeneic model after administration of (i) saline solution (circles); (ii) 10 mg / kg anti-CD22 (upward triangles); (iii) 10 mg / kg anti-PD-L1 (downward triangles); (iv) 10 mg / kg CD22-CpG (SB-337) (squares); or (v) 10 mg / kg CD22-CpG (SB-337) + 10 mg / kg anti-PD-L1 (diamonds). Anti-CD22 and CD22-CpG were administered intravenously on days 10, 12, and 14; anti-PD-L1 was administered intraperitoneally on days 10, 13, and 17. *p=0.01; **p=0.001.

[0175] Figure 63B shows the MC38 colorectal isogeneic mouse model after intravenous administration of saline on days 10, 12, and 14. The progression of tumor volume increase in each mouse using the delta is shown.

[0176] Figure 63C shows MC38 rectal colonization after intravenous administration of 10 mg / kg anti-CD22 mAb on days 10, 12, and 14. The progression of tumor volume increase in each mouse using the intestinal syngeneic model is shown.

[0177] Figure 63D shows MC38 colorectal tumors following intraperitoneal administration of 10 mg / kg anti-PD-L1 on days 10, 13, and 17. The progression of tumor volume increase in each mouse using a syngeneic model is shown.

[0178] Figure 63E shows the results of MC38 after intravenous administration of 10 mg / kg CD22-CpG (SB-337) on days 10, 12, and 14. The progression of tumor volume increase in each mouse using a colorectal syngeneic model is shown.

[0179] Figure 63F shows the effect of 10 mg / kg of CD22-CpG (SB-337) administered intravenously on days 10, 12, and 14, MC38 colorectal syngeneic model after intraperitoneal administration of 10 mg / kg anti-PD-L1 on days 10, 13, and 17 The progression of tumor volume increase in each mouse used is shown.

[0180] [Figure 64] Figure 64A shows the progression of mean tumor volume growth in mice using the B16F10 melanoma model after administration of (i) saline solution (circles); (ii) 10 mg / kg anti-CD22 (squares); (iii) 10 mg / kg CD22-CpG (SB-337) (triangles); or (iv) 10 mg / kg CD22-CpG (SB-337) + 10 mg / kg anti-PD-L1 (diamonds) on days 10, 12, and 14. Anti-CD22 and CD22-CpG were administered intravenously; anti-PD-L1 was administered intraperitoneally. **p=0.08; ***p=0.03.

[0181] Figure 64B shows (i) saline solution (circles); (ii) 10 mg / kg CD22-CpG (SB-337) (circles); (iii) 10 mg / kg (iv) 10 mg / kg CD22-CpG(SB-337) + 10 mg / kg anti-PD1 (upward pointing triangle) (v) 10 mg (vi) 10 mg / kg CD22-CpG + 10 mg / kg anti-PD-L1 (diamond); Figure 1 shows the progression of mean tumor volume increase in mice using the LLC1 Lewis lung carcinoma model after treatment with anti- CD22 and CD22-CpG were administered intravenously on days 7, 10, and 13; anti-PD-L1 and anti-PD-1 were administered intravenously on days 7, 10, and 1 On the fourth day, the mice were administered intraperitoneally. ** p=0.023.

[0182] [Figure 65] Figure 65A shows the progression of mean tumor volume increase in mice using the CT26 colorectal model after intravenous administration of (i) saline solution (circles); (ii) 10 mg / kg CD22-CpG (SB-337) (triangles); or (iii) 10 mg / kg DEC205-CpG (SB-3096) on days 12, 17, 20, and 24, respectively.

[0183] Figure 65B shows the CT26 colon after intravenous administration of saline on days 12, 17, 20, and 24. The progression of tumor volume increase in each mouse using the rectal model is shown.

[0184] Figure 65C shows the results of intravenous administration of 10 mg / kg of CD22-CpG (SB-337) on days 12, 17, 20, and 24. 1 shows the progression of tumor volume increase in each mouse using the CT26 colorectal model after treatment.

[0185] Figure 65D shows the results of intravenous administration of 10 mg / kg of DEC205-CpG (SB-3096) on days 12, 17, 20, and 24, respectively. Figure 1 shows the progression of tumor volume increase in each mouse using the CT26 colorectal model after administration of 100 mg / kg of IgG. .

[0186] [Figure 66]Figure 66A shows the progression of mean tumor volume increase in mice using the CT26 colorectal model after administration of (i) saline solution (small circles); (ii) CD4 depletion (large circles); (iii) 3 mg / kg CD22-CpG (SB-337) (squares); or (iv) CD4 depletion plus 3 mg / kg CD22-CpG (SB-337) (diamonds). CD22-CpG was administered intravenously on days 10, 13, and 15. CD4 depletion was performed using anti-CD4.

[0187] Figure 66B shows (i) saline solution (circles); (ii) CD4 depletion (upward pointing triangles); (iii) 3 mg / kg CD22-CpG (SB-337) (squares); or (iv) CD4 depletion plus 3 mg / kg CD22-CpG(SB-337) (downward-pointing triangles). The graph shows the progression of mean tumor volume increase in mice using the A20 lymphoma model after CD22-Cp G was administered intravenously on days 10, 12, and 14. CD4 depletion was performed using anti-CD4.

[0188] [Figure 67] Figure 67A shows the mean fluorescence intensity (MFI) of CD40, CD70, CD80, CD86, MHC-I, MHC II, and 4-1 BBL surface expression on CD19+ / B220+ B cells after in vitro incubation with 1 nM CD22 Ab (checkered pattern); 1 nM CpG (SB-4715) (horizontal line); or 1 nM CpG-Ab (SB-337) (vertical line).

[0189] Figure 67B shows saline (solid line); 10 mg / kg CD22 Ab (checkered); 10 mg / kg CpG (SB-4715). (horizontal line); or CD19+ / B220+ B cells after in vivo administration of 10 mg / kg CpG-Ab (SB-337) (vertical line). The mean fluorescence intensity (MFI) of CD40, CD80, CD86, and MHC II surface expression is shown above.

[0190] [Figure 68] Figure 68A shows the percent of activated T cells (CD71+, CD3+) relative to the total T cell (CD3+) population in mice treated with (i) saline (solid line); (ii) Ab (anti-CD22) (checkered pattern); (iii) CpG-Ab (SB-337) (horizontal); or (iv) CpG (SB-4715) (vertical).

[0191] Figure 68B shows (i) saline (solid line); (ii) Ab (anti-CD22) (checkered pattern); (iii) CpG-Ab (SB-337) (water (iv) the effect of CpG (SB-4715) on the total T cell (CD3+) population in mice treated with CpG (SB-4715) (vertical); Figure 1 shows the percentage of activated T cells (Ki67+, CD3+) present in the sera.

[0192] [Figure 69] Figure 69A shows the progression of mean tumor volume increase in mice using the CT26 colorectal model after intravenous administration of (i) saline solution (circles); (ii) 10 mg / kg CD22-CpG (SB-337) (squares); (iii) 10 mg / kg CD22 (upward triangles); or (iv) free CpG (P347) (downward triangles) on days 10, 12, and 14, respectively.

[0193] Figure 69B shows (i) saline solution (small circles); (ii) 10 mg / kg CD22-CpG (SB-337) (small squares). (iii) Draining lymph nodes from mice treated with 10 mg / kg CD22 (small up-pointing triangles). cells; or (iv) free CpG (P347) (small downward-pointing triangle); or (v) saline solution (diamond); vi) 10 mg / kg CD22-CpG(SB-337) (large circle); (vii) 10 mg / kg CD22 (large square); or (v iii) Non-draining lymph node from a mouse treated with free CpG (P347) (large up-pointing triangle). Progression of mean tumor volume increase in mice using the CT26 colorectal model after adoptive transfer of cells It shows.

[0194] Figure 69C shows (i) saline solution (narrow upward diagonal line); (ii) 10 mg / kg CD22-CpG (SB-337) (lower (iii) 10 mg / kg CD22 (grid); or (iv) free CpG (P347) (wide downward-pointing Draining lymph node cells from mice treated with (dark hatched lines); or (v) saline solution (solid lines); (vi) 10 mg / kg CD22-CpG(SB-337) (checkered); (vii) 10 mg / kg CD22 (horizontal); or (viii ) after adoptive transfer of non-draining lymph node cells from mice treated with free CpG (P347) (empty) Figure 1 shows the mean tumor volume at day 24 in mice using the CT26 colorectal model.

[0195] [Figure 70] Figure 70A shows plasma concentrations of IL-6 in untreated mice treated intravenously with (i) saline (solid line); (ii) 10 mg / kg Ab(CD22) (checkered pattern); (iii) 5.7 ug / dose free CpG(p347) (horizontal); or (iv) 10 mg / kg CpG-mAb(SB-337) (vertical).

[0196] Figure 70B shows (i) saline (solid line); (ii) 10 mg / kg Ab(CD22) (checkered); (iii) 5.7 ug / dose (iv) untreated mice intravenously treated with 10 mg / kg of free CpG (p347) (horizontal); or (iv) 10 mg / kg of CpG-mAb (SB-337) (vertical). Plasma concentrations of IL-1β in treated mice are shown.

[0197] Figure 70C shows (i) saline (solid line); (ii) 10 mg / kg Ab(CD22) (checkered); (iii) 5.7 ug / dose (iv) untreated mice intravenously treated with 10 mg / kg of free CpG (p347) (horizontal); or (iv) 10 mg / kg of CpG-mAb (SB-337) (vertical). Plasma concentrations of IL-10 in treated mice are shown.

[0198] Figure 70D shows (i) saline (solid line); (ii) 10 mg / kg Ab(CD22) (checkered); (iii) 5.7 ug / dose (iv) treated intravenously with 10 mg / kg of free CpG (Sp347) (horizontal); or (iv) 10 mg / kg of CpG-mAb (SB-337) (vertical). Plasma concentrations of IL-12p70 in untreated mice are shown.

[0199] Figure 70E shows (i) saline (solid line); (ii) 10 mg / kg Ab(CD22) (checkered); (iii) 5.7 ug / dose (iv) untreated mice intravenously treated with 10 mg / kg of free CpG (p347) (horizontal); or (iv) 10 mg / kg of CpG-mAb (SB-337) (vertical). Plasma concentrations of IFNγ in treated mice are shown.

[0200] Figure 70F shows (i) saline (solid line); (ii) 10 mg / kg Ab(CD22) (checkered); (iii) 5.7 ug / dose (iv) untreated mice intravenously treated with 10 mg / kg of free CpG (p347) (horizontal); or (iv) 10 mg / kg of CpG-mAb (SB-337) (vertical). Plasma concentrations of TNFα in treated mice are shown.

[0201] [Figure 71] Figure 71A shows the percentage of B cells (B220+) relative to total cells in spleens from mice using the CT26 colorectal model after intravenous administration of (i) saline (circles); or (ii) 10 mg / kg CpG-mAb (SB-337) (squares) on days 10, 13, and 17, respectively. *p<0.05

[0202] Figure 71B shows the results of infusion of (i) saline (circles); or (ii) 10 mg / kg CpG-mAb (SB-337) (squares) at 10, 13, and 24 h. Whole spleens from mice using the CT26 colorectal model after intravenous administration on days 10 and 17. Germinal center (GC) cells (B220 + , IgD lo , Fas + ) percentage. * p< 0.05

[0203] Figure 71C shows the results of infusion of (i) saline (circles); or (ii) 10 mg / kg CpG-mAb (SB-337) (squares) at 10, 13, and 24 h. Whole spleens from mice using the CT26 colorectal model after intravenous administration on days 10 and 17. T follicular helper (T fh ) cells (CD4 + , CXCR5 + , PD-1 + ) percentage There are. * p<0.05

[0204] Figure 71D shows the results of treatment with (i) saline; or (ii) 10 mg / kg CpG-mAb (SB-337) on days 10, 13, and 17. Relative fold change of IL-21 from mice using the CT26 colorectal model after intravenous administration of each The figure shows the rate. * p<0.05

[0205] Figure 71E shows the results of treatment with (i) saline; or (ii) 10 mg / kg CpG-mAb (SB-337) on days 10, 13, and 17. Relative fold change of Bcl-6 from mice using the CT26 colorectal model after intravenous administration of each The figure shows the rate. * p<0.05

[0206] Figure 71F shows the results of treatment with (i) saline; or (ii) 10 mg / kg CpG-mAb (SB-337) on days 10, 13, and 17. Relative fold change of IRF-4 from mice using the CT26 colorectal model after intravenous administration of each The figure shows the rate. * p<0.05

[0207] [Figure 72] Figure 72A shows the relative fold change in IL-6 in spleens from mice using the CT26 colorectal model after intravenous administration of (i) saline; or (ii) 3 mg / kg CpG-mAb (SB-337) on days 10, 13, and 17, respectively.

[0208] Figure 72B shows the results of treatment with (i) saline; or (ii) 3 mg / kg CpG-mAb (SB-337) on days 10, 13, and 17. IL-10 expression in spleens from mice using the CT26 colorectal model after intravenous administration of Relative fold changes are shown.

[0209] Figure 72C shows the results of treatment with (i) saline; or (ii) 3 mg / kg CpG-mAb (SB-337) on days 10, 13, and 17. IL-1β expression in spleens from mice using the CT26 colorectal model after intravenous administration of Relative fold changes are shown.

[0210] Figure 72D shows the results of treatment with (i) saline; or (ii) 3 mg / kg CpG-mAb (SB-337) on days 10, 13, and 17. TNFα levels in spleens from mice using the CT26 colorectal model after intravenous administration of Relative fold changes are shown.

[0211] [Figure 73]Figure 73A shows the relative fold change in IL-6 in draining lymph nodes from mice using the CT26 colorectal model after intravenous administration of (i) saline; or (ii) 3 mg / kg CpG-mAb (SB-337) on days 10, 13, and 17, respectively.

[0212] Figure 73B shows the results of treatment with (i) saline; or (ii) 3 mg / kg CpG-mAb (SB-337) on days 10, 13, and 17. In the draining lymph nodes from mice using the CT26 colorectal model after intravenous administration The relative fold change in IL-10 in the 14 patients is shown.

[0213] Figure 73C shows the results of treatment with (i) saline; or (ii) 3 mg / kg CpG-mAb (SB-337) on days 10, 13, and 17. In the draining lymph nodes from mice using the CT26 colorectal model after intravenous administration The relative fold change in IL-1β in the 14 patients is shown.

[0214] Figure 73D shows the results of treatment with (i) saline; or (ii) 3 mg / kg CpG-mAb (SB-337) on days 10, 13, and 17. In the draining lymph nodes from mice using the CT26 colorectal model after intravenous administration The relative fold change in TNFα in the 100% control group is shown.

[0215] [Figure 74] Figure 74A shows the concentration of IgM in mice using the CT26 colorectal model after intravenous administration of (i) saline; or (ii) 3 mg / kg CpG-mAb (SB-337) on days 10, 13, and 16. *p<0.05.

[0216] Figure 74B shows the results of treatment with (i) saline; or (ii) 3 mg / kg CpG-mAb (SB-337) on days 10, 13, and 16. The concentrations of IgG2a in mice using the CT26 colorectal model after intravenous administration of each are. * p<0.05

[0217] Figure 74C shows the results of treatment with (i) saline; or (ii) 3 mg / kg CpG-mAb (SB-337) on days 10, 13, and 16. The IgG concentration in mice using the CT26 colorectal model after intravenous administration of each There are. * p<0.05

[0218] [Figure 75] Figure 75 shows the scheme and quantification of mouse anti-AH1 IgG2a in serum from mice treated intravenously with saline (circles) or 3 mg / kg CpG-mAb (SB-337) (squares) as measured using a commercially available secondary anti-mouse IgG2a-HRP antibody, secondary Ab1; or measurement of treatment with saline (downward pointing triangles) or 3 mg / kg CpG-mAb (SB-337) (diamonds) using a second commercially available secondary anti-mouse IgG2a-HRP antibody, secondary Ab2.

[0219] [Figure 76] Figure 76A shows the percentage of regulatory B cells (Breg; CD19+, B220+, CD1dhi) relative to total B cells (B220+) in the spleen from mice after weekly intravenous administration of (i) saline (circles); or (ii) 10 mg / kg CpG-mAb (SB-337) (squares). *p<0.001

[0220] Figure 76B shows the results of weekly intravenous administration of (i) saline (circles); or (ii) 10 mg / kg CpG-mAb (SB-337) (squares). Regulatory B cells (Breg; CD19) were expressed on all spleen cells from mice after administration. + , B220 + , CD1d hi ) percentage. *p<0.001

[0221] [Figure 77] Figure 77A shows the percentage of splenic myeloid dendritic cells (mDCs; B220-, CD11C+; DEC205hi) relative to total cells in splenic lymph nodes from mice using the CT26 colorectal model treated intravenously with (i) saline (circles); (ii) 10 mg / kg CpG-mAb (SB-337) (squares); or (iii) 10 mg / kg CpG (triangles) on days 14, 17, and 30, respectively. *p=0.0002, &p=0.003, #p=0.002.

[0222] Figure 77B shows the effect of (i) saline (circles); (ii) 10 mg / kg CpG-mAb (SB-337) (squares); or (iii) 10 mg / kg CpG (triangle); using the CT26 colorectal model treated intravenously on days 14, 17, and 30, respectively. Pooled lymph node (LN) bone marrow dendritic cells (mDCs; B220) versus whole cells from mice - , C D11C + ; CD8 + The percentages of lymph nodes (dLN) and non-draining lymph nodes (NLLN) are shown. The samples were taken from the entry lymph nodes (ndLN).

[0223] [Figure 78] Figure 78A shows the progression of mean tumor volume increase in mice using the CT26 colorectal model after treatment on days 10, 13, and 15, respectively, with (i) saline solution (circles); (ii) plasmacytoid dendritic cell (pDC) depletion (downward triangles); (iii) 3 mg / kg CD22-CpG(SB-337) (squares); or (iv) pDC depletion plus 3 mg / kg CD22-CpG(SB-337) (upward triangles).

[0224] Figure 78B shows (i) saline solution (small circles); (ii) plasmacytoid dendritic cell (pDC) depletion (diamonds); i) 3 mg / kg CD22-CpG(SB-337) (square); or (iv) pDC depletion + 3 mg / kg CD22-CpG(SB-337) (large The mean values ​​of mice using the A20 lymphoma model after treatment with 10, 12, and 14 days of IFN-γ (white circles) were obtained. The progression of tumor volume increase is shown.

[0225] [Figure 79] Figure 79A shows the relative fold change in gene expression of T cell genes from mice using the CT26 colorectal model after intravenous administration of (i) saline (solid line); or (ii) 3 mg / kg CpG-mAb (SB-337) (checkered pattern) on days 10, 12, and 14, respectively.

[0226] Figure 79B shows the results of infusion of (i) saline (solid line); or (ii) 3 mg / kg CpG-mAb (SB-337) (horizontal line) at 10, 12, and 24 h. The mouse-derived macrophage colonic leukemia (CLL) was evaluated using the CT26 colorectal model after intravenous administration on days 10 and 14. The relative fold change in gene expression of phage genes is shown.

[0227] Figure 79C shows the results of 10, 12, and 20-well platelets treated with (i) saline (solid line); or (ii) 3 mg / kg CpG-mAb (SB-337) (vertical line). Cytokines derived from mice using the CT26 colorectal model after intravenous administration on days 10 and 14. The relative fold change in gene expression of the in-genes is shown.

[0228] Figure 79D shows (i) saline (solid line); (ii) 3 mg / kg CpG-mAb (SB-337) (upward diagonal line); (iii) antibody PD-L1 (downward diagonal line); (iv) 3 mg / kg CpG-mAb + anti-PD-L1 (SB-337) (grid) on days 10, 12, and 14 Apoptotic enzymes derived from mice using the CT26 colorectal model after intravenous administration to each eye The relative fold change in gene expression of the elemental genes is shown.

[0229] [Figure 80] Figure 80A shows dose-response curves for the concentration of IL-6 derived from human primary B cells in response to in vitro treatment with (i) CpG(p425) (squares); (ii) CpG-Ab(SB-430) (triangles); or (iii) Ab (diamonds) for 24 to 72 hours.

[0230] Figure 80B shows the results of in vivo analysis of (i) CpG(p425) (triangles); or (ii) CpG-Ab(SB-430) (circles) for 24 to 72 hours. Dose of MHC II expression on human primary B cells in response to thrombus treatment with mean fluorescence intensity (MFI) Response curves are shown.

[0231] Figure 80C shows the results of in vivo analysis of (i) CpG(p425) (triangles); or (ii) CpG-Ab(SB-430) (circles) for 24 to 72 hours. Dose-response curves for mean fluorescence intensity (MFI) of CD86 expression on human primary B cells in response to thrombin treatment. The response curve is shown.

[0232] Figure 80D shows the results of in vivo analysis of (i) CpG(p425) (triangles); or (ii) CpG-Ab(SB-430) (circles) for 24 to 72 hours. Dose-response curves for mean fluorescence intensity (MFI) of CD70 expression on human primary B cells in response to thrombin treatment. The response curve is shown.

[0233] Figure 80E shows the results of in vivo analysis of (i) CpG(p425) (triangles); or (ii) CpG-Ab(SB-430) (circles) for 24 to 72 hours. Dose response of mean fluorescence intensity (MFI) of CD20 expression on human primary B cells in response to treatment with thrombin. The response curve is shown.

[0234] [Figure 81]Figure 81 shows dose-response curves for the concentration of IL-6 derived from primary human splenocytes in response to in vitro treatment with (i) hCD22-hCpG(SB-430) (squares); (ii) free human CpG 7909 (downward triangles); or (iii) free human CpG Solstice(p425) (downward arrows) for 24 hours.

[0235] [Figure 82] Figure 82A shows a scheme of the humanized mouse model experiment using subcutaneous implantation of Daudi Burkitt lymphoma cells and fresh human peripheral blood mononuclear cells (hPBMCs) injected intraperitoneally (IP) before intravenous (IV) treatment on each of days 12, 14, and 16.

[0236] Figure 82B shows the results of subcutaneous implantation of Daudi Burkitt lymphoma cells and the results of the results at 12, 14, and 16 days, respectively. (i) saline (circles); (ii) 5 mg / kg hCD22 Ab (squares); (iii) 5.7 μg / dose CpG(p425) (open circles) or (iv) intravenous (IV) treatment with 5 mg / kg hCD22-CpG(SB-430) (filled triangle). Average tumor volume in a humanized mouse model previously injected intraperitoneally with fresh human peripheral blood mononuclear cells This shows the progression of product increase.

[0237] [Figure 83] Figure 83 shows the pharmacokinetic profile of CpG-antibody conjugate SB-337 DAR1 in mice administered intravenously or subcutaneously.

[0238] [Figure 84] Figure 84 shows the pharmacokinetic profile of CpG-antibody conjugate SB-337 DAR1 in mice administered intravenously.

[0239] [Figure 85]Figure 85 shows the pharmacokinetic profile of CpG-antibody conjugate SB-337 DAR1 in mice administered intravenously.

[0240] [Figure 86] Figure 86 shows the pharmacokinetic profiles of CpG-antibody conjugates SB-337 DAR1 and SB-337 DAR2 in mice administered intravenously.

[0241] [Figure 87] Figures 87A and 87B show the pharmacokinetic profile of CpG-antibody conjugates in mice administered intravenously. DETAILED DESCRIPTION OF THE INVENTION

[0242] (Detailed explanation) (definition) As used herein, the term "abasic spacer" refers to a divalent group of the structure : R 1 -L 1 -[-L 2 -(L 1 ) n1 -] n2 -R 2 , (I) (where: n1 is 0 or 1, n2 is an integer from 1 to 6, R 1 is the bond to the nucleoside in the immunomodulatory polynucleotide, R 2 The bond to the nucleoside or the bond to the capping group in the immunomodulatory polynucleotide is a combination, Each L 1 are independently a phosphodiester or a phosphotriester, and Each L 2 is a sugar analogue, however, When the abasic spacer is an internucleoside abasic spacer, each n1 is 1. R 2 is a bond to a nucleoside, and When the abasic spacer is a terminal abasic spacer, each n1 is independently 0 or 1. and R 2 is the bond to the capping group).

[0243] As used herein, the term "about" refers to a value that is ±10% of the recited value.

[0244] As used herein, the term "alkane-tetrayl" means, unless otherwise specified, represents a tetravalent acyclic straight-chain or branched-chain saturated hydrocarbon group having 1 to 16 carbon atoms. The tetrayl may be optionally substituted as described for alkyl. .

[0245] As used herein, the term "alkane-triyl" means, unless otherwise specified, 1 Alkane- represents a trivalent acyclic straight- or branched-chain saturated hydrocarbon group having up to 16 carbons. The triyl may be optionally substituted as described for alkyl.

[0246] As used herein, the term "alkanoyl" refers to the alkanoyl group of a parent molecular group via a carbonyl group. represents a hydrogen or alkyl group bonded to the hydroxy), acetyl, propionyl, butyryl, and iso-butyryl. An unsubstituted alkanoyl group contains 1 to 7 carbon atoms. and the alkyl group may be unsubstituted or substituted as described herein for alkyl groups. (e.g., optionally substituted C 1-7alkanoyl). The ending "-oil" is Other groups as defined in the specification, such as aryl, cycloalkyl, and heterocyclyl , and can be added to "aryloyl", "cycloalkanoyl", and "(heterocyclyl)o These groups may be defined as aryl, cycloalkyl, or hexyl, respectively. It represents a carbonyl group bonded to a tetracyclyl. " and "(heterocyclyl)oyl" are each defined as "aryl", "cycloalkoxy", and "cycloalkyl", respectively. optionally substituted as defined for "heterocyclyl" or "heterocyclyl" good.

[0247] The term "alkenyl" as used herein refers to an alkyl group having one, two, or three carbon-carbon double bonds. The alkenyl group represents an acyclic monovalent straight or branched hydrocarbon group containing a bond. Examples include ethenyl, prop-1-enyl, prop-2-enyl, 1-methylethenyl, butadiene, -1-enyl, but-2-enyl, but-3-enyl, 1-methylprop-1-enyl, 2-methylprop- Alkenyl groups include 1-methylprop-1-enyl and 1-methylprop-2-enyl. and optionally substituted as defined herein.

[0248] As used herein, the term "alkenylene" refers to an alkenylene group that has had one hydrogen removed, resulting in The alkenylene group refers to a divalent, straight-chain or branched-chain alkenyl group. Non-limiting examples include ethene-1,1-diyl; ethene-1,2-diyl; prop-1-ene-1,1-diyl prop-2-ene-1,1-diyl; prop-1-ene-1,2-diyl, prop-1-ene-1,3-diyl Prop-2-ene-1,1-diyl; Prop-2-ene-1,2-diyl; But-1-ene-1,1-diyl; Buta -1-ene-1,2-diyl;but-1-ene-1,3-diyl;but-1-ene-1,4-diyl;but-2-ene-1,1 -diyl;but-2-ene-1,2-diyl;but-2-ene-1,3-diyl;but-2-ene-1,4-diyl;but-2-ene-1,4-diyl But-3-ene-1,1-diyl; But-3-ene-1,2-diyl; But-3-ene-1,1-diyl ,3-diyl;Buta-3-ene-2,3-diyl;Buta-1,2-diene-1,1-diyl;Buta-1,2-diene-1,3- Buta-1,2-diene-1,4-diyl; Buta-1,3-diene-1,1-diyl; Buta-1,3-diene-1,2 -diyl;Buta-1,3-diene-1,3-diyl;Buta-1,3-diene-1,4-diyl;Buta-1,3-diene-2, buta-2,3-diene-1,1-diyl; and buta-2,3-diene-1,2-diyl. The alkenylene group may be unsubstituted or substituted as described for alkyl. It may be optionally substituted (eg, optionally substituted alkenylene).

[0249] The term "alkoxy" as used herein refers to a chemical substituent of formula -OR, , R is C unless otherwise specified 1-6 In some embodiments, The alkyl group may be further substituted as defined herein. The term "cyclooxy" may be used interchangeably with other terms defined herein, such as aryl, cyclo, In combination with alkyl or heterocyclyl, "arylalkoxy", "cycloalkoxy" and "cycloalkoxy" are also used. "(heterocyclyl)alkoxy" and "(heterocyclyl)alkoxy" groups can be defined. These groups may each be substituted by an aryl, cycloalkyl, or heterocyclyl. "arylalkoxy", "cycloalkylalkoxy", and "(heterocyclyl)alkoxy" are each as defined herein for each individual moiety. It may be optionally substituted as defined.

[0250] As used herein, the term "alkyl" means, unless otherwise specified, an alkyl group. Unless otherwise specified, it refers to an acyclic, straight or branched chain saturated hydrocarbon group having 1 to 12 carbons. In certain preferred embodiments, the unsubstituted alkyl has 1 to 6 carbons. is methyl; ethyl; n-propyl and isopropyl; n-butyl, sec-butyl, isobutyl butyl, and tert-butyl; neopentyl, and the like; and, where valence permits, amino ;Aryl;Aryloxy;Azido;Cycloalkyl;Cycloalkoxy;Cycloalkenyl ;Cycloalkynyl;Halo;Heterocyclyl;(Heterocyclyl)oxy;Hydroxy;Nitro; Thiol; Silyl; Cyano; =O; =S; =NR' (where R' is H, alkyl, aryl, or hydroxyl). 1, 2, 3, or 2 or more carbon atoms independently selected from the group consisting of: tetracyclyl; In the case of an alkyl group, it may be optionally substituted with four or more substituents, each of which is It may itself be unsubstituted, or, where valences permit, each respective group may be substituted. and optionally substituted with unsubstituted substituents as defined herein.

[0251] As used herein, the term “alkylamino” refers to a group of the formula —N(R N1 )2 or -NHR N1 (In the ceremony , RN1 refers to a group having an alkyl group (wherein the alkyl group is alkyl as defined herein). The alkyl portion of may be optionally substituted as defined for alkyl. Each optional substituent on a substituted alkylamino may itself be unsubstituted. or, where valences permit, a non-substituted group as defined herein for each respective group. It may be substituted with a substituent.

[0252] As used herein, the term "alkylcycloalkylene" refers to a group having two valencies. refers to a saturated divalent hydrocarbon group that is an alkylcycloalkane, having a hydrogen atom substituted therein. Preferably, at least one of the two valencies is present in a cycloalkane moiety. The alkane and cycloalkane moieties may be as described herein as individual groups. It may be optionally substituted.

[0253] As used herein, the term "alkylene" refers to a group having two valencies replacing two hydrogen atoms. As used herein, "a" refers to a saturated divalent hydrocarbon group that is a straight or branched chain saturated hydrocarbon, substituted with . The valence of the defined alkylene does not include any substituents. Typical examples are methylene, ethane-1,2-diyl, ethane-1,1-diyl, propane-1,3- Diyl, Propane-1,2-diyl, Propane-1,1-diyl, Propane-2,2-diyl, Butane-1, 4-diyl, butane-1,3-diyl, butane-1,2-diyl, butane-1,1-diyl, and butane-2, 2-diyl, butane-2,3-diyl. x-y The term "alkylene" refers to x to y alkylene groups. Exemplary values ​​of x are 1, 2, 3, 4, 5, and 6, and y represents an alkylene group having 1, 2, 3, 4, 5, and 6 carbon atoms. Exemplary values ​​of are 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12. Alkylene is an alkyl group. The alkyl may be optionally substituted as described herein.

[0254] As used herein, the term "alkylsulfenyl" refers to a group of formula -S-(alkyl). Alkylsulfenyl is optionally substituted as defined for alkyl. It may also be used.

[0255] As used herein, the term "alkylsulfinyl" refers to a group of the formula -S(O)-(alkyl) The alkylsulfinyl represents a group optionally substituted as defined for alkyl. It may be done.

[0256] As used herein, the term "alkylsulfonyl" refers to a group of the formula -S(O)-(alkyl) The alkylsulfonyl represents a group optionally substituted as defined for alkyl. It may be done.

[0257] As used herein, the term "alkynyl" refers to an alkynyl group having at least one carbon-carbon triple bond. represents a monovalent linear or branched hydrocarbon group of 2 to 6 carbon atoms containing a bond, and is exemplified by ethynyl, 1- The alkynyl group may be unsubstituted or may be substituted as defined for alkyl (e.g., optionally substituted (Alkynyl).

[0258] As used herein, the term "5-alkynyluridine" refers to a nucleobase that is represents a 5-alkynyluracil nucleoside having the structure: [ka] wherein R is a bond to the anomeric carbon of the pentafuranose of the nucleoside; and X is alkynyl. In some embodiments, X is ethynyl or propynyl. (e.g., X is ethynyl).

[0259] As used herein, the term "alkynylene" refers to an alkynylene having one or two carbon-carbon triple bonds. and, if unsubstituted, straight or branched chain divalent substituted alkyls containing only C and H. Non-limiting examples of the alkynylene group include ethyne-1,2-diyl; Propane-1,3-diyl;Propane-2-yn-1,1-diyl;Buta-1-yn-1,3-diyl;Buta-1-yn-1,4-diyl But-2-yn-1,1-diyl; But-2-yn-1,4-diyl; But-3-yn-1,1-diyl; But-3 buta-3-yne-2,2-diyl; and buta-1,3-diyne-1,4-diyl. The alkynylene group may be unsubstituted or may have the same substituted groups as described for the alkynyl group. It may be substituted as indicated (eg, optionally substituted alkynylene).

[0260] As used herein, the term "amino" refers to -N(R N1 )2, where amino is substituted If not converted, both R N1 is H; or if amino is substituted, each R N1 are independently H, -OH, -NO2, -N(R N2 )2, -SO2OR N2 , -SO2R N2 , -SOR N2 , -COOR N2 , N-protected Groups, alkyl, alkenyl, alkynyl, alkoxy, aryl, arylalkyl, aryloxy, cycloalkyl, cycloalkenyl, heteroalkyl, or heterocyclo Krill, but with at least one R N1 is not H and each R N2 are independently, H , alkyl, or aryl. Each of the substituents may itself be unsubstituted. or substituted with unsubstituted substituents as defined herein for each respective group. In some embodiments, the amino is an unsubstituted amino (i.e. , -NH2) or substituted amino (e.g., -NHR N1 ), where R N1 are independently -OH, -SO2OR N 2 , -SO2R N2 , -SOR N2 , -COOR N2 , optionally substituted alkyl, or optionally substituted aryl and each R N2 is an optionally substituted alkyl or an optionally substituted aryl In some embodiments, the substituted amino is alkylamino. wherein the alkyl group is as defined herein for alkyl. In some embodiments, the amino group is optionally substituted with R N1 is arbitrarily replaced -NHR is alkyl N1 R N1 is optionally substituted alkyl, -NHR N1 Non-limiting Suitable examples include: optionally substituted alkylamino, proteinogenic amino acids, protein-containing amino acids, and amino acids containing methyl groups. Non-protein-forming amino acids, C of protein-forming amino acids 1-6 Alkyl esters, and non-proteinogenic amino acid C 1-6 Alkyl esters are included.

[0261] As used herein, the term "aminoalkyl" means an amino group, as defined herein. It represents an alkyl substituted with one, two, or three amino groups. may be further optionally substituted as described for

[0262] As used herein, the term "arene-tetrayl" refers to an arene-tetrayl group having three hydrogen atoms as valence atoms. represents a tetravalent group that is a substituted aryl group. may be optionally substituted as described herein.

[0263] As used herein, the term "aryl" refers to a monocyclic group having one or two aromatic rings. The aryl group represents a bicyclic or polycyclic carbocyclic ring system containing 6 to 10 carbon atoms. All atoms in an unsubstituted carbocyclic aryl group are carbon atoms. Non-limiting examples of aryl groups include phenyl, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and the like. tetrahydronaphthyl, fluorenyl, indanyl, indenyl, etc. The alkyl group may be unsubstituted or may be substituted with an alkyl; alkenyl; alkynyl; alkoxy; Alkyl; alkylsulfinyl; alkylsulfenyl; alkylsulfonyl; amino; aryl; Aryloxy;Azide;Cycloalkyl;Cycloalkoxy;Cycloalkenyl;Cycloa Alkynyl;Halo;Heteroalkyl;Heterocyclyl;(Heterocyclyl)oxy;Hydroxy;Ni 1, 2, 3, 4, or 5 independently selected from the group consisting of thiol; silyl; and cyano. is optionally substituted with 5 substituents, each of which is itself unsubstituted. may be unsubstituted or may be unsubstituted substituents as defined herein for each respective group. It may be substituted.

[0264] As used herein, the term "arylalkyl" refers to an alkyl group substituted with an aryl group. The aryl and alkyl moieties may be independently selected as described herein. may be optionally substituted as a group.

[0265] As used herein, the term "arylalkylene" refers to an alkyl group having one hydrogen atom attached to its valence. The arylalkylene represents an arylalkyl group substituted with arylalkyl. The alkyl may be optionally substituted as described herein.

[0266] The term "arylene" as used herein means an arylene group in which one hydrogen atom replaces a valence atom. Arylene represents an aryl group as defined herein for aryl. It may be optionally substituted as shown.

[0267] The term "aryloxy" as used herein refers to a chemical substituent of formula -OR, where R is an aryl group unless otherwise specified. In C, the aryl group may optionally be as described herein for aryl. It has been replaced.

[0268] As used herein, the term "auxiliary moiety" refers to a hydrophilic polymer, a polymer having a positive charge, or a polymer having a represents a monovalent group containing a polymer or sugar alcohol.

[0269] As used herein, the term "optionally substituted N" refers to a divalent -N(R N1 )-group or trivalent - N= represents a group. An aza group is R N1 If is H or absent, even if unsubstituted Well, or R N1 R unless is not H N1 is defined as "amino" In some cases, it may be substituted. Two aza groups are joined to form a "diaza." It may also be used.

[0270] As used herein, the term "optionally substituted N-protected amino" refers to any of the groups defined herein. represents a substituted amino as defined above, wherein at least one substituent is an N-protecting group, and the other is H when the N-protected amino is unsubstituted, or is H when the N-protected amino is substituted If present, it is a substituent other than H.

[0271] The term "azido" as used herein refers to an -N3 group.

[0272] As used herein, the term "bulky group" refers to any substituent as defined herein. represents a substituent or group of substituents, where the radical bonded to the disulfide is Lu is sp 3 If it is a hybridized carbon, it may contain up to one hydrogen atom or the radical may be sp 2 Hybrid Carbon is a carbon atom that does not carry a hydrogen atom. The radical is an sp hybridized carbon. The bulky group is bonded to the disulfide only through a carbon atom.

[0273] As used herein, the term "5'-5' cap" refers to a group of the formula R'-Nuc 1 -O-(L P ) n - represents the group In the formula, R' is phosphate, phosphorothioate, phosphorodithioate, phosphonate, diester, phosphodiester, hydroxyl, or hydrogen; Nuc 1 is a nucleoside and each L P are independently, -P(=X E1 )(-X E2 -R E2A )-O-; and n is 1, 2, or 3. the law of nature; Here, each X E1 and each X E2 is independently O or S, and each R E2A is independent The hydroxyl groups are linked to hydrogen, bioreversible groups, non-bioreversible groups, auxiliary moieties, conjugated groups, and targeting moieties. a linker, or a linker attached to a targeting moiety and one or more (e.g., 1 to 6) auxiliary moieties. and wherein R' is attached to the 3'-carbon of the nucleoside and -O- is attached to the 5'-carbon of the nucleoside. It is bound to the element.

[0274] As used herein, the term "capping group" refers to a 5'- or 3'-terminated portion of a polynucleotide. '-represents a monovalent or divalent group located at the terminal. The capping group is a terminal phosphate ester; Phosphate; Triphosphate; Ancillary moiety; Bioreversible group; Non-bioreversible group; 5' Cap ( e.g., a 5'-5' cap); a solid support; a targeting moiety and optionally one or more (e.g., 1-6) complements. a linker attached to the auxiliary moiety; or a group -OR' (where R' is hydrogen, a bioreversible group, a non-bioreversible group, The group -OR', diphosphine, hydroxypropyl ... phosphate, triphosphate, bioreversible group, non-bioreversible group, solid support, and auxiliary moiety is an example of a monovalent capping group. Terminal phosphate ester is a monovalent (terminal phosphate ester does not contain a linker to the targeting moiety), or bivalent (where the terminal phosphate ester is a targeting moiety) These are examples of capping groups that can be either The linker (with or without the auxiliary moiety) attached to the targeting moiety is Here is an example.

[0275] As used herein, the term "carbocyclic" refers to an optionally substituted C 3-16 Monocyclic, Bicyclic represents a cyclic or tricyclic structure, in which the rings are carbon atoms, which may be aromatic or non-aromatic. The carbocyclic structures include cycloalkyl, cycloalkenyl, cyclopentyl, Chloroalkynyl and certain aryl groups are included.

[0276] The term "carbonyl" as used herein refers to a -C(O)- group.

[0277] As used herein, "C x-y " means that the group whose name immediately follows this expression is When the group is unsubstituted, it means that it contains a total of x to y carbon atoms. For example, arylalkyl), C x-y The part whose name immediately follows this expression If the group is unsubstituted, it contains a total of x to y carbon atoms. For example, (C 6-10 -aryl)-C 1-6 - alkyl is a total of 6 to 1 when the aryl moiety is not substituted 0 carbon atoms, and when the alkyl moiety is unsubstituted, a total of 6 to 10 It is a group containing carbon atoms.

[0278] As used herein, the term "cyano" refers to a -CN group.

[0279] As used herein, the term "cycloaddition reaction" refers to a reaction that is free of activation, activated by a chemical catalyst, or and n is 1, 2, or 3. When a bond is formed, a total of [4n+2] π electrons are involved in the reaction of the two components. The cyclization reaction involves [4n] π-electrons when photochemical activation is present and n is 1, 2, or 3. It is also a reaction of two components involving [4n+2] π electrons. Involved in this reaction is n=1. A typical cycloaddition reaction is the reaction of an alkene with a 1,3-diene ( Diels-Alder reaction), reaction of alkenes with α,β-unsubstituted carbonyls (heterodimers) Ruth-Alder reaction), and reactions of alkynes with azides (e.g., Huisgen cycloaddition) Examples include:

[0280] As used herein, unless otherwise specified, the term "cycloalkenyl" refers to a ring A non-aromatic carbocyclic group having at least one double bond and 3 to 10 carbons (e.g., C 3-C 10 Non-limiting examples of cycloalkenyl include cyclopro cycloprop-1-enyl, cycloprop-2-enyl, cyclobut-1-enyl, cyclobut-1-enyl, cyclobut-2-enyl, Clobut-2-enyl, cyclopent-1-enyl, cyclopent-2-enyl, cyclopent-3- norbornenyl, norbornen-1-yl, norbornen-2-yl, norbornen-5-yl, and nor The cycloalkenyl group may be unsubstituted or It may be substituted as described for cycloalkyl (e.g., optionally substituted). substituted cycloalkenyl).

[0281] As used herein, the term "cycloalkenylalkyl" refers to any group as defined herein. The cycloalkenyl group represents an alkyl group substituted with a cycloalkenyl group, as defined above. and alkyl moieties may be substituted as individual groups as defined herein.

[0282] As used herein, the term "cycloalkenylene" refers to a group in which one hydrogen atom has a valence Cycloalkenylene represents a divalent group that is a cycloalkenyl group substituted with Cycloalkyl may be optionally substituted as described herein. A non-limiting example of a cycloalkenylene is cycloalkene-1,3-diyl.

[0283] As used herein, the term "cycloalkoxy" refers to a chemical substituent of formula -OR. wherein R is a cycloalkyl group unless otherwise specified. wherein the cycloalkyl group is further substituted as defined herein. Good too.

[0284] As used herein, the term "cycloalkyl" means a group consisting of 3 to 1 alkyl groups, unless otherwise specified. Cyclic alkyl groups with 0 carbons (e.g., C3-C 10 It refers to cycloalkyl. The alkyl group may be monocyclic or bicyclic. Bicyclic cycloalkyl groups include bicyclo[pq .0] alkyl type, where each of p and q is independently 1, 2, 3, 4, 5 , 6, or 7, provided that the sum of p and q is 2, 3, 4, 5, 6, 7, or 8. Cyclic cycloalkyl groups include bridged cycloalkyl structures, such as bicyclo[pqr]alkyl. wherein r is 1, 2, or 3; and each of p and q is independently 1, 2, or 3. , 3, 4, 5, or 6, provided that the sum of p, q, and r is 3, 4, 5, 6, 7, or 8. The cycloalkyl group may be a spirocyclic group, e.g., spiro[pq]alkyl, wherein where p and q are each independently 2, 3, 4, 5, 6, or 7, provided that the sum of p and q is 4, 5, , 6, 7, 8, or 9. Non-limiting examples of cycloalkyl include cyclopropyl, ... Cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-bicyclo[2.2.1.]heptyl butyl, 2-bicyclo[2.2.1.]heptyl, 5-bicyclo[2.2.1.]heptyl, 7-bicyclo[2.2.1.]heptyl .]heptyl, and decalinyl. The cycloalkyl groups are unsubstituted or alkyl; alkenyl; alkynyl; alkoxy; alkylsulfinyl; alkoxy alkylsulfenyl; alkylsulfonyl; amino; aryl; aryloxy; azido; cyclo Alkyl;Cycloalkoxy;Cycloalkenyl;Cycloalkynyl;Halo;Heteroalkyl; Heterocyclyl; (heterocyclyl)oxy; hydroxy; nitro; thiol; silyl; cyano; = The group consisting of: O; ═S; ═NR′ (R′ is H, alkyl, aryl, or heterocyclyl): and optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from , optionally substituted cycloalkyl). Each of the substituents may itself be unsubstituted. or substituted with unsubstituted substituents as defined herein for each respective group. It may be replaced.

[0285] As used herein, the term "cycloalkylalkyl" refers to any group as defined herein. The cycloalkyl and alkyl groups are substituted with each other. The alkyl moiety may be optionally substituted as the individual groups described herein.

[0286] As used herein, the term "cycloalkylene" refers to a group of cycloalkylenes in which one hydrogen atom is valenced. represents a divalent group that is a substituted cycloalkyl group. A typical example is cycloalkane-1,3-diyl. and optionally substituted as described herein.

[0287] As used herein, the term "cycloalkynyl" means, unless otherwise specified, 1 or a monovalent carbocyclic group having two carbon-carbon triple bonds and 8 to 12 carbons The cycloalkynyl may contain one transannular bond or bridge. Non-limiting examples include cyclooctynyl, cyclononynyl, cyclodecynyl, and cyclohexyl. The cycloalkynyl group may be unsubstituted or substituted, and may be substituted with cycloalkynyl or cyclohexyl. or optionally substituted as defined for cycloalkyl (e.g., optionally substituted cycloalkynyl).

[0288] As used herein, the term "dihydropyridazine group" refers to a 1,2,4,5-tetrazine group. represents a divalent radical obtained via cycloaddition between and a strained cycloalkenyl.

[0289] As used herein, the term "halo" refers to an alkyl group selected from bromine, chlorine, iodine, and fluorine. represents the halogen selected.

[0290] As used herein, the term "5-halouridine" refers to a nucleobase having the following structure: represents the nucleoside 5-halouracil: [ka] wherein R is a bond to the anomeric carbon of the pentafuranose of the nucleoside; and X is fluoro, chloro, bromo, iodo). In some embodiments, X is It is bromo or iodo.

[0291] As used herein, the term "heteroalkane-tetrayl" refers to an alkyl group containing one heteroatom. once by one heteroatom; twice, each time independently by one heteroatom; an alkyl group interrupted three times, independently each time; or four times, independently each time, by one heteroatom; Each heteroatom is independently O, N, or S. In embodiments, the heteroatom is O or N. Unsubstituted C X-Y Heteroalkane-tetra The alkyl group contains X to Y carbon atoms and heteroatoms as defined herein. The tetraalkane-tetrayl group may be unsubstituted or may be substituted with a heteroalkyl group. and optionally substituted as described (e.g., optionally substituted heteroalkane- Tetrayl).

[0292] As used herein, the term "heteroalkane-triyl" refers to an alkyl group having one heteroatom. Therefore, once; by one heteroatom, each time independently, twice; by one heteroatom, each time independently an alkane interrupted three times independently; or four times independently by one heteroatom -triyl group. Each heteroatom is independently O, N, or S. In embodiments, the heteroatom is O or N. Unsubstituted C X-Y Heteroalkane-triyl The heteroatom contains X to Y carbon atoms and heteroatoms as defined herein. The can-triyl group may be unsubstituted or substituted as described for heteroalkyl. and optionally substituted as desired (e.g., optionally substituted heteroalkane-triyl). ).

[0293] As used herein, the term "heteroalkyl" refers to an alkyl group containing one or two heteroatoms. once by one or two heteroatoms; twice by one or two heteroatoms; three times independently by a heteroatom; or three times independently by one or two heteroatoms , refers to an alkyl, alkenyl, or alkynyl group that is interrupted four times. The heteroatoms are independently O, N, or S. In some embodiments, the heteroatoms are O or is N. No heteroalkyl group contains two adjacent oxygen or sulfur atoms. The heteroalkyl group may be unsubstituted or substituted (e.g., For example, optionally substituted heteroalkyl). When heteroalkyl is substituted and the substituent When attached to a heteroatom, the substituent may be any group depending on the nature and valence of the heteroatom. Thus, substituents attached to heteroatoms may be selected as ═O, if valence allows. , -N(R N2)2, -SO2OR N3 , -SO2R N2 , -SOR N3 , -COOR N3 , N-protecting group, alkyl, alkenyl, Alkynyl, aryl, cycloalkyl, cycloalkenyl, cycloalkynyl, hetero cyclyl, or cyano, wherein each R N2 are independently, H, Al alkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, or heterocyclo Krill and each R N3 are independently alkyl, cycloalkyl, cycloalkenyl Each of these substituents is aryl, cycloalkynyl, aryl, or heterocyclyl. , which may themselves be unsubstituted or substituted as defined herein for each respective group. Heteroalkyl may be substituted with unsubstituted substituents as defined above. and when a substituent is attached to a carbon, the substituent may be any of the substituents described for alkyl. provided that the substituent on the carbon atom attached to the heteroatom is either Cl or Br. It is understood that the carbon atom is found at the terminus of a heteroalkyl group. .

[0294] As used herein, the term "heteroaryloxy" refers to a heteroaryl group where R is heteroaryl. Heteroaryloxy is defined as for heterocyclyl. It may be optionally substituted as desired.

[0295] As used herein, the term "heterocyclyl" means a fused heterocyclic ring, unless otherwise specified. or a bridged 5-, 6-, 7-, or 8-membered ring, and Monocyclic, bicyclic, tricyclic, or tetracyclic rings containing 1, 2, 3, or 4 heteroatoms The heterocyclyl may be aromatic or non-aromatic. Tetracyclyl has zero or one double bond, and non-aromatic 6- and 7-membered heterocyclyl groups are A non-aromatic 8-membered heterocyclyl group has 0 to 2 double bonds and / or Heterocyclyl groups have zero or one carbon-carbon triple bond, unless otherwise specified. and contain 1 to 16 carbon atoms. Certain heterocyclyl groups can contain up to 9 carbon atoms. Non-aromatic heterocyclyl groups include pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolinyl, Lazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, homopiperidinyl, Piperazinyl, pyridazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl , thiomorpholinyl, thiazolidinyl, isothiazolidinyl, thiazolidinyl, tetrahydrofuran Drofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, dihydro Indolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, pyranyl, dihydropyranyl Heterocyclic ring systems with at least one aromatic resonance include thiazolyl, thiazolyl, and dithiazolyl. When a compound has a structure or at least one aromatic tautomer, such a structure is Non-limiting examples of heteroaryl groups include tetracyclyl (i.e., heteroaryl). Examples include benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, and benzo Oxazolyl, furyl, imidazolyl, indolyl, isoindazolyl, isoquinolinyl , isothiazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl quinazolinyl, purinyl, pyrrolyl, pyridinyl, pyrazinyl, pyrimidinyl, quinazolinyl olinyl), quinolinyl, thiadiazolyl (e.g., 1,3,4-thiadiazole), thiazolyl, Examples include thienyl, triazolyl, and tetrazolyl. The term refers to a ring in which one or more carbon and / or heteroatoms bridge two non-adjacent members of a monocyclic ring. Heterocyclic compounds having a bridged polycyclic structure, such as quinuclidine, tropane, or It also refers to diaza-bicyclo[2.2.2]octane. The term "heterocyclyl" refers to the above heterocyclic groups. Any of the bicyclic rings may be one, two, or three carbocyclic rings, e.g., aryl rings, cyclohexyl rings, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring, or another monocyclic heterocyclic ring Examples of fused heterocyclyls include bicyclic, tricyclic, and tetracyclic groups fused to a bicyclic ring. 1,2,3,5,8,8a-hexahydroindolizine; 2,3-dihydrobenzofuran; 2,3- dihydroindole; and 2,3-dihydrobenzothiophene. The alkyl group may be unsubstituted or may be substituted with alkyl; alkenyl; alkynyl; alkoxy; Alkyl sulfinyl; Alkyl sulfenyl; Alkyl sulfonyl; Amino; Aryl; A Aryloxy; Azido; Cycloalkyl; Cycloalkoxy; Cycloalkenyl; Cycloalkenyl Quinyl;Halo;Heteroalkyl;Heterocyclyl;(Heterocyclyl)oxy;Hydroxy;Nitro thiol; silyl; cyano; =O; =S; =NR' (where R' is H, alkyl, aryl, or or heterocyclyl): 1, 2, 3, 4, or 5 independently selected from the group consisting of Each of the substituents may be unsubstituted or substituted. or substituted with unsubstituted substituents as defined herein for each respective group. It may be done.

[0296] As used herein, the term "heterocyclylalkyl" refers to any group as defined herein. The heterocyclyl and alkyl groups are substituted with each other. The alkyl moiety may be optionally substituted as the individual groups described herein.

[0297] As used herein, the term “(heterocyclyl)aza” refers to a heterocyclyl group of the formula —N(R N1 )(R N2 ) Chemistry represents a substituent, N1 is a heterocyclyl group, and R N2 are H, -OH, -NO2, -N(R N2 )2, -SO2OR N2 , -SO2R N2 , -SOR N2 , -COOR N2 , N-protecting group, alkyl, alkenyl, alkyl aryl, alkoxy, aryl, arylalkyl, aryloxy, cycloalkyl, cycloalkyl Preferably, R is chloroalkenyl, heteroalkyl, or heterocyclyl. N2 is H be.

[0298] As used herein, the term "heterocyclylene" refers to a heterocyclylene in which one hydrogen atom is valenced. The heterocyclylene represents a substituted heterocyclyl group. The heterocyclylene may be optionally substituted as described above. A typical example is heterocycle-1,3-diyl.

[0299] As used herein, the term "(heterocyclyl)oxy" refers to a chemical substituent of formula -OR. where R is a heterocyclyl group unless otherwise specified. )oxy may be optionally substituted as described for heterocyclyl .

[0300] The terms "hydroxyl" and "hydroxy" are used interchangeably herein and refer to -O Represents the H group.

[0301] As used herein, the term "immunomodulatory polynucleotide" refers to an internucleoside linker. and optionally an internucleoside abasic spacer, independently selected from the group consisting of: A total of 6 to 50 consecutive nucleosides covalently linked by internucleoside bridging groups The present invention also relates to a polynucleotide construct containing a nucleotide sequence of the immunomodulatory polynucleotide. The nucleotides are capped at the 5'- and 3'-ends by 5'- and 3'-capping groups, respectively. The immunomodulatory polynucleotide may be, for example, in antigen-presenting cells that have been delivered (e.g., other antigens to which the immunomodulatory polynucleotide has not been delivered). Changes in NFκB activation (compared to the original presentation cells) or at least one inflammatory cytokine or autoimmune disease, as determined by altered secretion of at least one type I interferon. The immunomodulatory polynucleotide is capable of modulating the innate immune response. When a polynucleotide is part of a conjugate, it may be combined with a targeting moiety and optionally one or more (e.g., linkers attached to auxiliary moieties (e.g., polyethylene glycol) The conjugated group or the linker may contain a phosphotriester or end-capping group. It can be a part.

[0302] As used herein, the term "immunostimulatory polynucleotide" refers to, e.g., an immunostimulatory In antigen-presenting cells to which the polynucleotide has been delivered (e.g., immunostimulatory polynucleotides), Increased activation of NFκB or at least Increased secretion of one inflammatory cytokine or at least one type I interferon Immunomodulatory polynucleotides capable of activating an innate immune response as determined by In some embodiments, the immunostimulatory polynucleotide represents at least one Cytidine-p-guanosine (CpG) sequences (where p is an internucleoside phosphodiester (e.g. phosphate or phosphorothioate) or internucleoside phosphotriester As used herein, CpG refers to a CpG fragment containing a CpG amino acid sequence that is a CpG amino acid sequence or a CpG phosphothiotriester. The immunostimulatory polynucleotides may be naturally occurring, such as CpG ODNs of bacterial or viral origin. For example, in some embodiments, In this case, the CpG sequence in the immunostimulatory polynucleotide contains 2'-deoxyribose. In some embodiments, the CpG sequences in the immunostimulatory polynucleotide are methylated. In some embodiments, the immunostimulatory polynucleotide is not In some embodiments, the immunostimulatory The polynucleotide is an oligonucleotide of formula (B) provided herein.

[0303] As used herein, the term "immunosuppressive polynucleotide" refers to a polynucleotide that is capable of inhibiting, e.g., In antigen-presenting cells to which the polynucleotide has been delivered (e.g., immunosuppressive polynucleotides), Decreased activation of NFκB or at least Decreased secretion of one inflammatory cytokine or at least one type I interferon and immunomodulatory polynucleotides capable of suppressing an innate immune response as determined by represent.

[0304] As used herein, the term "internucleoside bridging group" refers to an internucleoside phosphate Represents an ester or internucleoside abasic spacer.

[0305] As used herein, the term "5-modified cytidine" refers to a nucleobase having the following structure: represents a nucleoside that is: [ka] wherein R is a bond to the anomeric carbon of the pentafuranose of the nucleoside; and X is halogen, alkynyl, alkenyl, alkyl, cycloalkyl, heterocyclyl In some embodiments, the 5-modified cytidine is a 5-halocytidine. In other embodiments, the cytidine is 5-iodocytidine or 5-bromocytidine. The 5-modified cytidine is a 5-alkynylcytidine.

[0306] As used herein, the term "5-modified uridine" refers to a nucleobase having the following structure: represents a nucleoside that is: [ka] wherein R is a bond to the anomeric carbon of the pentafuranose of the nucleoside; and X is halogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl , or aryl, with the proviso that the 5-modified uridine is not thymidine). In embodiments, the 5-modified uridine is a 5-halouridine (e.g., 5-iodouridine or 5 In another embodiment, the 5-modified uridine is a 5-alkynyl uridine. In some embodiments, the 5-modified uridine contains 2-deoxyribose. It is a nucleoside having the following structure:

[0307] The term "nitro" as used herein refers to the group --NO.sub.2.

[0308] As used herein, the term "non-bioreversible" refers to a molecule present inside an endosome. refers to a chemical group that is resistant to degradation under certain conditions. Non-bioreversible groups include thioesters and / or Does not contain disulfides.

[0309] As used herein, the term "nucleobase" refers to a nucleotide or nucleoside. The nucleobase represents a nitrogen-containing heterocyclic ring attached to the 1'-position of the sugar moiety of the As used herein, "unmodified" or "natural" refers to a molecule that is naturally occurring or unmodified. Nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases These include thymine (T), cytosine (C), and uracil (U). Modified nucleobases include other compounds. Synthetic and natural nucleobases, such as 5-methylcytosine (5-me-C or m5c), 5-hydroxymethylcytosine (5-me-C or m5c), Cytosine, xanthine, hypoxanthine, 2-aminoadenine, adenine and guanine 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other derivatives of adenine and guanine alkyl derivatives of 2-thiouracil, 2-thiothymine, and 2-thiocytosine, 5-halouracil uracil and cytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine, and Thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thio alkyl, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo , in particular 5-iodo, 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and silyl groups. uracil, 5-alkynyl (e.g., 5-ethynyl)uracil, 5-acetamidouracil, 7-methyluracil, Chiruguanine, 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine These include guanine and 7-deazaadenine, as well as 3-deazaguanine and 3-deazaadenine. Additional nucleobases include those disclosed in U.S. Pat. No. 3,687,808; polymers; The Concise Encyclopedia of Polymer Science and Engineering Engineering), pp. 858-859, edited by Kroschwitz, JI, John Wiley & Sons, 1990 Englisch et al., Angewandte Chemie, International Edition, 1991 , 30, 613; and Sanghvi, YS, Chapter 15, Antisense Research and Applications (Antisense Research and Applications), pp. 289-302 (Crooke et al., eds., CRC Pr ess, 1993). 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and O-6 substituted purines, including 2-aminopropynyl adenine, 5-propynyl purines, Certain nucleobases, including cytosine, 5-propynylcytosine, and 5-propynylcytosine, are useful in the hybridization of the present invention. It is particularly useful for increasing the binding affinity of soybean polynucleotides. Tosine substitution has been shown to increase the stability of nucleic acid duplexes by 0.6-1.2°C (Sanghvi , Antisense Research and Applications, 1993, CRC P Ress, Boca Raton, pp. 276-278. These include, in certain embodiments, 2'-O-methoxyl groups. These modified nucleobases and other modified nucleobases can be combined with methyl sugar modifications. U.S. patents that teach the preparation of some of the cleobases include U.S. Pat. No. 3,688,562, cited above. No. 7,808; No. 4,845,205; No. 5,130,302; No. 5,134,066; No. 5,175,273; No. 5,367,066; No. No. 5,432,272; No. 5,457,187; No. 5,459,255; No. 5,484,908; No. 5,502,177; No. 5,525,711 No. 5,552,540; No. 5,587,469; No. 5,594,121; No. 5,596,091; No. 5,614,617; and No. 5 For purposes of this disclosure, the following references are intended to be illustrative and not restrictive: The "modified nucleobases" used may further include one or more protecting groups as described herein. It represents natural or unnatural nucleobases.

[0310] As used herein, the term "nucleoside" refers to a pentafuranose-nucleoside salt. The pentafuranose represents a combination of groups. The 2-position of the pentafuranose is OR, R, halo (e.g., F), SH, SR, N H, NHR, NR, or CN, where R is an optionally substituted C 1-6 Alkyl ( For example, C 1-6 Alkyl or (C 1-6 Alkoxy)-C 1-6 -alkyl) or optionally substituted ( C 6-14 Aryl)-C 1-4 -alkyl, 2-deoxyribose or modified forms thereof. In an embodiment, position 2 is substituted with OR or F, wherein R is C 1-6 Alkyl or ( C 1-6 -alkoxy)-C 1-6 The pentafuranose is nucleophilic at the anomeric carbon. In some embodiments, the term "nucleoside" refers to a refers to a divalent group having the structure: [ka] (where B 1 is a nucleobase; Y is H, halogen (e.g., F), hydroxyl, Optionally substituted C 1-6 Alkoxy (e.g., methoxy or methoxyethoxy), or protected hydroxyl group; Y 1 is H or C 1-6 alkyl (e.g., methyl); and Each of the 3' and 5' indicates the point of attachment to another group).

[0311] As used herein, the term "nucleotide" refers to a phosphate, phosphorothioate, or It refers to a nucleoside linked to a thiol, thiol, thiol-, or thiol-phosphorodithioate.

[0312] As used herein, the term "oxo" refers to a divalent oxygen atom (e.g., oxo The structure may be depicted as =O).

[0313] As used herein, the term "patient" refers to a human or non-human animal (e.g., a mammal). In some embodiments, the subject is a clinically relevant sample from a patient. With or without a floor examination, a qualified professional (e.g., a physician or nurse practitioner) Having a tumor (e.g., liquid tumor or solid tumor) as determined by the That's fine.

[0314] The term "Ph" as used herein refers to phenyl.

[0315] As used herein, the term "phosphate ester" refers to a phosphate group in which at least one valence is non- Covalently bonded to a hydrogen substituent, provided that at least one non-hydrogen substituent is phosphate, phosphorothioate, or phosphorothioate, which are nucleoside-containing groups of Represents a dithioate-containing group. Only one valence is shared by the nucleoside-containing group. The bound phosphate is the terminal phosphate. A phosphate covalently linked to a phosphate-containing group is an internucleoside phosphate. The phosphate ester may be a group of the following structure: [ka] (where, X E1 and X E2 each is independently O or S; R E1 and R E3 each independently represents hydrogen or a bond to a nucleoside; an abasic spacer sugar analogues of; bioreversible groups; non-bioreversible groups; auxiliary moieties; conjugation groups; and targeting moieties. a linker connecting the targeting moiety and one or more (e.g., 1 to 6) auxiliary moieties; or is the formula -P(=X E1 )(-X E2 -R E2A )-O- group, where R E2A is hydrogen, bioreversible group, non-bioreversible group, auxiliary moiety, conjugation group, targeting moiety a linker attached to a targeting moiety or a linker attached to a targeting moiety and one or more (e.g., 1 to 6) auxiliary moieties a linker that binds to the R E2 is attached to hydrogen, bioreversible groups, non-bioreversible groups, auxiliary moieties, conjugated groups, and targeting moieties a linker linking the targeting moiety and one or more (e.g., 1 to 6) auxiliary moieties; a linker; However, R E1 and R E3 At least one of the amino acids contains at least one nucleoside. (The bond is to a group that is R E1 and R E3 each independently being linked to at least one nucleoside-containing group In some cases, the phosphate is an internucleoside phosphate. E1 and R E3 Of If one of the bonds is to a non-nucleoside-containing group, the phosphate ester is It is an acid ester.

[0316] As used herein, the term "phosphodiester" refers to a group of esters in which two of the three valencies are phosphate esters substituted with non-hydrogen substituents while the remaining valences are replaced with hydrogen Phosphodiester refers to phosphate, phosphorothioate, or phosphorodithioate. oate; one or two bonds with a nucleoside, an abasic spacer, and / or a phosphoryl group and the phosphodiester is a nucleoside, an abasic spacer, or a phosphoryl group. When the compound contains only one bond of the following: bioreversible group; non-bioreversible group; auxiliary moiety; conjugate group; target a linker connecting the targeting moiety; and the targeting moiety and one or more (e.g., 1 to 6) auxiliary moieties. The terminal phosphonate is a linker bonded to a group independently selected from the group consisting of: The diesters are nucleoside-containing groups, as well as bioreversible groups; non-bioreversible groups; auxiliary groups. a conjugation group; a phosphoryl group; and a targeting moiety and optionally one or more (e.g., 1 to 6) auxiliary moieties. The nucleic acid molecule comprises one bond to a group selected from the group consisting of a linker bonded to a nucleic acid molecule. An internucleoside phosphodiester contains two bonds to a nucleoside-containing group. The ter may be a group of the following structure: [ka] (where, X E1 and X E2 each is independently O or S; R E1 and R E3 each independently represents hydrogen or a bond to a nucleoside; an abasic spacer sugar analogues of; bioreversible groups; non-bioreversible groups; auxiliary moieties; conjugation groups; and targeting moieties. a linker connecting the targeting moiety and one or more (e.g., 1 to 6) auxiliary moieties; or is the formula -P(=X E1 )(-X E2 -R E2A )-O- group, where R E2A is hydrogen, bioreversible group, non-bioreversible group, auxiliary moiety, conjugation group, targeting moiety a linker attached to a targeting moiety or a linker attached to a targeting moiety and one or more (e.g., 1 to 6) auxiliary moieties a linker that binds to the R E2 is attached to hydrogen, bioreversible groups, non-bioreversible groups, auxiliary moieties, conjugated groups, and targeting moieties a linker linking the targeting moiety and one or more (e.g., 1 to 6) auxiliary moieties; a linker; However, R E1 , R E2 , and R E3 is hydrogen; and However, R E1 and R E3 At least one of the amino acids contains at least one nucleoside. (The bond is to a group that is

[0317] R E1 and R E3 When both of the groups are bonds with at least one nucleoside-containing group, A phosphodiester is an internucleoside phosphodiester. E1 and R E3 Only one of If one of the bonds is to a nucleoside-containing group, the phosphodiester is the terminal phosphodiester. It is an ester.

[0318] As used herein, the term "phosphoryl" refers to a group of the formula -P(=X E1 )(-X E2 -R E2A )-OR E3A of refers to a substituent, where: X E1 and X E2 each is independently O or S; R E2A is attached to hydrogen, bioreversible groups, non-bioreversible groups, auxiliary moieties, conjugated groups, and targeting moieties a linker linking the targeting moiety and one or more (e.g., 1 to 6) auxiliary moieties; a linker; and R E3Ais hydrogen or an open valence.

[0319] When a group is specified as being attached to a phosphoryl, the group is attached to the phosphorus atom of the phosphoryl. It is bonded.

[0320] As used herein, the term "phosphotriester" refers to a phosphoester in which all three valencies are non-aqueous. The phosphotriester refers to a phosphate ester substituted with a phosphate group. nucleotides, phosphorothioates, or phosphorodithioates; nucleosides or abasic species one or two bonds to the enzyme, and / or a phosphoryl group; and a bioreversible group; a non-bioreversible group. a reversible group; an auxiliary moiety; a conjugated group; and a targeting moiety and optionally one or more (e.g., 1 to 6) auxiliary moieties. The terminal end of the linker is one or two groups independently selected from the group consisting of Phosphotriesters are nucleoside-containing groups, as well as bioreversible groups; non-bioreversible groups. a group; an auxiliary moiety; a conjugate group; a phosphoryl group; and a targeting moiety and optionally one or more (e.g., 1 to 6) and a linker bonded to the auxiliary moiety of In some embodiments, the terminal phosphotriester is a phosphodiester that is a phosphodiester containing a targeting moiety and an optional phosphotriester. Optionally, it contains one or zero linkers attached to one or more (eg, 1-6) auxiliary moieties. An internucleoside phosphotriester contains two bonds to a nucleoside-containing group. The phototriester may be a group of the following structure: [ka] (where, X E1 and X E2 each is independently O or S; R E1 and R E3each independently comprising: a nucleoside; a sugar analog of an abasic spacer; a bioreversible a non-bioreversible group; an auxiliary moiety; a conjugate group; a linker attached to a targeting moiety; a targeting moiety and and a linker connecting one or more (e.g., 1 to 6) auxiliary moieties; or a linker of the formula -P(=X E1 )(-X E2 -R E2A )-O- group to the phosphorus atom, where R E2A represents hydrogen; bioreversible group; non-bioreversible group; auxiliary moiety; conjugation group; targeting moiety. or a linker attached to a targeting moiety and one or more (e.g., 1 to 6) auxiliary moieties a linker that R E2 The term "bioreversible group" refers to a group consisting of: a bioreversible group; a non-bioreversible group; an auxiliary moiety; a conjugated group; a linker bonded to a targeting moiety. or a linker connecting a targeting moiety and one or more (e.g., 1 to 6) auxiliary moieties. can be; However, R E1 and R E3 At least one of the amino acids contains at least one nucleoside. (The bond is to a group that is R E1 and R E3 When both of the groups are bonds with at least one nucleoside-containing group, Phosphotriesters are internucleoside phosphotriesters. E1 and R E3 Our If only one of the bonds is to a nucleoside-containing group, the phosphotriester is It is a suphotriester.

[0321] As used herein, the term "physiological conditions" refers to the conditions experienced by professional mammals in living mammals. The physiological conditions refer to the conditions that can exist inside a naive antigen-presenting cell. These include temperature and an aqueous pH of about 6 to about 8.

[0322] As used herein, the term "protecting group" refers to a group that is a hydroxy, amino, or carbonyl represents a group intended to protect from participating in one or more undesired reactions during chemical synthesis. As used herein, the term "O-protecting group" refers to a group that protects a hydroxy or carbonyl group. represents a group intended to protect a compound from participating in one or more undesired reactions during chemical synthesis. As used herein, the term "N-protecting group" refers to a nitrogen-containing (e.g., amino or hydra) The hydroxyl group is intended to protect the hydroxyl group from participating in one or more undesired reactions during chemical synthesis. represents a group. Commonly used O- and N-protecting groups are incorporated herein by reference. Greene, "Protective Groups in Organic Synthesis" , 3rd Edition (John Wiley & Sons, New York, 1999). Exemplary O- and N-protected The groups include alkanoyl, aryloyl, or carbamyl groups, for example, formyl, acetonitrile, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl acetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl butyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, t- Butyldimethylsilyl, tri-isopropylsilyloxymethyl, 4,4'-dimethoxytri ethyl, isobutyryl, phenoxyacetyl, 4-isopropyl phenoxyacetyl (pehenox yacetyl), dimethylformamidino, and 4-nitrobenzoyl.

[0323] Exemplary O-protecting groups for protecting carbonyl-containing groups include: acetals, acylates, Examples of suitable amines include 1,3-dithiane, 1,3-dioxane, 1,3-dioxolane, and 1,3-dithiolane. However, it is not limited to these.

[0324] Other O-protecting groups include: substituted alkyl, aryl, and aryl-alkyl ethers (e.g., For example, trityl; methylthiomethyl; methoxymethyl; benzyloxymethyl; siloxymethyl 2,2,2-Trichloroethoxymethyl;Tetrahydropyranyl;Tetrahydrofuranyl;Ethyl 1-[2-(trimethylsilyl)ethoxy]ethyl; 2-Trimethylsilylethyl; t-Butyl ether; p-chlorophenyl, p-methoxyphenyl, p-nitrophenyl, benzene silyl, p-methoxybenzyl, and nitrobenzyl); silyl ethers (e.g., trimethylsilyl Silyl; Triethylsilyl; Triisopropylsilyl; Dimethylisopropylsilyl; t-Butyl butyldimethylsilyl; t-butyldiphenylsilyl; tribenzylsilyl; triphenylsilyl and diphenylmethylsilyl); carbonates (e.g., methyl, methoxymethyl, 9-fluoro Oleylmethyl; Ethyl; 2,2,2-Trichloroethyl; 2-(Trimethylsilyl)ethyl; Vinyl , allyl, nitrophenyl; benzyl; methoxybenzyl; 3,4-dimethoxybenzyl; and nitrobenzyl), but not limited to

[0325] Other N-protecting groups include chiral auxiliaries, such as protected or unprotected D, L, or D, L-amino acids, such as alanine, leucine, phenylalanine, etc.; sulfonyl-containing groups such as benzenesulfonyl, p-toluenesulfonyl, etc.; carbamate-forming groups; For example, benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl p-Nitrobenzyloxycarbonyl, p-Nitrobenzyloxycarbonyl, 2-Nitrobenzyloxy Carbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl 4-Methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxy Carbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methyl methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, Benzhydryloxycarbonyl, t-butyloxycarbonyl, diisopropylmethoxy Carbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl , allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyl butyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl aryl-alkyl groups such as benzyl, triflate, and the like; phenylmethyl, benzyloxymethyl, etc., and silyl groups, for example, trimethylsilyl, etc. Useful N-protecting groups include, but are not limited to, formyl, acetyl, phenyl, etc. benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).

[0326] As used herein, the term "pyrid-2-ylhydrazone" refers to a group of the following structure: represent: [ka] wherein each R' is independently H or an optionally substituted C 1-6 (Alkyl). Pyrido-2- The ylhydrazone may be unsubstituted (ie, each R' is H).

[0327] As used herein, the term "stereochemically enriched" refers to a group of recited groups. Indicates the local stereochemical preference of a stereoisomeric configuration over the opposite stereoisomeric configuration of the same group. Therefore, stereochemically condensed phosphorothioate-containing polynucleotides The phosphorothioates of a given stereochemistry are preferred over phosphorothioates of the opposite stereochemistry. This preference is based on the fact that for phosphorothioates of a given stereochemistry, The diastereomeric ratio of a given phosphorothioate can be expressed numerically. The diastereomeric ratio for the oates is determined by the specific phosphoroates with a given stereochemistry. The diastereomers with thioates are identified as phosphorothioates with opposite stereochemistry. The molar ratio of the diastereomer with a given stereochemistry to the diastereomer with a given phosphorothioate is The diastereomeric ratio for the oates is 1.1 or greater (e.g., 4 or greater, 9 or greater, 19 or greater, or can be 39 or more).

[0328] As used herein, the term "Q-tag" refers to a compound containing an -NH2 amine. and providing a conjugate containing a portion of the polypeptide upon insu-glutaminase-mediated reaction. "glutamine" refers to a portion of a polypeptide containing a glutamine residue comprising: Q-tags are known in the art as containing amide-modified side chains attached to the compound. Non-limiting examples of Q-tags are LLQGG and GGGLLQGG.

[0329] As used herein, the term "strained cycloalkenyl" refers to a group in which an open valence is replaced with H. Cycloalkenyl groups that, when substituted, have a ring strain energy of at least 16 kcal / mol Refers to...

[0330] As used herein, the term "sugar analog" refers to a sugar analog that has two hydroxyl groups replaced by phosphate groups. the oxygen atom in the capping group, phosphorothioate, or phosphorodithioate C modified to replace the bond to the hydroxyl group 3-6 Monosaccharide or C 3-6 Alditols (e.g. The sugar analogs represent divalent or trivalent groups (such as glycerol, hydroxyl ... Sugar analogs do not contain nucleobases that can participate in hydrogen bonding. Further optional modifications that can be included in the sugar analogues include: the remaining hydroxyl groups or carbons One, two, or three of the bonded hydrogen atoms and H; optionally substituted C 1-6 alkyl; Defined - Link A (-T) p ;Conjugated group;-(CH2) t1 -OR Z (where t1 is an integer from 1 to 6, And R Z is an arbitrarily substituted C 1-6 Alkyl, optionally substituted C 2-6 alkenyl, optionally substituted Replaced C 2-6 Alkynyl, optionally substituted C 6-14 Aryl, optionally substituted C3-8 Shik alkyl, optionally substituted (C 1-9 Heterocyclyl)-C 1-6 -alkyl, optionally substituted (C 6-10 Aryl)-C 1-6 -alkyl, or optionally substituted (C 3-8 Cycloalkyl)-C 1-6 -a the introduction of one or two unsaturations (e.g., one or two double bonds); and One, two, or three hydrogen or hydroxyl groups and an alkyl, alkenyl, cycloalkyl, or cycloalkyl group. Substitution with the substituents defined for chloroalkenyl or heterocyclyl. Non-limiting examples of analogs include optionally substituted C 2-6 Alkylene, optionally substituted C 2-6 Al cycloalkane-1,3-diyl, optionally substituted C5 cycloalkane-1,3-diyl, optionally substituted C5 cycloalkane-1,3-diyl alkene-1,3-diyl, optionally substituted heterocycle-1,3-diyl (e.g., optionally substituted pyrrolidine-2,5-diyl, optionally substituted tetrahydrofuran-2,5-diyl, or optionally substituted tetrahydrofuran-2,5-diyl substituted tetrahydrothiophene-2,5-diyl), or optionally substituted (C 1-4 Archi (C 3-8 cycloalkylene) (e.g., optionally substituted (C alkyl)-(C cycloalkylene) Ren)).

[0331] As used herein, the term "sulfide" refers to a divalent -S- or =S group. Fido is -SS-.

[0332] As used herein, the term "targeting moiety" refers to a moiety that targets a given target cell population (e.g., an antibody APCs (artificially expressed cells; e.g., professional APCs (e.g., B cells, pDCs, or macrophages) specifically bind to or react with a receptor or other receptor moiety associated with the phage a moiety (e.g., a small molecule, e.g., a carbohydrate) that is sexually associated with or complexed with The conjugates of the present invention contain a targeting moiety. The targeting moiety may be an antibody or or antigen-binding fragments or modified derivatives thereof (e.g., Fcabs or fusion proteins ( For example, it can be an scFv. The targeting moiety can be a polypeptide. Alternatively, the targeting moiety may be a small molecule (e.g., mannose) or a cluster of small molecules (e.g., The conjugates of the invention containing a targeting moiety can be a mannose cluster (e.g., a cluster of mannose). The gate is set to a K of less than 100 nM for the target to which the targeting moiety binds. d It can be shown that K d is the technology Using methods known in the art, for example, using surface plasmon resonance (SPR), for example, BIA Measurement was performed using the CORE™ system (GE Healthcare, Little Chalfont, the United Kingdom). It is determined.

[0333] As used herein, the term "1,2,4,5-tetrazine group" refers to a group of the formula: [ka] (wherein R' is an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted cycloalkyl, optionally substituted heterocyclyl; and R'' is optionally substituted optionally substituted alkylene, optionally substituted heteroalkylene, optionally substituted arylene, optionally substituted aryl ... substituted cycloalkylene, optionally substituted heterocyclylene, or a group -R a -R b -(child So, R a and R b each independently represents an optionally substituted alkylene, an optionally substituted heterocyclic group, optionally substituted aryl, optionally substituted cycloalkylene, if or optionally substituted heterocyclylene).

[0334] The term "therapeutic effect" refers to the effect of a pharmacologically active agent on a subject, particularly a mammal. It refers to local or systemic effects in animals, and more particularly in humans. in the diagnosis, cure, mitigation, treatment, or prevention of disease, or for any desired purpose in animals or humans "Absorbent" means any substance intended for use in the promotion of healthy physical and mental development and condition. The term "therapeutically effective amount" or "therapeutically effective dose" as used herein refers to the amount of the disease to be treated. Immunomodulation necessary to improve, treat, or at least partially arrest the symptoms The effective amount for this use is determined based on the severity of the disease. and the weight and general condition of the subject. can provide useful guidance regarding amounts useful for in vivo administration of pharmaceutical compositions, and The model can be used to determine effective dosages for the treatment of a particular disease.

[0335] The term "thiocarbonyl" as used herein refers to a C(=S) group.

[0336] As used herein, the term "thioheterocyclylene" refers to the group -SR-, wherein and R is heterocyclylene. Thioheterocyclylene is a heterocyclyl It may be optionally substituted as described.

[0337] The term "thiol" as used herein refers to a -SH group.

[0338] The term "treating" as used in the context of a disease or condition in a patient is intended to By administering the polynucleotide or conjugate of the invention to a patient, is intended to refer to obtaining a beneficial or desired result, e.g., a clinical result. The desired or anticipated result is relief or amelioration of one or more symptoms of a disease or condition; a decrease in the severity of the disease or condition; stabilization of the disease or condition (i.e., it does not get worse); Prevention; delay or slowing of the progression of a disease or condition; palliation of a disease or condition; and remission (whether partial or "Alleviating" a disease or condition means "alleviating" a condition, whether it is a generalized or total alleviation of the condition. , the extent or duration in the absence of treatment with the polynucleotide or conjugate of the present invention The severity and / or undesirable clinical symptoms of the disease or condition are reduced compared to the previous course. This means that the progression of the disease will be slower and / or the time course of progression will be slower.

[0339] As used herein, the term "triazolocycloalkenylene" refers to the ring atoms All of the atoms are carbon atoms and the bridgehead atoms are sp 2 1,2,3- fused to an 8-membered ring with hybridized carbon atoms Triazocycloalkenylene refers to a heterocyclylene containing a triazole ring. It may be optionally substituted as described for terocyclyl.

[0340] As used herein, the term "triazoloheterocyclylene" refers to at least one Heterocyclyls containing a 1,2,3-triazole ring fused to an eight-membered ring containing a heteroatom The bridgehead atom in a triazoloheterocyclylene is a carbon atom. Heterocyclylene is optionally substituted as described for heterocyclyl. That's fine.

[0341] "Immunomodulating polynucleotides," "immunostimulatory polynucleotides," "immunosuppressive polynucleotides" The terms "immunomodulatory polynucleotide," "antibody," and "conjugate" refer to immunomodulatory polynucleotides, respectively. and salts of the immunostimulatory polynucleotide, the immunosuppressive polynucleotide, and the conjugate. For example, "immunomodulatory polynucleotides," "immunomodulatory polynucleotides," "immunostimulatory polynucleotides," "immunosuppressive polynucleotides," and "conjugates" The term refers to the protonation of a phosphate, phosphorothioate, or phosphorodithioate. The neutral form (P-XH moiety, where X is O or S) and phosphate, phosphorothioate the deprotonated ionic form of the ester, or phosphorodithioate (PX - part, where , X is O or S). E1 , R E2 , and R E3 One of the Phosphoesters and phosphodiesters described as having multiple hydrogen atoms are The ester, phosphorothioate, or phosphorodithioate is in the deprotonated ionic form. It should be understood that the term "compound" encompasses salts present in various forms.

[0342] The terms "innate immune response" and "innate immunity" are art-recognized and are used to describe the immune response to pathogens. It refers to a non-specific defense mechanism initiated by the body's immune system when it recognizes body-associated molecular patterns. This involves various forms of cellular activity, including cytokine production and cell death via various pathways. As used herein, an innate immune response is one mediated by toll-like receptor 9 (TLR9). cellular responses to CpG-containing immunostimulatory polynucleotides mediated by the Although it is not known whether it is a steroid hormone, it is thought to be a steroid hormone that may increase the production of inflammatory cytokines (e.g., type I interferon or IL-10 production). activation of the NFκB pathway, increased proliferation, maturation, differentiation, and / or survival of immune cells; and In some cases, this includes the induction of cell apoptosis. Activation of innate immunity is a method known in the art. This can be detected using known methods, for example, by measuring (NF)-κB activation.

[0343] The terms "adaptive immune response" and "adaptive immunity" are art-recognized and It refers to the antigen-specific defense mechanism initiated by the body's immune system when it recognizes a target antigen, and includes: It includes both humoral and cell-mediated responses. As used herein, the adaptive immune response and cellular responses elicited and / or enhanced by CpG-containing immunostimulatory polynucleotides. In some embodiments, the immunostimulatory polynucleotide or portion thereof is antigen-specific. In another embodiment, the immunostimulatory polynucleotide is an antigenic target of the allergic adaptive immune response. Although the antigen is not the antigen target of the antigen-specific adaptive immune response, it nevertheless Activation of the adaptive immune response can be achieved by methods known in the art, e.g., by enhancing antigen-specific responses. using measurements of the level of specific antibody production or cytotoxicity mediated by antigen-specific cells. It can be detected.

[0344] The term "Toll-like receptor" (or "TLR") is art-recognized and originally is a pattern recognition receptor identified as a sensor of the innate immune system that recognizes microbial pathogens. TLRs are often referred to as "PAMPs" (pathogen-associated molecular patterns). Recognizes unique structures within microorganisms. Binding of ligands to TLRs initiates innate immune responses and / or initiates a cascade of intracellular signaling pathways that induce an adaptive immune response. As used, the term "toll-like receptor" or "TLR" refers to a toll-like receptor expressed by a cell. Also refers to functional fragments of TLR proteins. In humans, TLR-1, -2, -3, -4, -5, -6, and -7 Ten TLRs have been identified, including -1, -8, and -9, the contents of which are incorporated herein by reference in their entirety. D'Arpa and Leung, Adv. Wound Care, 6:330-343 (2017), incorporated herein by reference. The encoding human gene is known.

[0345] Toll-like receptor 9 (TLR9), also known as CD289 (cluster of differentiation 289), is a toll-like receptor (TLR) phagocytosis inhibitor. Du et al., the contents of which are incorporated herein by reference in their entirety. Eur. Cytokine Netw., 11:362-371(2000). TLR9 binds to dendritic cells (DCs), B lymphocytes, Expressed in immune system cells, including macrophages, natural killer cells, and other antigen-presenting cells TLR9 activation is a signal that bridges innate and adaptive immunity. Martinez-Campos et al., Viral Immunol., 30:98-105 (201 6); Notley et al., Sci. Rep., 7:42204 (2017); the contents of each of these are incorporated herein by reference. Natural TLR-9 agonists include unmethylated cytosine- Examples include guanine dinucleotide (CpG)-containing oligodeoxynucleotides (CpG ODN). TLR-9 ligands that find use in the present disclosure include naturally occurring or synthetic CpG ODNs, as well as other CpG-containing immunostimulatory polynucleotides and / or polypeptides provided herein. or immunoconjugates. Activation of the IL-1 receptor can be achieved by methods known in the art, such as mobilization of myeloid differentiation antigen 88 (MyD88), nuclear factor ( NF)-κB, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase ( Activation of MAPK signaling pathways, activation of interferon regulatory factor-7, and cytokines , e.g., type I interferon (IFN), interleukin (IL)-6, IL-10, and IL-12. the expression level of one or more of the above, one or more immune cell populations, e.g., NK cells, natural killer cells, - Activation of T cells, monocytes, and levels of cytotoxic lymphocyte (CTL) and T helper-1 (Th1) responses This can be detected using measurements of the level of immunoglobulin secretion and the level of immunoglobulin secretion.

[0346] As used herein, the term "TLR-expressing cells" refers to cells that express toll-like receptors and When toll-like receptors bind to agonists, they activate the toll-like receptor signaling pathway. The toll-like receptor is located on the cell surface and / or on one or more subunits of the cell. It can be expressed in the membrane of an intracellular compartment, e.g., an endosome or phagosome TLR-expressing cells may further express one or more cell surface antigens other than toll-like receptors. Immune cells express TLRs, and activation of the TLR signaling pathway in these immune cells contributes to the regulation of innate immunity. TLR signaling pathways activate immune responses and / or adaptive immune responses. Cells can help eliminate other diseased cells from the body. For example, cancer cells or virus-infected cells express TLRs, and TLR signaling in the diseased cells is Activation of the pathway can result in the death of the diseased cells, for example, through the induction of apoptosis. Examples of TLR9-expressing cells include dendritic cells (DCs), B cells, T cells, and Langerhans cells. These include cells, keratinocytes, mast cells, endothelial cells, myofibroblasts, and primary fibroblasts. The present invention is not limited to the following: When the cells express any toll-like receptor (e.g., TLR9), Determining whether a toll-like receptor is present can be accomplished by methods known in the art, for example, by assaying the mRNA of the toll-like receptor in the cell. This can be done using detection of

[0347] The term "immune cell" is art-recognized and as used herein , any cell involved in host defense mechanisms, e.g., cells that produce pro-inflammatory cytokines Immune cells refer to cells involved in tissue damage and / or disease pathogenesis. Examples of immune cells include T cells, B cells, natural killer cells, neutrophils, mast cells, macrophages, antigen-presenting cells ( APCs), basophils, and eosinophils.

[0348] The term "antigen-presenting cell" or "APC" is art-recognized and is used to describe specific Processing and presenting antigens for recognition by lymphocytes, e.g., T cells refers to a heterogeneous population of immune cells that mediate the cellular immune response. Exemplary Types of Antigens Presenting cells include, for example, B cells, monocytes, dendritic cells, and Langerhans cells. Professional antigen-presenting cells, as well as cells such as keratinocytes, endothelial cells, astrocytes, and Other antigen-presenting cells include cytos, fibroblasts, and oligodendrocytes. As used herein, the term "antigen-presenting cell" refers to, but is not limited to, , antigen-presenting cells found in vivo and in vitro cell cultures derived from in vivo cells As used herein, antigen-presenting cells include antigen-presenting cells that are artificially modified, e.g., to express a toll-like receptor (e.g., TLR9) or toll-like receptor Also included are APCs that have been genetically modified to regulate the expression levels of a specific receptor (e.g., TLR9).

[0349] The term "dendritic cell" or "DC" is art-recognized and refers to a specialized antigen-binding Human DCs are a heterogeneous population of receptor and antigen-presenting cells (APCs). Human DCs are divided into three major subsets: They are classified into plasmacytoid DCs (pDCs), myeloid DCs (mDCs), and monocyte-derived DCs (MDDCs). Curr. Opin. Immunol., 32:13-20 (2015); the contents of which are incorporated herein by reference in their entirety. DC subsets can be identified based on distinct TLR expression patterns. For example, the myeloid or "conventional" subset of DCs (mDCs), when stimulated, can produce T They express LR1-8 and a range of activation markers (e.g., CD80, CD86, MHC class I and II, CCR7 ), pro-inflammatory cytokines, and chemokines are produced. The result of the resulting expression is the priming of antigen-specific CD4+ and CD8+ T cells. DCs acquire an enhanced ability to take up antigens and present them in an appropriate form to T cells. The plasmacytoid subset of NDCs (pDCs) expresses TLR7 and TLR9 upon activation, resulting in the expression of N Resulting in activation of K cells and T cells.

[0350] As used herein, the term "antigen" includes both the innate and adaptive immune responses. As used herein, the term "antibody" refers to a molecule or antigenic fragment thereof that is capable of eliciting an immune response, including an immune response to an antigen. In some cases, antigens may be proteins, peptides, polysaccharides, lipids, nucleic acids, particularly RNA and DNA, nucleic acids, The substance can be a nucleotide, a nucleotide analog, or other biological or biochemical substance that induces an immune response. The term "stimulating" refers to the stimulation of immune cells in vivo in response to a stimulus such as an antigen. The immune response consists of a cellular immune response, e.g., T cell and macrophage stimulation, and a humoral immune response, e.g., For example, an immune response may consist of both B cell and complement stimulation and antibody production. using techniques well known in the art, including antibody immunoassays, proliferation assays, and others. It can be measured.

[0351] The terms "antigenic fragment" and "antigen-binding fragment" are used interchangeably herein. As used herein, an antigenic fragment is a fragment that specifically reacts with an antigen-binding molecule, e.g., an antibody. The specific reaction referred to herein is when an antigen or antigenic fragment is , react in a highly selective manner with their corresponding antibodies and cannot be elicited by other antigens. The specificity of such a reaction is determined by the presence of one or more antigens in the antigen. As used herein, the term "antibody" refers to a molecule that is specifically or partially identifiable by an antigen. An antigen or antigenic fragment thereof may have one epitope or may have multiple epitopes. It may have a loop.

[0352] As used herein, the term "T cell epitope" refers to an antigen produced by a T cell. It refers to any epitope of interest.

[0353] As used herein, the term "tumor-associated antigen" or "TAA" is expressed by or on cancer cells. is receiving therapeutic or prophylactic care provided herein (e.g., a therapeutic dose of immunization Immunostimulatory polynucleotides or CpG-Ab immunoconjugates TAAs refer to antigens expressed in the stroma of tumors. TAAs may or may not be targeted in preventative care. TAAs are overexpressed on cancer cells. It does not have to be activated, mutated, or misregulated; any TAA is considered normal. In some embodiments, the cellular components of the endothelial cells may have the same characteristics as those of the endothelial cells. In this study, TAAs are overexpressed, mutated, or misregulated in cancer cells. TAAs can be proteins, nucleic acids, lipids, or other antigens. The TAA can be a cell surface expressed TAA, an intracellular TAA, or an intranuclear TAA. In the context of tumors, TAAs can be expressed in the stroma of solid tumor masses. The term "stroma" as used herein refers to components in a solid tumor mass other than cancer cells. For example, The stroma may include fibroblasts, epithelial cells, other vascular components, or extracellular matrix components. As used herein, the term "stroma" refers to components of the immune system, For example, immune cells (e.g., B cells, T cells, dendritic cells, macrophages, natural killer Various TAAs are known in the art. The identity of a TAA is within the skill of the art. The methods are well known in the art, for example, those disclosed in Zhang et al., Methods Mol. Biol., 520:1-10 (2009). The method can be carried out using the method described in the publication, the contents of which are incorporated herein by reference. It can be done.

[0354] As used herein, the term "antibody" refers to a molecule that binds to a corresponding antigen non-covalently and reversibly. polypeptides of the immunoglobulin family that can bind efficiently and specifically to For example, natural IgG antibodies consist of a small number of peptides interconnected by disulfide bonds. It is a tetramer containing at least two heavy (H) chains and two light (L) chains. Each heavy chain contains a heavy chain variable region. (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region consists of three Each light chain is composed of a light chain variable region (referred to herein as a light chain variable region) and a light chain variable region (referred to herein as a light chain variable region). The light chain constant region consists of one domain, CL. The VH and VL regions are composed of more conserved regions called framework regions (FR). These are subjected to regions of hypervariability called complementarity-determining regions (CDRs), which are interspersed with regions that are highly variable. Each VH and VL can be subdivided into the following from the amino terminus to the carboxy terminus: Three CDRs and four FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of antibodies are responsible for the binding of immunoglobulins and various cells of the immune system (e.g., effector cells). It can mediate binding to host tissues or factors, including the first component of the classical complement system (Clq) and the first component of the classical complement system (Clq).

[0355] As used herein, antibodies include monoclonal antibodies, human antibodies, humanized antibodies, Camelid antibodies, chimeric antibodies, and anti-idiotypic (anti-Id) antibodies (e.g., the anti-Ids of the present invention) Antibodies include, but are not limited to, antibodies against any antigen (including anti-Id antibodies against the antigen). Isotype / class (e.g., IgG, IgE, IgM, IgD, IgA, and IgY) or subclass The antibodies can be of the following classes (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2).

[0356] Both the light and heavy chains are divided into regions of structural and functional homology. The term "variable" is used in a functional sense. In this context, the light chain (VL) and heavy chain (VH) portions It will be appreciated that both the variable domains of the antibody and the antibody determine antigen recognition and specificity. The constant domain of the light chain (CL) and the constant domain of the heavy chain (CH1, CH2, or CH3) are, for example, They confer important biological properties such as secretion, transplacental transfer, Fc receptor binding, and complement fixation. Therefore, the numbering of constant region domains is based on whether the domain is located at the antigen binding site or amino-terminus of the antibody. The more distant the region, the more variable the N-terminus, and the constant region at the C-terminus; The CH3 and CL domains are in fact the carboxy-terminal domains of the heavy and light chains, respectively. Includes

[0357] As used herein, depending on the context, the term "antibody" refers to the antigen binding of an antibody molecule. As used herein, the term "antigen-binding fragment" can also refer to a fragment (e.g., The antigen's epitope and specificity are determined (e.g., by binding, steric hindrance, stabilization / destabilization, spatial distribution) A binding fragment refers to one or more portions of an antibody that retain the ability to interact specifically with the antibody. Examples of binding fragments include a single Single chain Fv (scFv), disulfide-linked Fv (sdFv), Fab fragment, F(ab') fragment, VL, VH, CL, and CH1 domain a monovalent fragment consisting of the F(ab)2 fragment, linked at the hinge region by a disulfide bridge; a bivalent fragment containing two Fab fragments; an Fd fragment consisting of the VH and CH1 domains; a VL and CH2 fragment consisting of a single arm of an antibody; Fv fragments consisting of the VH domain; dAb fragments consisting of the VH or VL domain (Ward et al., Nature, 341:544-546(1989)); single domain antibodies (VHH), as well as isolated complementarity determining regions (CDRs), or other epitope-binding fragments of antibodies.

[0358] The terms "specifically bind," "selectively bind," or similar terms refer to two Refers to a chemical interaction between molecules, compounds, cells, and / or particles, where a first entity is a second target with greater specificity and affinity than it binds to a third entity that is a non-target In some embodiments, "specific binding" refers to binding to a third, non-target entity. At least 10 times, at least 50 times, at least 100 times, at least 500 times, fold, at least 1000-fold, or more, affinity of the first entity for the second target entity In some embodiments, "specific binding" can refer to binding to an antigen (or its used in the context of describing the interaction between an antigenic fragment) and an antibody (or its antigen-binding fragment) In certain embodiments, "specific binding" refers to binding with a dissociation constant (KD) of 10 or less. -5 M or less, 10 -6 M and below, Or 10 -7 The binding of an antibody with a specific antigen that is less than M or KD is non-specific to a specific antigen Binding of an antibody to a given antigen that is at least two-fold less than its KD for binding to the target antigen. In some embodiments, specific binding is used to identify heterogeneous protein populations and and other biologics, e.g., in biological samples, e.g., blood, serum, plasma, or tissue samples. The presence of a given antigen can be determined. Thus, under certain specified immunoassay conditions, In this study, antibodies or binders with specific binding specificity were identified as being capable of binding to specific antigens and background antigens. and does not bind appreciably more to other antigens present in the sample. In one embodiment, antibodies with particular binding specificity are identified under specified immunoassay conditions. The antibody or binding agent may be a specific antigen and at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 times more likely to bind and not bind appreciably more to other antigens present in the sample. Specific binding of an antibody or binding agent under suitable conditions indicates that the antibody or agent binds to a specific protein. It may be desirable or necessary for the antibody to be selected for its specificity for Where appropriate, this selection will include cross-reactivity with molecules from other species (e.g., mouse or rat). This can be achieved by subtracting out antibodies or other subtypes that are specific to the antibody. In some embodiments, antibodies or antibody fragments that cross-react with a particular desired molecule are selected. will be done.

[0359] The term "cancer" or "tumor" refers to a tumor characterized by uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation. possess characteristics typical of cancer-initiating cells, such as proliferation rate and certain characteristic morphological features In some embodiments, such cells express PD-1, PD-L1 and / or due to the expression and activity of immune checkpoint inhibitors such as CTLA-4 Cancer cells can be identified, partially or completely, by, for example, CAT scans, MR images, etc. Detectable by means of tumor mass, such as imaging, x-ray, ultrasound, or palpation. and / or detectable due to expression of one or more cancer-specific antigens in a sample obtained from the patient. In some embodiments, the solid tumor is Cancer cells do not have to have measurable dimensions. Cancer cells may also be in the form of liquid tumors, which The cancer cells may be present singly or disseminated within an animal. The terms "disseminated tumor" and "liquid tumor" are used interchangeably and include, but are not limited to, Includes leukemia and lymphoma and other blood cell cancers.

[0360] The term "leukemia" is characterized by an abnormal increase in immature white blood cells called "blasts." Refers to a type of cancer of the blood or bone marrow. Leukemia is a broad term that covers a wide variety of diseases. Furthermore, it can affect the blood, bone marrow, and lymphatic system, all known as hematological neoplasms. Leukemia is part of a broader group of diseases that affect the body. acute myeloid (or myeloid or non-lymphocytic) leukemia (ALL), acute myeloid (or myeloid or non-lymphocytic) leukemia (AML), chronic lymphocytic It can be divided into four major categories: chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and myeloid leukemia (MYL). Additional types of leukemia include hairy cell leukemia (HCL), T-cell prolymphocytic leukemia (TCL), and -PLL), large granular lymphocyte leukemia, and adult T-cell leukemia.

[0361] The term "lymphoma" refers to a group of blood cell tumors that arise from lymphoid cells. The two major categories of lymphoma are Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). Lymphoma includes any neoplasm of lymphoid tissue. The major classes are lymphatic and hematologic. It is a cancer of the lymphocytes, a type of white blood cell that belongs to and spreads to both the lymph nodes and the thyroid gland.

[0362] As used herein, the term "cancer" includes pre-malignant and malignant cancers, and includes primary A tumor (e.g., a tumor whose cells have not spread to parts of the subject's body other than the site of the original tumor) tumors) and secondary tumors (e.g., migration of tumor cells to secondary sites different from the site of the original tumor) This includes tumors arising from metastases, recurrent cancers, and refractory cancers.

[0363] The terms "cancer recurrence" and "cancer relapse" are used interchangeably. This refers to the return of signs, symptoms, or disease after a period of remission. Recurrent cancer cells are those that have not progressed to the original stage. Cancer cells may reappear at the same site of the primary tumor or at another location, e.g., in a secondary cancer. The recurrence may be in the same disease form as the primary cancer or in a different disease form. For example, in some embodiments, In another embodiment, the primary cancer is a solid tumor and the recurrent cancer is a liquid tumor. The primary cancer is a liquid tumor and the recurrent cancer is a solid tumor. The primary and recurrent cancers may both be solid tumors or both be liquid tumors. In embodiments, the recurrent tumor contains at least one tumor that is also expressed by the primary tumor. They express tumor-associated antigens.

[0364] As used herein, the term "refractory cancer" refers to a cancer that does not respond to treatment, e.g., Cancers that are resistant at the start of treatment (e.g., immunotherapy treatment) or that may become resistant during treatment The terms "responsive," "response," or "responsiveness" refer to, for example, tumor size. These terms refer to an anti-cancer response in the sense of a reduction in tumor size or an inhibition of tumor growth. Time to first recurrence censored due to second primary cancer as first event Increased time to recurrence or death without recurrence between treatments or any It can also refer to improved prognosis reflected in increased overall survival, the time until death from any cause. To respond or have a response is to achieve a beneficial endpoint when exposed to a stimulus. Alternatively, negative or adverse symptoms occur when exposed to a stimulus. The tumor or subject is prevented from undergoing the desired response. Evaluating the likelihood of a tumor or subject showing a desired response (i.e., It is understood that this is equivalent to assessing the likelihood of a patient showing a lack of response or being non-responsive. It will be done.

[0365] As used herein, cancer includes B-cell cancers, e.g., multiple myeloma, Waldenstrom's disease, and Strom's macroglobulinemia, e.g., alpha chain disease, gamma chain disease, and mu chain disease Heavy chain diseases such as leukemia, benign monoclonal gammopathy, and immunocytic amyloidosis Cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer , bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer , oral or pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendix cancer, salivary gland cancer, These include, but are not limited to, adenocarcinoma, adrenal carcinoma, osteosarcoma, chondrosarcoma, and cancers of the blood tissue. Other non-limiting examples of cancer types that may be amenable to the methods encompassed by the present invention include: Human sarcomas and carcinomas, such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, Chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovium, mesothelioma, euthyroid Intestinal tumors, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer Adenocarcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystic gland carcinoma Cancer, medullary carcinoma, bronchial carcinoma, renal cell carcinoma, liver cancer, bile duct cancer, liver cancer, choriocarcinoma, seminoma, embryonal carcinoma , Wilms' tumor, cervical cancer, bone cancer, brain tumor, testicular cancer, lung cancer, small cell lung cancer, bladder cancer, epithelial Cancer, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma , oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma; leukemia, e.g., acute lymphoblastoma Myeloblastic leukemia and acute myelocytic leukemia (myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia) leukemia, monocytic leukemia, and erythroleukemia); chronic leukemia (chronic myelocytic (granulocytic) leukemia and diffuse lymphocytic leukemia); and polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), Multiple myeloma, Waldenstrom's macroglobulinemia, and heavy chain disease In some embodiments, the cancer is epithelial, such as bladder cancer, breast cancer, cervical cancer, colon cancer, or the like. , gynecological cancer, kidney cancer, laryngeal cancer, lung cancer, oral cancer, head and neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, or In another embodiment, the cancer is breast cancer, prostate cancer, or a combination thereof. In yet another embodiment, the epithelial cancer is non-small cell lung cancer, non-small cell lung cancer, or colon cancer. papillary renal cell carcinoma, cervical cancer, ovarian cancer (e.g., serous ovarian carcinoma), or breast cancer. , including but not limited to, serous, endometriotic, mucinous, clear cell, Brenner, or undifferentiated It can be characterized in a variety of other ways, including by type.

[0366] As used herein, the term "cancer therapy" or "cancer therapeutic agent" refers to a compound that exerts an anti-tumor effect. refers to a therapy or agent that can have anti-tumor effects or anti-tumor activity. Antitumor activity is typically demonstrated as a reduction in the rate of tumor cell growth, viability, or metastatic activity. A possible way to demonstrate antitumor activity is to measure the rate of proliferation of abnormal cells that occur during treatment. Such activity is limited to a reduction in tumor size or a stabilization or reduction in tumor size. However, to investigate the antitumor activity in xenograft models, allograft models, MMTV models, and

[0013] Generally accepted in vitro models, including other known models known in the art, of Alternatively, it can be evaluated using an in vivo tumor model.

[0367] As used herein, "preventing," "preventing" or "preventing" any disease or disorder means or "prevention" refers to the prevention of the onset of a disease or disorder, or a symptom thereof, as described herein. "Prevention" means the total or partial prevention of the onset, recurrence, or spread of a disease.

[0368] As used herein, a subject is a person who is in a state of being cured biologically, medically, or in terms of quality of life. If a subject would benefit from treatment, then such a subject is "in need of" such treatment. do.

[0369] The term "therapeutic agent" is art-recognized and is intended to describe a therapeutic agent administered to a subject in need thereof. When administered, it is biologically, physiologically, or pharmacologically active and has local or systemic activity. It refers to any substance that acts on the body to exert a beneficial therapeutic effect on the subject.

[0370] As used herein, "immunoconjugate" or "antibody-drug-conjugate (ADC)" The term "antigen-binding moiety" refers to an antigen-binding portion (e.g., an antibody or antigen-binding fragment thereof) described herein. The term "covalent or non-covalent linkage" refers to the linkage of an immunomodulatory polynucleotide to a target polypeptide. Interactions can be interactions, including chelation. A variety of linkers provided herein can be utilized to form immunoconjugates. In some embodiments, the immunoconjugate can be any of the immunoconjugates provided herein. It is a conjugate of formula (C).

[0371] As used herein, the term "antigen-binding moiety" refers to a molecule capable of specifically binding to an antigen. This refers to a moiety capable of binding to a target molecule, including, but not limited to, antibodies and antigen-binding fragments.

[0372] As used herein, the term "CpG-Ab immunoconjugate" or "CpG-Ab" refers to an antibody an antibody (Ab) or antigen-binding fragment thereof and a CpG-containing immunostimulatory polynucleotide as described herein It refers to the connection with.

[0373] As used herein, the term "T cell agonist" refers to a T cell agonist derived from a mixed starting cell population. It refers to any agent that selectively stimulates the proliferation, differentiation, and / or survival of T cells. The resulting cell population is enriched with an increased number of T cells compared to the starting cell population. T cell agonists that find use in the present disclosure include those that specifically bind to the T cell receptor (TCR). These include, but are not limited to, antigenic molecules and T cell costimulatory molecules. Examples of molecules include OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), 4-1BB(CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, C D160, B7-H3, and CD83 ligand. In certain embodiments, the T cell agonist is an antibody against a T cell costimulatory molecule. In certain embodiments, the T cell agonist is a tumor-associated antigen (TAA). , the T cell agonist is a pathogenic antigen.

[0374] As used herein, the term "immune checkpoint" or "immune checkpoint molecule" refers to a Immune checkpoint molecules are molecules of the immune system that regulate signaling. It is a checkpoint molecule, i.e., it enhances a signal or inhibits an inhibitory checkpoint. In a specific embodiment, , immune checkpoints are expressed by either T cells or antigen-presenting cells (APCs) Certain types of cancer cells secrete proteins to evade immune clearance. Expressing checkpoint proteins. Immune checkpoints expressed by cancer cells Interactions between immune checkpoint proteins and immune checkpoint proteins expressed by T cells The use of immune checkpoint modulators to block the effects of these drugs has been shown to be effective in treating certain cancers. It has been proven to be effective.

[0375] As used herein, an "immune checkpoint modulator" refers to an agent that inhibits or reduces the activity of immune checkpoints in a subject. In one embodiment, the agent is an agent capable of altering the activity of an immune checkpoint. In this regard, immune checkpoint modulators include, but are not limited to, PD-1, PD-L1, PD-L2, TIM-3, LAG-3, CEACAM-1, CEACAM-5, VISTA, BTLA, TIGIT, LAIR1, CD160, CD47, 2B4, and TGFR. Checkpoint modulators are immune checkpoint agonists or antagonists. In some embodiments, the immune checkpoint modulator is an immune checkpoint modulator. Epidemiological checkpoint binding proteins (e.g., antibodies, antibody Fab fragments, bivalent antibodies, antibody drug complexes) The antibody is a conjugate, scFv, fusion protein, bivalent antibody, or tetravalent antibody. In certain embodiments, the immune checkpoint modulator is a small molecule. wherein the immune checkpoint modulator is an anti-PDl or anti-PD-Ll antibody.

[0376] As used herein, the term "targeted delivery" or the verb form "target" refers to a over any organ, tissue, cell, or subcellular compartment (called non-target locations) specific organs, tissues, cells, and / or subcellular compartments (called target locations) It refers to a process that facilitates the delivery of a delivered agent (e.g., an immunostimulatory polynucleotide) to the target tissue. Targeted delivery can be achieved using methods known in the art, for example, by directing a target cell population after systemic administration. By comparing the concentration of the drug to be delivered in the target cell population with the concentration of the drug to be delivered in the non-target cell population, As provided herein, targeted delivery can be detected at non-target locations. Targeted delivery involves combining a targeting moiety with a targeting moiety, resulting in a concentration at least two-fold higher at the target location compared to the target moiety. This can be achieved by specific binding of a receptor moiety associated with the cell. In this case, the receptor moiety associated with the target cell may be located on the surface or within the cytosol of the target cell. In some embodiments, the receptor moiety is an antigen associated with a target cell.

[0377] "Abnormal" when used in relation to an organism, tissue, cell, or component thereof The term "patient" refers to a patient who has at least one observable or detectable characteristic (e.g., age, treatment, Organisms, tissues, cells, or organisms that exhibit "normal" (expected) respective characteristics (e.g., time) refers to an organism, tissue, cell, or component thereof that is distinct from the components of that organism. is a characteristic that is normal for a tissue type or expected for a cell or tissue type, It may be abnormal for a different cell or tissue type. Normal cells are cancer cells.

[0378] The term "combination therapy" refers to a combination of two or more compounds that are effective in treating a condition or disorder (e.g., cancer) described in this disclosure. Such administration refers to the administration of two or more therapeutic agents in a substantially simultaneous manner. Co-administration of these therapeutic agents, e.g., administering a single formulation having a fixed ratio of therapeutic agents, or administering each Each therapeutic agent may be administered in a separate formulation (e.g., capsule and / or intravenous formulation). Moreover, such administration may be in a sequential or separate manner, at about the same time. The use of each type of therapeutic agent either simultaneously or at different times is also encompassed. Such administrations may be administered at different times and / or via different routes of administration. In any case, the formulation of each component as a separate preparation is also included. The treatment regimen provides beneficial therapeutic effects in treating the conditions or disorders described herein. To provide.

[0379] As used herein, the terms "co-administering" or "co-administration" and similar The term refers to a combination of two or more therapeutic agents (e.g., an immunoconjugate and an immune checkpoint module). Co-administration refers to the act of administering a drug, compound, therapy, etc. simultaneously or nearly simultaneously. The various therapeutic agents of the present disclosure, e.g., immunoconjugates, T cell agonists, immunothrombin inhibitors, checkpoint modulators, or other chemotherapy drugs may be combined in the same formulation or can refer to simultaneous administration in which the compounds may be formulated separately for simultaneous administration to a subject. The administration of various therapeutic agents of the present invention, e.g., immunoconjugates, can also be referred to as sequential administration. ductase, T-cell agonist, immune checkpoint modulator, or other chemotherapy The sequence or order in which the drugs are administered may vary and is not limited to any particular sequence. Co-administration means that two or more agents are administered to different body regions or by different delivery schemes. In situations where one agent is administered systemically and the second agent is administered intratumorally, for example. Alternatively, a first agent may be administered intratumorally and a second agent may be administered systemically into the blood or near the tumor. Co-administration can also refer to the situation in which a first agent is administered intratumorally. and a second agent is administered intratumorally by the same delivery scheme; It can also refer to the above drugs.

[0380] "Intratumoral injection" refers to the administration of an agent provided herein into the tumor cell mass and / or tumor microenvironment. As used herein, the tumor microenvironment refers to the direct administration of a tumor microenvironment containing the tumor microenvironment where neoplastic processes occur. The neoplastic environment creates a structural and / or functional environment for the growth, proliferation, or expansion of cells. The tumor microenvironment encompasses the environment surrounding one or more neoplastic cells that form the tumor. It is composed of cells, molecules, fibroblasts, extracellular matrix, and blood vessels that provide nutrients. Examples of cells or tissues within the tumor microenvironment include tumor vasculature, tumor-infiltrating lymphocytes, and lymphocytes. fibroblast reticular cells, endothelial progenitor cells (EPCs), cancer-associated fibroblasts, pericytes, other stromal cells, Components of the extracellular matrix (ECM), dendritic cells, antigen-presenting cells, T cells, regulatory T cells, These include macrophages, neutrophils, and other immune cells located near the tumor. Examples of cellular functions that affect the tumor microenvironment include, but are not limited to, cytokines and and / or chemokine production, responses to cytokines, antigen processing of peptide antigens regulation of leukocyte chemotaxis and migration; regulation of gene expression; complement activation; signal transduction Regulation of delivery pathways, cell-mediated cytotoxicity, cell-mediated immunity, humoral immune responses, and other innate or adaptive These include, but are not limited to, immune responses. To determine.

[0381] The terms "subject," "patient," "individual," and similar terms are used interchangeably herein. and whether in vitro or in vivo, as described herein. It refers to any animal or cell thereof suitable for the methods provided. In this context, a patient, subject, or individual may be a mammal, e.g., a human, or other animal, e.g., a wild-type animal. Animals (e.g., herons, storks, cranes, etc.), livestock (e.g., ducks, geese, etc.), if or experimental animals (e.g., orangutans, monkeys, rats, mice, rabbits, guinea pigs, marmots, ground squirrels, etc.

[0382] The term "survival" as used in the context of cancer includes any of the following: overall survival Survival to death (where the death is regardless of the cause or tumor involved) also known as "recurrence-free survival" (where the term recurrence includes both local and distant recurrence); metastasis-free survival; disease-free survival (wherein the term disease refers to cancer and its associated diseases); The length of survival is measured from a defined starting point (e.g., time of diagnosis or start of treatment). It can be calculated by reference to the starting point (start time) and the end point (e.g., death, recurrence, or metastasis). In addition, the criteria for efficacy of treatment include response to chemotherapy, probability of survival, and probability of metastasis within a given period. The data can be expanded to include the rate of recurrence, and the probability of tumor recurrence.

[0383] The present invention provides a method for the preparation of a polypeptide comprising a targeting moiety and one or more immunomodulatory (e.g., immunostimulatory) polynucleotides. Immunomodulatory (e.g., immunostimulatory) polynucleotides and conjugates are provided. The immunomodulatory polynucleotide may contain a 5-modified uridine or a 5-modified cytidine. 5'-modifications at the 5'-end of a regulatory polynucleotide (e.g., between the two 5'-terminal nucleosides) The inclusion of uridine (e.g., 5-ethynyl-uridine) enhances the immunomodulatory properties of the polynucleotide. The immunomodulatory polynucleotide may be a typical polynucleotide having a length of 18 to 28 nucleotides. The CpG ODN may be shorter than the CpG ODN (e.g., a total of 6-16 nucleotides or 12-14 nucleotides). Shorter immunomodulatory polynucleotides of the invention (e.g., containing a total of 6-16 amino acids). nucleotides or 12-14 nucleotides) are longer than typical CpG ODNs. and may retain the immunomodulatory activity of longer CpG ODNs, and exhibit higher immunomodulatory activity (e.g., For example, by NFκB activation or by the induction of at least one cytokine (e.g., IL-6 or IL-10) Advantageously, shorter immunomodulatory responses may be observed (as measured by changes in the expression levels of The polynucleotides are synthesized in smaller quantities than full-length typical CpG ODNs. The immunomodulatory polynucleotides are easy to prepare and economical because they involve a synthetic step of the nucleotide. The nucleotides may contain one or more abasic spacers and / or internucleoside phosphotriesters. It may contain.

[0384] The immunomodulatory polynucleotides of the present invention can be synthesized without substantially sacrificing their immunostimulatory activity. Mostly internucleoside phosphates (e.g., more than 50% internucleoside phosphates) CpG ODNs containing hydroxybenzoates have superior stability (e.g., resistance to nucleases) compared to CpG ODNs containing hydroxybenzoates. This effect can be, for example, at least 50% (e.g., at least 70%). Incorporation of an internucleoside phosphorothioate or phosphorodithioate of or by internucleoside phosphotriesters and / or internucleoside abasic This can be achieved by the inclusion of a spacer. The phosphate-based phosphates are also suitable for conjugation with targeting moieties. The phosphorotriester and abasic spacer are used to prepare poly(Asp-1, Asp-2) with a complete phosphorothioate backbone. It may also be used to reduce off-target activity compared to nucleotides. Without wishing to be bound, this effect may be mediated by a targeting moiety. This can be achieved by reducing self-delivery without interfering with delivery to cells. Thus, the polynucleotides of the present invention may contain up to 15 consecutive internucleoside phosphorothioates. nucleotides (e.g., 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, or 10 or fewer consecutive internucleoside For example, a nucleotide sequence containing a total of 12 to 16 nucleosides may be used. The immunostimulatory polynucleotide may contain 10 or fewer consecutive phosphorothioate internucleoside residues. It may contain.

[0385] The immunostimulatory polynucleotides of the invention may contain a total of 50 or fewer nucleosides (e.g., 30 or fewer, 2 The immunostimulatory polynucleotides of the present invention may contain up to 8 or up to 16 nucleosides. The nucleotides are a mixture of at least six nucleosides in total (e.g., 10 or more or 12 or more nucleosides). For example, the immunostimulatory polynucleotide of the present invention may contain a total of 6 to 30 nucleosides (e.g., 6-28 total nucleosides, 6-20 total nucleosides, 6- 16 nucleosides, 10-20 total nucleosides, 10-16 total nucleosides, 12-28 total nucleosides, 12-20 nucleosides in total, or 12-16 nucleosides in total) It is possible.

[0386] The immunostimulatory polynucleotides of the invention may be substituted with one or more phosphotriesters (e.g., nucleosides). intersidic phosphotriesters) and / or phosphorothioates (e.g., 1 to 6 or 1 to 4) , for example, at one or both ends (e.g., 6 nucleosides at the 5'-end or 3'-end It may contain one or more internucleoside phosphotriesters and The inclusion of ribonucleotides and / or phosphorothioates reduces the rate of exonuclease-mediated degradation. This can enhance the stability of the polynucleotide.

[0387] In some embodiments, the immunostimulatory polynucleotides of the invention are phosphotriester or contains a terminal phosphodiester, wherein the phosphotriester or the terminal phosphodiester The ester is linked to a targeting moiety or conjugate group and optionally to one or more (e.g., 1 to 6) auxiliary moieties. In certain embodiments, the immunostimulatory polynucleotide comprises a linker In some embodiments, the immunostimulatory polynucleotide contains only one linker. The deconjugated group contains only one conjugated group.

[0388] The polynucleotides of the invention (e.g., immunostimulatory polynucleotides) may comprise strands and their partial fragments. or a hybridized polynucleotide containing the entire complement. The hybridized polynucleotides are at least six (e.g., six, seven, eight, nine, ten, eleven, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23). The total number of nucleotides present in the shorter strand may be up to the total number of nucleotides present in the hybrid. The hybridized portions of the purified polynucleotide are 6, 7, 8, 9, 10, 11, 12, It may contain 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 base pairs.

[0389] The conjugates of the invention comprise a targeting moiety and one or more immunomodulatory (e.g., immunostimulatory) polynucleotides. Nucleotides (e.g., 1 to 6 or 1 to 4 (e.g., 1 or 2)) for immunomodulation (e.g., immunostimulation) In the conjugate, the immunomodulatory polynucleotide Each of the peptides independently comprises a linker, and the targeting moiety is covalently attached to the linker. The linker may be a nucleobase, an abasic spacer, a phosphodiesterase, or a nucleotide sequence in the immunomodulatory polynucleotide. The nucleotides may be linked to phosphate, phosphorothioate, or phosphorodithioate. The cells targeted by the conjugates are professional APCs (e.g., B cells). The targeting moiety can be an antigen-binding moiety (e.g., an antibody). or antigen-binding fragments thereof), polypeptides, aptamers, or one or more small molecules (e.g., In the conjugates of the present invention, the targeting moiety can be a group containing The conjugate of the present invention may comprise an antibody or antibody fragment and the one or more immunomodulatory polynucleotides covalently attached to a Q-tag in the antibody or antibody fragment thereof The Q-tag can be at the N-terminus or C-terminus. or may be located in the heavy or light chain of the antibody fragment. The use of targeting moieties for delivery of immunomodulatory polynucleotides of the invention can be used to enhance immune responses in vivo. This overcomes the drawback of the normally uneven distribution of immunoregulatory polynucleotides. The delivery of immunomodulatory polynucleotides of the present invention based on the moiety of the immunomodulatory polynucleotide There may be advantages to systemic administration or administration to a target tissue; Administration to the tissue preferably results in the release of the immunomodulatory polynucleotide through the blood circulation in vivo. The conjugates of the present invention, even when administered systemically, can result in inconsistent distribution. This is because they can undergo intracellular delivery, primarily in target tissues or cells. The points are short immunomodulatory polynucleotides (e.g., 6-16 nucleosides in total (e.g., 1 Immunomodulatory polynucleotides containing 0 to 16 or 12 to 16 nucleosides This may be particularly noticeable in conjugates.

[0390] The conjugates of the invention may comprise one or more (e.g., 1 to 6) auxiliary moieties (e.g., polyethylene The auxiliary moiety may further comprise a capping group, a bioreversible group, or a non-bioreversible group. The auxiliary moiety may be attached to the linker (e.g., immunomodulatory (e.g., For example, phosphate, phosphorothioate, or phospho in an immunostimulatory (immunostimulatory) polynucleotide. The conjugates of the present invention may be bonded to a linker which is bonded to a rhododithioate. The inclusion of an auxiliary moiety (e.g., PEG) in a conjugate is comparable to a reference conjugate lacking such an auxiliary moiety. The conjugate may have improved pharmacokinetic and / or biodistribution properties compared to the hydroxybenzoate.

[0391] One or more of the immunomodulatory polynucleotides of the invention are administered to antigen-presenting cells (APCs; e.g., , targeting professional APCs (e.g., B cells, pDCs, or macrophages) The endosomal toll can be conjugated to a binding moiety (e.g., an antigen-binding moiety). Cells containing TLR-like receptors (e.g., TLR9) (e.g., antigen-presenting cells (APCs; e.g., protease inhibitors) and administering the immunomodulatory polypeptides of the present invention to a primary APC (e.g., B cell, pDC, or macrophage). Delivery of nucleotides or conjugates of the invention can be used to induce intracellular endosomal toll-like The receptors are stimulated (in the case of immunostimulatory polynucleotides) or inhibited (in the case of immunosuppressive polynucleotides). Without being bound by theory, Activation of inflammatory toll-like receptors leads to the production of pro-inflammatory cytokines (e.g., IL-6, IL-10, and / or This activity is associated with a variety of tumors (e.g., patients with It is thought to be useful in the treatment of solid and liquid tumors.

[0392] In one embodiment, provided herein is an oligonucleotide of formula (A): a stereoisomer, a mixture of two or more diastereomers, a tautomer, or two or more tautomers of a mixture of isomers; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; X 5' -(X N ) b -Y P -(X N ) c -X 3' (A) (In the formula: Each X N are independently nucleotides; X 3' is the 3' terminal nucleotide; X 5' is the 5' terminal nucleotide; Y P is an internucleoside phosphotriester; and b and c are each an integer ranging from about 0 to about 25; provided that their sum is 5 or greater; wherein the oligonucleotide comprises nucleotides having modified nucleobases).

[0393] In some embodiments, b is an integer ranging from about 1 to about 15. b is about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, or about 15. In certain embodiments, b is an integer of about 3, about 4, about 11, or about 14. In some embodiments, b is an integer of about 3. In some embodiments, b is In some embodiments, b is an integer of about 4. In some embodiments, b is an integer of about 11. and b is an integer of about 14.

[0394] In some embodiments, c is an integer ranging from about 0 to about 10. c is an integer of about 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10. In some embodiments, c is an integer from about 0 to about 8. In some embodiments, c is an integer from about 0 to about 8. In some embodiments, c is an integer of about 8.

[0395] In some embodiments, b is an integer of about 3 and c is an integer of about 8. wherein b is an integer of about 4 and c is an integer of about 8. In some embodiments, b is , is an integer of about 11, and c is an integer of about 0. In some embodiments, b is an integer of about 14. and c is an integer about 0.

[0396] In some embodiments, the sum of b and c is in the range of about 5 to about 20. In some embodiments, the sum of b and c is in the range of about 5 to about 15. , about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, or about 15. wherein the sum of b and c is about 8, about 9, about 10, about 11, about 12, about 13, or about 14. In one embodiment, the sum of b and c is about 11. In another embodiment, the sum of b and c is about 12. In some embodiments, the sum of b and c is about 14.

[0397] In some embodiments, each X N are independently 2'-deoxyribonucleotides or 2'-modified In some embodiments, each X is a modified ribonucleotide. N are independently 2'-deoxy Adenosine (A), 2'-deoxyguanosine (G), 2'-deoxycytidine (C), 5-halo-2'-deoxy Cytidine, 2'-deoxythymidine (T), 2'-deoxyuridine (U), 5-halo-2'-deoxy Uridine, 2'-fluororibonucleotide, 2'-methoxyribonucleotide, or 2'-(2-methyl In some embodiments, each X is a ribonucleotide. N is independently , 2'-deoxyribonucleotides. In some embodiments, each X N are independently, 2 '-Deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, 5-halo-2'-deoxy 2'-deoxycytidine, 2'-deoxythymidine, 2'-deoxyuridine, or 5-halo-2'-deoxyuridine In some embodiments, each X is lysine. N are independently 2'-deoxyadenosine, 2 '-Deoxyguanosine, 2'-deoxycytidine, 2'-deoxythymidine, 5-bromo-2'-deoxy xyluridine, or 5-iodo-2'-deoxyuridine.

[0398] In some embodiments, X 3'is a 2'-deoxyribonucleotide or a 2'-modified ribonucleic acid In one embodiment, X 3' is a 2'-deoxyribonucleotide. In one embodiment, X 3' is 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxy 2'-deoxycytidine, 5-halo-2'-deoxycytidine, 2'-deoxythymidine, 2'-deoxyuridin ribonucleotides, 5-halo-2'-deoxyuridine, 2'-fluororibonucleotides, 2'-methoxyribonucleotides In some embodiments, the ribonucleotide is a ribonucleotide, a ribonucleotide, or a 2'-(2-methoxyethoxy)ribonucleotide. Te, X 3' are 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, 5- Halo-2'-deoxycytidine, 2'-deoxythymidine, 2'-deoxyuridine, or 5-halo-2 In one embodiment, X is 1'-deoxyuridine. 3' is 2'-deoxythymidine In one embodiment, X 3' is a 2'-deoxyribonucleoside with a substituted pyrimidine base In one embodiment, X 3' is a 2'-deoxy 5-substituted pyrimidine base In some embodiments, X is a ribonucleotide. 3' is 2'-deoxythymidine, 5-halo In one embodiment, the amino acid sequence is 5-halo-2'-deoxyuridine, 5-halo-2'-deoxyuridine, or 5-halo-2'-deoxyuridine. , X 3' 2'-deoxythymidine, 5-bromo-2'-deoxycytidine, 5-iodo-2'-deoxy It is cytidine, 5-bromo-2'-deoxyuridine, or 5-iodo-2'-deoxyuridine. In some embodiments, X 3'2'-deoxythymidine, 5-bromo-2'-deoxyuridine, or 5-iodo-2'-deoxyuridine. 3' 3' capped In certain embodiments, the 3' capping group is a terminal nucleotide comprising: In certain embodiments, the 3' capping group is a 3-hydroxyl group. Cyl-propylphosphoryl (i.e., -P(O2)-CH2CH2CH2OH).

[0399] In some embodiments, X 5' is a 2'-deoxyribonucleotide or a 2'-modified ribonucleic acid In one embodiment, X 5' is a 2'-deoxyribonucleotide. In one embodiment, X 5' is 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxy 2'-deoxycytidine, 5-halo-2'-deoxycytidine, 2'-deoxythymidine, 2'-deoxyuridin ribonucleotides, 5-halo-2'-deoxyuridine, 2'-fluororibonucleotides, 2'-methoxyribonucleotides In some embodiments, the ribonucleotide is a ribonucleotide, a ribonucleotide, or a 2'-(2-methoxyethoxy)ribonucleotide. Te, X 5' are 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, 5- Halo-2'-deoxycytidine, 2'-deoxythymidine, 2'-deoxyuridine, or 5-halo-2 In one embodiment, X is 1'-deoxyuridine. 5' has a substituted pyrimidine base In one embodiment, X is a 2'-deoxyribonucleotide. 5' is a 5-substituted pyrimidine In some embodiments, X is a 2'-deoxyribonucleotide having a 2'-amino acid base. 5' is 2' -deoxythymidine, 5-halo-2'-deoxycytidine, or 5-halo-2'-deoxyuridine In one embodiment, X 5' is 5-halo-2'-deoxycytidine. In your opinion, X 5' is 5-halo-2'-deoxyuridine. In certain embodiments, X 5' teeth , 2'-deoxythymidine, 5-bromo-2'-deoxycytidine, 5-iodo-2'-deoxycytidine uridine, 5-bromo-2'-deoxyuridine, or 5-iodo-2'-deoxyuridine. In the embodiment, X 5' is 2'-deoxythymidine, 5-bromo-2'-deoxyuridine, or 5- iodo-2'-deoxyuridine. In one embodiment, X 5' is 5-bromo-2'-deoxy In one embodiment, X is xylidine. 5' is 5-iodo-2'-deoxyuridine In one embodiment, X 5' has a 3'-phosphorosoate group In one embodiment, X 5' has a 3'-phosphorosoate group with chirality Rp In one embodiment, X 5' is a 3'-phosphorozoate with Sp chirality It has a group.

[0400] In one embodiment, Y P is an internucleoside phosphothiotriester.

[0401] In one embodiment, Y P teeth: [ka] where Z is O or S; and d is an integer ranging from about 0 to about 50. In some embodiments, Z is O. In some embodiments, Z is S. In some embodiments, d is an integer ranging from about 0 to about 5. In some embodiments, d is an integer of about 0, about 1, about 2, about 3, about 4, or about 5. In some embodiments, d is an integer of about 0, about 1, or about 3.

[0402] In one embodiment, Y P teeth: [ka] where Z is O or S; and d is an integer ranging from about 0 to about 50. In some embodiments, Z is O. In some embodiments, Z is S. In some embodiments, d is about 0 to In some embodiments, d is an integer ranging from about 0 to about 5. In some embodiments, d is an integer of about 0, about 1, about 2, about 3, about 4, or about 5. wherein d is an integer of about 0, about 1, or about 3.

[0403] In certain embodiments, the oligonucleotide of Formula (A) contains one additional internucleoside In one embodiment, the additional internucleoside phosphotriester Stell is C 1-6 In another embodiment, the further nucleic acid is an alkyl phosphotriester. The intercreoside phosphotriester is an ethyl phosphotriester.

[0404] In some embodiments, the oligonucleotide of Formula (A) comprises one 5-halo-2'-deoxyurethane group. In one embodiment, the 5-halo-2'-deoxyuridine includes 5-fluoro-2'-deoxyuridine. 2'-deoxyuridine, 5-bromo-2'-deoxyuridine, or 5-iodo-2'-deoxyuridine. In another embodiment, the 5-halo-2'-deoxyuridine is 5-bromo-2'-deoxyuridine. In yet another embodiment, the 5-halo-2'-uridine is 5-iodo-2'-deoxyuridine. In yet another embodiment, the 2'-deoxyuridine is 5-fluoro-2'-deoxyuridine. In the present invention, the 5-halo-2'-deoxyuridine is 5-bromo-2'-deoxyuridine. In another embodiment, the 5-halo-2'-deoxyuridine is 5-iodo-2'-deoxyuridine. is.

[0405] In certain embodiments, the oligonucleotide of Formula (A) contains three or more 2'-deoxycytidines. In some embodiments, the oligonucleotide of Formula (A) comprises three 2'-deoxyribonucleotides. Including gin.

[0406] In certain embodiments, the oligonucleotide of Formula (A) contains four or more 2'-deoxyguanosine residues. In some embodiments, the oligonucleotide of Formula (A) comprises four 2'-deoxyguanidines. Contains anosine.

[0407] In some embodiments, the oligonucleotide of Formula (A) comprises three 2'-deoxycytidines and and four 2'-deoxyguanosines. In some embodiments, the oligonucleotide of Formula (A) In some embodiments, the oligonucleotide of formula (A) comprises one, two, or three CG dinucleotides. A dinucleotide contains three CG dinucleotides.

[0408] In certain embodiments, the oligonucleotide of Formula (A) contains three or more 2'-deoxythymidines. In some embodiments, the oligonucleotide of Formula (A) comprises 3, 4, 5, 6, 7, or 8 In one embodiment, the oligonucleotide of Formula (A) comprises one 2'-deoxythymidine. , 3, 4, 5, or 8 2'-deoxythymidines.

[0409] In certain embodiments, the oligonucleotide of Formula (A) does not contain 2'-deoxyadenosine. In some embodiments, the oligonucleotide of Formula (A) does not have one or two 2'-deoxy amino acids. Contains denosine.

[0410] In some embodiments, the oligonucleotide of Formula (A) comprises about 5 to about 20 or about 6 to about 15 nucleotides. In some embodiments, the oligonucleotide of Formula (A) is , about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, or about 15. In an embodiment, the oligonucleotide of Formula (A) is about 10, about 11, about 12, about 13, about 14, or has a length of about 15.

[0411] In certain embodiments, the oligonucleotide of Formula (A) contains one or more internucleoside phosphonates. In some embodiments, the nucleoside in the oligonucleotide of Formula (A) comprises a thiolate. All internucleoside phosphoesters are internucleoside phosphorothioates. wherein the oligonucleotide of formula (A) comprises one or more chiral internucleoside phosphorothioates. Includes ports.

[0412] In certain embodiments, the oligonucleotide of Formula (A) is p275, p276, p313, or p347 In some embodiments, the oligonucleotide of Formula (A) is selected from the group consisting of p236, p238, p243, p24 In certain embodiments, the oligonucleotide of Formula (A) is p306, p308, p361, p362, or p425. Chid is p236, p238, p243, p246, p275, p276, p308, p313, p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479, p480, p481, p482, p483, p4 84, p485, p486, p487, p488, or p489.

[0413] In certain embodiments, the oligonucleotide of Formula (A) is an immune modulatory oligonucleotide. is.

[0414] In one embodiment, provided herein is a method for treating a pulmonary arthritis, comprising administering to a patient a therapeutically effective amount of a pulmonary arthritis relieving ... 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 An array called T or a stereoisomer thereof, or a mixture of two or more diastereomers thereof , tautomers, or mixtures of two or more tautomers; or pharmaceutically acceptable salts thereof. a salt, solvate, or hydrate thereof; where: x is an integer ranging from 1 to 4; N 1 is absent or 2'-deoxythymidine; N 2 is a 2'-deoxyribonucleotide having a modified nucleobase; N 3 is 2'-deoxyadenosine or 2'-deoxyadenosine, each optionally containing a 3'-phosphotriester. is oxythymidine; N 4is 2'-deoxyadenosine or 2'-deoxythymidine; N 5 is 2'-deoxythymidine, optionally containing a 3'-phosphotriester; and C is 2'-deoxycytidine and G is 2'-deoxyguanosine.

[0415] In one embodiment, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 In T, x is an integer of 1, 2, 3, or 4. In one embodiment, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 In T, x is an integer equal to 1. In an embodiment, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 In T, x is an integer equal to 4.

[0416] In one embodiment, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 T, N 1 In some embodiments, Leave it, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 T, N 1 is 2'-deoxythymidine.

[0417] In one embodiment, N 1 N 2 CGN 3 CG(T) xGN 4 CGN 5 T, N 2 has a substituted pyrimidine base In some embodiments, N is a 2'-deoxyribonucleotide. 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 During T , N 2 is a 2'-deoxyribonucleotide having a 5-substituted pyrimidine base. In N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 T, N 2 is 5-halo-2'-deoxycytidine or 5-halo-2 In some embodiments, N' is N'-deoxyuridine. 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 T, N 2 is 5-bu bromo-2'-deoxyuridine or 5-iodo-2'-deoxyuridine.

[0418] In one embodiment, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 T, N 3 3'-phosphotriester In some embodiments, N is a 2'-deoxyadenosine. 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 T, N 3 is 2'-deoxythymidine. 1 N2 CGN 3 CG(T) x GN 4 CGN 5 T, N 3 teeth , 2'-deoxythymidine containing a 3'-phosphotriester.

[0419] In one embodiment, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 T, N 4 is 2'-deoxyadenosine In one embodiment, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 T, N 4 is 2'-deoxythymidine do.

[0420] In one embodiment, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 T, N 5 is 2'-deoxythymidine In some embodiments, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 T, N 5 contains a 3'-phosphotriester The most common is 2'-deoxythymidine.

[0421] In one embodiment, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 The oligonucleotide T consists of one or more nucleic acids. In some embodiments, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 The oligonucleotide T contains at least one chiral internucleoside phosphorothioate. Includes.

[0422] In one embodiment, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 The oligonucleotides for T are p275 and p276. In one embodiment, N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 T oligonucleotide The peptide is p236, p238, p243, p246, p308, p361, p362, or p425. N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 The oligonucleotides for T are p236, p238, p243, p246, and p275. , p276, p308, p313, p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479, p480, p481, p482, p483, p484, p485, p486, p487, p488, or p489 is.

[0423] (immunostimulatory polynucleotides) The immunostimulatory polynucleotides of the invention can function as PAMPs and stimulate innate immunity. Activating a response or inducing TLR9 signaling (e.g., as a TLR9 agonist) The immunostimulatory polynucleotides of the present invention can stimulate adaptive immune responses. The sequences that can be used in this context are those known in the art for class B CpG polynucleotides. or a modified form thereof including 5-halouridine or 5-alkynyluridine, or a truncation thereof The truncated versions of the present invention are those containing a total of 6 to 16 nucleosides. The immunostimulatory polynucleotides (e.g., those containing a total of 6 to 16 nucleosides) are A truncated class B CpG polynucleotide sequence (e.g., one or more 3'-terminal nucleotides removed) or one or more nucleotides in said sequence are excised. The nucleic acid sequence may contain a nucleic acid sequence (nucleotide sequence).

[0424] The immunostimulatory polynucleotides of the invention contain at least one immunostimulatory sequence (ISS). For example, the immunostimulatory polynucleotides of the invention may contain 1, 2, 3, or 4 ISSs. The ISS in the immunostimulatory polynucleotide is determined by the target organism. A common feature of ISSs used in immunostimulatory polynucleotides is the cytidine-p-guanosine a syn-sequence, where p is an internucleoside phosphodiester (e.g., phosphate or phosphorothioate) or internucleoside phosphotriester. In fact, the cytidine and guanosine in ISS contain 2'-deoxyribose. In some embodiments, the immunostimulatory polynucleotides of the invention contain one, two, or three human ISSs. For example, the human ISS can be CG or NCG, where N is uridine, cysteine, or methyl. uridine or cytidine modifications as disclosed herein. versions (e.g., 5-halouridine (e.g., 5-iodouridine or 5-bromouridine) uridine), 5-alkynyluridine (e.g., 5-ethynyluridine or 5-propynyluridine) ), 5-heteroaryluridine, or 5-halocytidine); and G is guanosine or and modified versions thereof (e.g., 7-deazaguanosine) as disclosed herein. For example, the human ISS is NCG (e.g., where N is 5-halouridine). In some embodiments, the human ISS is UCG (e.g., where U is 5-alkynyluricoside). Preferably, the immunogens of the present invention target humans. The immunostimulatory polynucleotide is a polynucleotide consisting of four adjacent nucleotides, including the 5'-terminal nucleotide. Contains an ISS (e.g., the immunostimulatory polynucleotides of the invention contain a 5'-terminal ISS) The mouse ISS is a hexameric nucleotide sequence: Pu-Pu-CG-Py-Py, where each Pu is , independently, a purine nucleotide, and each Py is independently a pyrimidine nucleotide. It is Do.

[0425] In some embodiments, the 5'- to CpG in the immunostimulatory polynucleotides of the invention The flanking nucleotides do not contain 2'-alkoxyribose. The 5'-adjacent nucleotide to the CpG in the stimulatory polynucleotide is a 2'-deoxyribose It contains malt as sugar.

[0426] Structural features of the immunostimulatory polynucleotides of the present invention include: (1) a high content of phosphorothioates; nucleotides (e.g., at least 50%, at least 60%, at least 70%, or (2) lack of a poly-G tail; (3) The nucleosides in the immunostimulatory polynucleotide are 2'-deoxyribose or 2'-modified Ribose (e.g., 2'-halo (e.g., 2'-fluoro) or optionally substituted 2'-alkoxy (4) inclusion of a 5'-terminal ISS that is NCG (e.g., 2'-methoxy) wherein N is uridine, cytidine, or thymidine, or any of the uridine, cytidine, or thymidine groups disclosed herein. modified versions of uridine or cytidine (e.g., 5-halouridine (e.g., 5-iodouridine) or 5-bromouridine), 5-alkynyluridine (e.g., 5-ethynyluridine or 5-propynyluridine, 5-heteroaryluridine, or 5-halocytidine); and G is guanosine or a modified version thereof disclosed herein (e.g., 7-deazaguanosine, Shin) can be mentioned as one of the

[0427] In some embodiments, the conjugate comprises one targeting moiety (e.g., an antibody or and an antigen-binding fragment thereof) and one immunomodulatory polynucleotide covalently linked to the targeting moiety. Contains do.

[0428] (immunosuppressive polynucleotides) The polynucleotides of the present invention inhibit the activation of TLR9 signaling (for example, inhibit TLR9 signaling). By reducing the immune response (through the immune system), the adaptive immune response can be suppressed. In embodiments, the immunosuppressive polynucleotide of the present invention has the following formula: 1 -N 2 -CG (wherein N 1 Reach BiN 2 each independently contains a 2'-alkoxyribose (e.g., 2'-methoxyribose). at least two nucleotides 5' to the CpG, described by It contains two 2'-alkoxynucleotides.

[0429] (Structural features of polynucleotides) (Abasic spacer) The immunomodulatory polynucleotides disclosed herein may be prepared by one or more (e.g., one or two) desalting steps. Group spacers (e.g., internucleoside abasic spacers and / or terminal abasic spacers When the immunomodulatory polynucleotide contains two or more abasic spacers, the abasic spacers may be The base spacer structures may be the same or different.

[0430] The abasic spacer is of formula (I): R 1 -L 1 -[-L 2 -(L 1 ) n1 -] n2 -R 2 ,(I) (In the formula, n1 is 0 or 1, n2 is an integer from 1 to 6, R 1 is the bond to the nucleoside in the immunomodulatory polynucleotide, R 2 The bond to the nucleoside or the bond to the capping group in the immunomodulatory polynucleotide is a combination, Each L 1 are independently a phosphodiester or a phosphotriester, and Each L2 is a sugar analogue).

[0431] In certain embodiments, the abasic spacer is an internucleoside abasic spacer. If n1 is 1, and R 2 is a bond with a nucleoside, and the abasic spacer is at the end When the abasic spacer is 2 is the bond with the capping group be.

[0432] In some embodiments, the abasic spacer is an internucleoside abasic spacer or an abasic spacer at the 3'-end. L 2 The group is L 1 groups (e.g., two adjacent L 2 Located between the bases L 1 (In this case, n1 is 1).

[0433] In certain embodiments, the immunostimulatory polynucleotide is containing an ISS located within four consecutive nucleotides including the 5'-terminal nucleotide, wherein the ISS is NCG, where N is uridine, cytidine, or thymidine, or are modified versions of uridine or cytidine (e.g., 5-halourine) as disclosed herein. uridines (e.g., 5-iodouridine or 5-bromouridine), 5-alkynyluridines (e.g., For example, 5-ethynyluridine or 5-propynyluridine), 5-heteroaryluridine , or 5-halocytidine), and N and C are linked to each other via a phosphodiester or phosphotriester.

[0434] (sugar analog) Sugar analogs have two hydroxyl groups bonded to (i) the oxygen atom in one phosphate ester and (ii) the oxygen atom in the other phosphate ester. and (ii) a bond to an oxygen atom in another phosphate ester or to a capping group. C modified to convert 3-6 Monosaccharide or C 3-6 Alditols (e.g., glycerol) Sugar analogs can be cyclic or acyclic. The optional modifications are: one, two, or three of the remaining hydroxyl groups or carbon-bonded hydrogen atoms and H; optionally substituted C 1-6 Alkyl; -Link A(-T) as defined herein p ;conjugated groups; -(CH2) t1 -OR Z (where t1 is an integer from 1 to 6, and R Z is an arbitrarily substituted C 1-6 Al Kill, optionally replaced C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 6-14 Aryl, optionally substituted C 3-8 Cycloalkyl, optionally substituted (C 1-9 F Tetracyclyl)-C 1-6 -alkyl, optionally substituted (C 6-10 Aryl)-C 1-6 -alkyl, or Optionally substituted (C 3-8 Cycloalkyl)-C 1-6 -alkyl); one or two substituted Introduction of saturation (e.g., one or two double bonds); and one, two, or three hydrogen or hydroxyl groups and alkyl, alkenyl, cycloalkyl, cycloalkenyl, or heterocyclyl In some embodiments, R Z is optional C replaced by 1-6 Aminoalkyl (e.g., optionally substituted C containing —NH 1-6 amino alkyl).

[0435] Non-limiting examples of sugar analogs include optionally substituted C 2-6 Alkylene, optionally substituted C 2-6 Alkenylene, optionally substituted C5 cycloalkane-1,3-diyl, optionally substituted C5 cycloalkane-1,3-diyl chloroalkene-1,3-diyl, optionally substituted heterocycle-1,3-diyl (e.g., optionally substituted optionally substituted pyrrolidine-2,5-diyl, optionally substituted tetrahydrofuran-2,5-diyl, or optionally substituted tetrahydrothiophene-2,5-diyl), or optionally substituted (C 1-4 a Rukill)-(C 3-8 cycloalkylene) (e.g., optionally substituted (C alkyl)-(C cycloalkylene) Non-limiting examples of sugar analogs are: [ka] (where, R 1 and R 2 each is independently a bond to an oxygen atom in a phosphate ester; R 3 and R 4 each independently represents H; optionally substituted C 1-6 Alkyl;-(CH2) t1 -OR Z ;or-li Link AR T and; where t1 is an integer from 1 to 6; R Z is an arbitrarily substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6Alkynyl, optionally substituted C 6-14 Aryl, optionally substituted C 3-8 Cyclo Alkyl, optionally substituted (C 1-9 Heterocyclyl)-C 1-6 -alkyl, optionally substituted (C 6-10 Aryl)-C 1-6 -alkyl, optionally substituted (C 3-8 Cycloalkyl)-C 1-6 -Alkyl and; Link A is a linker; and R T represents the targeting moiety; the conjugation moiety; the optionally substituted C 1-6 Alkyl, optionally substituted Replaced C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 6-14 a Reel, optionally substituted C 3-8 Cycloalkyl, optionally substituted (C 1-9 Heterocyclyl) -C 1-6 -alkyl, optionally substituted (C 6-10 Aryl)-C 1-6 -alkyl, or optionally substituted (C 3-8 Cycloalkyl)-C 1-6 -alkyl).

[0436] In some embodiments, R Z is an arbitrarily substituted C 1-6 Aminoalkyl (e.g., -NH containing optionally substituted C 1-6 aminoalkyl).

[0437] (phosphoester) The immunomodulatory polynucleotides of the invention may comprise one or more internucleoside phosphotriesters and and / or one or two terminal phosphodiesters and / or phosphotriesters The phosphotriester may have one or two valencies linked to a nucleoside and / or an abasic spacer. and the remaining valence is substituted with a bioreversible group, a non-bioreversible group, a targeting moiety, a linker attached to the molecule, or a conjugate group attached to a phosphate, phosphorothioate, or The internucleoside phosphotriester may contain: It is bound to two nucleosides and / or abasic spacers, and the remaining valence is a bioreversible group, a non-bioreversible group, a linker attached to a targeting moiety, or a conjugate group An internucleoside phosphodiester is a nucleotide that connects two nucleosides and / or an abasic spacer. The terminal phosphodiester is linked to the 5'- or 3'-terminated portion of the immunomodulatory polynucleotide. containing terminal phosphate, phosphorothioate, or phosphorodithioate, One of the remaining two valencies can be attached to a bioreversible group, a non-bioreversible group, or a targeting moiety. The linker or conjugate group is connected to the

[0438] Linker and Conjugation Moieties The immunomodulatory polynucleotides of the invention are linked to a targeting moiety and, optionally, one or more auxiliary moieties. The linker may contain a linker having a molecular weight of 43 Da to 10 kDa (for example, 100 Da to 8 kDa, 100 The linker has a molecular weight of from 100 Da to 7 kDa, or from 100 Da to 3 kDa. The linker may be represented as A. The first valence of the linker is an internucleoside or terminal phosphonate. Phosphorothioate, internucleoside or terminal, Attached to terminal phosphorodithioates, abasic spacers, capping groups, or nucleobases The linker may be a polyvalent group having a first valence and a second valence attached to a targeting moiety. The anchor further comprises one or more valence atoms, each of which is independently attached to an ancillary moiety. In some embodiments (e.g., when the targeting moiety is a small molecule), immunomodulatory The polynucleotide contains multiple linkers to multiple targeting moieties. In such a case (e.g., when the targeting moiety is an antibody or an antigen-binding fragment thereof), the immunomodulatory polypeptide The nucleotide may contain one linker to the targeting moiety.

[0439] The immunomodulatory polynucleotides disclosed herein can include a conjugate group. Conjugation reactions (e.g., cycloaddition reactions (e.g., dipolar cycloaddition), amidation reactions or nucleophilic aromatic substitution), or the functional group is deprotected. At least one of the nucleotides that becomes capable of undergoing a conjugation reaction when protected Upon reaction with a complementary reactive group, the conjugate group becomes an immunoconjugate of the present invention. This generates a linker in the immunoregulatory polynucleotide.

[0440] In certain embodiments, the linker attached to the targeting moiety is an internucleoside phospho In some embodiments, the linker attached to the targeting moiety is a phototriester moiety. is part of the abasic spacer.

[0441] In some embodiments, the linker (e.g., Link A) or conjugate group is of formula (II): Because: -Z 1 -Q A1 -Z 2 -(-QA2 -Z 3 -) k -R T , (II) (In the formula, Z 1 is a divalent, trivalent, tetravalent, or pentavalent radical, where one of the valences is Q A1 and the second valence is either vacant or the formula (II) relates to the linker. If R T and each of the remaining valences, if present, is independently Attached to the auxiliary part; Z 2 is absent, a divalent group, a trivalent group, a tetravalent group, or a pentavalent group, where One is Q A1 and the second valence is Q A2 or R T and the remaining atoms each of the subvalents, if present, is independently attached to the auxiliary moiety; Z 3 is absent, a divalent group, a trivalent group, a tetravalent group, or a pentavalent group, where One is Q A2 and the second valence is R T and each of the remaining valences are, when present, independently attached to an auxiliary moiety; R T is absent or linked to a targeting moiety; k is 0 or 1).

[0442] When formula (II) relates to a linker, Q A1 and Q A2 are independently absent, optionally substituted C 2-12 Heteroalkylene (e.g., -C Heteroalkyl groups containing (O)-N(H)-, -N(H)-C(O)-, -S(O)2-N(H)-, or -N(H)-S(O)2- len), optionally substituted C 1-12 Thioheterocyclylenes (e.g., [ka] ), optionally substituted C 1-12 Heterocyclylenes (e.g., 1,2,3-triazole-1,4-diyl) Or [ka] ), cyclobut-3-ene-1,2-dione-3,4-diyl, pyrid-2-ylhydrazone, optionally substituted C 6-16 Triazoloheterocyclylenes (e.g., [ka] ), optionally substituted C 8-16 Triazolocycloalkenylene (e.g., [ka] ), or a dihydropyridazine group (e.g., [ka] ) and R T is the bond to the targeting moiety; However, Q A1 and Q A2 At least one of these exists.

[0443] When formula (II) relates to a conjugated group: (i)Q A2 does not exist and Q A1 represents a conjugation moiety, e.g., an optionally substituted C 2-12 Alkynyl, optionally substituted N-protected amino, azide, N-maleimide, S-protected thiol Lu, [ka] or N-protected versions of these, [ka] , optionally substituted C containing an endocyclic carbon-carbon triple bond 6-16 Heterocyclyl (e.g., [ka] ), 1,2,4,5-tetrazine groups (e.g., [ka] ), or optionally substituted C 8-16 Cycloalkynyl (e.g., [ka] ), -NHR N1 , optionally substituted C 4-8 Strained cycloalkenyl (e.g., trans-cyclooctenyl) norbornenyl or norbornenyl, or -COOR 12 or an optionally substituted C containing -CHO 1-1 6 alkyl; and Is k 0? or (ii) Q A1 is as defined for the linker, and Q A2 Is conjugation an optionally substituted C 2-12 Alkynyl, optionally substituted N-protected amino , azide, N-maleimide, S-protected thiol, [ka] or N-protected versions of these, [ka] , optionally substituted C containing an endocyclic carbon-carbon triple bond 6-16Heterocyclyl (e.g., [ka] ), 1,2,4,5-tetrazine groups (e.g., [ka] ), or optionally substituted C 8-16 Cycloalkynyl (e.g., [ka] ), -NHR N1 , optionally substituted C 4-8 Strained cycloalkenyl (e.g., trans-cyclooctenyl) norbornenyl or norbornenyl, or -COOR 12 or an optionally substituted C containing -CHO 1-1 6 alkyl; and k is 1; where: R N1 is H, an N-protecting group, or an optionally substituted C 1-6 is alkyl; Each R 12 are independently H or optionally substituted C 1-6 is alkyl; R 13 is a halogen (e.g., F); Z 3 and R T does not exist.

[0444] In some embodiments, Z 1 has a branching group and two divalent segments, a branched group is attached to each of the two divalent segments; where: One of the bivalent segments may be an internucleoside or terminal phosphate, Internucleoside or terminal phosphorothioates, internucleoside or terminal phosphorodithioates a base, an abasic spacer, or a nucleobase, and the remaining bivalent segment To Q A1 is bound to; The branched group may be an optionally substituted C 1-12 Alkane-triyl or optionally substituted C 2-12 F Tetraalkane-triyl, wherein the two valencies are substituted with the divalent segment. and the remaining valences are [ka] has been replaced with where: p1 is 1, 2, or 3; each s2 is independently an integer from 0 to 10; Each Q B and each Q D are independently absent, -CO-, -NH-, -O-, -S-, -SO2-, -OC(O)-, -COO-, -NHC(O)-, -C(O)NH-, -CH2-, -CH2NH-, -NHCH2-, -CH2O-, or -OCH2-; or t Each Q C are independently absent, optionally substituted C 1-12 Alkylene, optionally substituted C 2-12 Alkenylene, optionally substituted C 2-12 Alkynylene, optionally substituted C 2-12 Hetero Alkylene, optionally substituted C 1-9 heterocyclylene, or -P(Z)(OH)-, where Z is O or S; Each Q G are independently optionally substituted C 1-6 Alkane-triyl, optionally substituted C 1- 6-Alkane-tetrayl, optionally substituted C 2-6 heteroalkane-triyl, or optionally substituted Replaced C 2-6 Heteroalkane-tetrayl; and Each Q H are independently, R M1 or -Q G [(-Q B -Q C -Q D ) s2 -R M1 ] p1 where each R M1 teeth , independently, is a bond with an auxiliary moiety.

[0445] In some embodiments, Z 2 has a branching group and two divalent segments, a branched group is attached to each of the two divalent segments; where: One of the bivalent segments is a targeting moiety or Q A2 and the remaining divalent Segment is Q A1 is bound to; The branched group may be an optionally substituted C 1-12 Alkane-triyl or optionally substituted C 2-12 F Tetraalkane-triyl, wherein the two valencies are substituted with the divalent segment. and the remaining valences are [ka] has been replaced with where: p1 is 1, 2, or 3; each s2 is independently an integer from 0 to 10; Each Q B and each Q D are independently absent, -CO-, -NH-, -O-, -S-, -SO2-, -OC(O)-, -COO-, -NHC(O)-, -C(O)NH-, -CH2-, -CH2NH-, -NHCH2-, -CH2O-, or -OCH2-; or t Each Q C are independently absent, optionally substituted C 1-12 Alkylene, optionally substituted C 2-12 Alkenylene, optionally substituted C 2-12 Alkynylene, optionally substituted C 2-12 Hetero Alkylene, optionally substituted C 1-9 heterocyclylene, or -P(Z)(OH)-, where Z is O or S; Each Q G are independently optionally substituted C 1-6 Alkane-triyl, optionally substituted C 1- 6-Alkane-tetrayl, optionally substituted C 2-6 heteroalkane-triyl, or optionally substituted Replaced C 2-6 Heteroalkane-tetrayl; and Each Q H are independently, R M1 or -Q G [(-Q B -Q C -Q D ) s2 -R M1 ] p1 where each R M1 teeth , independently, is a bond with an auxiliary moiety.

[0446] In some embodiments, Z 3 has a branching group and two divalent segments, a branched group is attached to each of the two divalent segments; where: One of the bivalent segments is bound to a targeting moiety, and the remaining bivalent segments are bound to a targeting moiety. The answer is Q A2 is bound to; The branched group may be an optionally substituted C 1-12 Alkane-triyl or optionally substituted C 2-12 F Tetraalkane-triyl, wherein the two valencies are substituted with the divalent segment. and the remaining valences are [ka] has been replaced with where: p1 is 1, 2, or 3; each s2 is independently an integer from 0 to 10; Each Q B and each Q D are independently absent, -CO-, -NH-, -O-, -S-, -SO2-, -OC(O)-, -COO-, -NHC(O)-, -C(O)NH-, -CH2-, -CH2NH-, -NHCH2-, -CH2O-, or -OCH2-; or t Each Q C are independently absent, optionally substituted C 1-12 Alkylene, optionally substituted C 2-12 Alkenylene, optionally substituted C 2-12 Alkynylene, optionally substituted C 2-12 Hetero Alkylene, optionally substituted C 1-9 heterocyclylene, or -P(Z)(OH)-, where Z is O or S; Each Q G are independently optionally substituted C 1-6 Alkane-triyl, optionally substituted C 1- 6-Alkane-tetrayl, optionally substituted C 2-6 heteroalkane-triyl, or optionally substituted Replaced C 2-6 Heteroalkane-tetrayl; and Each Q H are independently, R M1 or -Q G [(-Q B -Q C -Q D ) s2-R M1 ] p1 where each R M1 teeth , independently, is a bond with an auxiliary moiety.

[0447] Z 1 , Z 2 , or Z 3 The bivalent segment in the -(-Q B -Q C -Q D -) s1 - may be, where: each s1 is independently an integer from 1 to 50 (e.g., 1 to 30); Each Q B and each Q D are independently absent, -CO-, -NH-, -O-, -S-, -SO2-, -OC(O)-, -COO-, -NHC(O)-, -C(O)NH-, -CH2-, -CH2NH-, -NHCH2-, -CH2O-, or -OCH2-; or t Each Q C are independently absent, optionally substituted C 1-12 Alkylene, optionally substituted C 2-12 Alkenylene, optionally substituted C 2-12 Alkynylene, optionally substituted C 2-12 Hetero Alkylene, or optionally substituted C 1-9 is a heterocyclylene; However, Q B , Q C , and Q D At least one of these exists.

[0448] In some embodiments, at least one Q C is present in the bivalent segment. In one embodiment, Q C is present in each monomer unit of the divalent segment. In one embodiment of the present invention, Z 1 Q existsC In a further embodiment, Te, Q B and Q D At least one of the 1 It is present in each monomer unit of the In another embodiment, Q B and Q D At least one of the 2 Each monomer unit of In certain embodiments, when present, Z 1 , Z 2 , and Z 3 It's one of Contains branched groups.

[0449] In still further embodiments, Z 1 , Z 2 , and Z 3 One, two, or three of the To, -(-Q B -Q C -Q D -) s1 -Q E -(-Q B -Q C -Q D -) s1 -, (III) where: each s1 is independently an integer from 1 to 50 (e.g., 1 to 30); Each Q B and each Q D are independently absent, -CO-, -NH-, -O-, -S-, -SO2-, -OC(O)-, -COO-, -NHC(O)-, -C(O)NH-, -CH2-, -CH2NH-, -NHCH2-, -CH2O-, or -OCH2-; or t Each Q C are independently absent, optionally substituted C 1-12 Alkylene, optionally substituted C 2-12 Alkenylene, optionally substituted C2-12 Alkynylene, optionally substituted C 2-12 Hetero Alkylene, optionally substituted C 1-9 heterocyclylene, or -P(Z)(OH)-, where Z is O or S; and Q E is absent or a branched group of formula (IV): [ka] During the ceremony, p1 is 1, 2, or 3; each s2 is independently an integer from 0 to 10; Q F is an arbitrarily substituted C 1-12 Alkane-triyl or optionally substituted C 2-12 Heteroa is rucan-triyl; and Each Q G are independently optionally substituted C 1-6 Alkane-triyl, optionally substituted C 1- 6-Alkane-tetrayl, optionally substituted C 2-6 heteroalkane-triyl, or optionally substituted Replaced C 2-6 Heteroalkane-tetrayl; and Each Q H are independently, R M1 or -Q G [(-Q B -Q C -Q D ) s2 -R M1 ] p1 where each R M1 teeth , independently, is a bond with an auxiliary moiety.

[0450] In formula (IV), when p1 is 1, Q G is not present; if p1 is 2 or 3, then at least Another Q G exists.

[0451] In certain embodiments, Z 1 Q exists C via the internucleoside or terminal phosphate thioate, internucleoside or terminal phosphorothioate, internucleoside or terminal phosphoro Dithioates, abasic spacers, capping groups, or nucleobases are attached.

[0452] In certain embodiments, Q B , Q C , Q D , and Q E At least one of the segments is a bivalent segment. present in the sample (e.g., at least one Q C Does Q exist? E exists or Q E There exists In some embodiments, each Q B and each Q D are independently absent, -CO-, - NH-, -O-, -S-, -SO2-, -NHC(O)-, -C(O)NH-, -CH2-, -CH2NH-, -NHCH2-, -CH2O-, or -O It is CH2-.

[0453] In some embodiments, -(-Q B -Q C -Q D -) s1 - combined to form the group: -Q B -(CH2) g1 -(CH2OCH2) g2 -(CH2) g3 -Q D - Forming where: (i) g2 is an integer from 1 to 50; (ii) g1 is 1 and Q B is -NHCO-, -CONH-, or -O-; or g1 is 0 and Q D is -NHCO-; and (iii) g3 is 1 and Q B is -NHCO-, -CONH-, or -O-; or g3 is 0 and Q D is -CONH-.

[0454] The conjugation moiety is conjugated to the polynucleotide until the auxiliary moiety is conjugated to the polynucleotide. For example, a protected conjugation moiety may be -COOR PGO or -NHR PGN where R PGO is an O-protecting group (e.g., a carboxyl protecting group) Yes and R PGN is an N-protecting group.

[0455] In a further embodiment, link A is [ka] and where: Q A1 and Q A2 each of which is an absent, independently optionally substituted C 2-12 Heteroalkylene (e.g. , -C(O)-N(H)-, -N(H)-C(O)-, -S(O)2-N(H)-, or -N(H)-S(O)2- alkylene), optionally substituted C 1-12 Thioheterocyclylenes (e.g., [ka] ), optionally substituted C 1-12 Heterocyclylenes (e.g., 1,2,3-triazole-1,4-diyl) Or [ka] ), cyclobut-3-ene-1,2-dione-3,4-diyl, pyrid-2-ylhydrazone, optionally substituted C 6-16 Triazoloheterocyclylenes (e.g., [ka] ), optionally substituted C 8-16 Triazolocycloalkenylene (e.g., [ka] ), or a dihydropyridazine group (e.g., [ka] ), where Q A1 and Q A2 At least one of is present; R T is the bond to the targeting moiety; R P is an internucleoside bridging group, a nucleobase, a capping group, or an abasic spacer It is a combination with; Q T is -CO-, -NH-, -NH-CH2-, or -CO-CH2-; Each Q S are independently optionally substituted C 2-12 Alkylene, optionally substituted C 2-12 Al kenylene, optionally substituted C 2-12 Alkynylene, or optionally substituted (C 6-10 aryl) -C 1-6 - alkylene; Each R M are independently H, ancillary moieties, -(CH2) q7 -CO-N(R M1 )2, or -C[-CH2O-(CH2) q7 -CO- N(R M1 )2]3, wherein each q7 is independently an integer from 1 to 5, and each RM1 teeth, independently, H or an auxiliary moiety; X 1 , X 3 , and X 5 each independently represents absent, —O—, —NH—, —CH—NH—, —C(O)—, —C(O)—NH— , -NH-C(O)-, -NH-C(O)-NH-, -OC(O)-NH-, -NH-C(O)-O-, -CH2-NH-C(O)-NH-, -CH2-OC( -O)-NH-, or -CH-NH-C(O)-O-; X 7 represents absence, -O-, -OP(O)(OH)-O-, -OP(S)(OH)-O-, -NH-, -CH2-NH-, -C(O)-, -C( O)-NH-, -NH-C(O)-, -NH-C(O)-NH-, -OC(O)-NH-, -NH-C(O)-O-, -CH2-NH-C(O)-NH-, -CH 2-OC(O)-NH-, or -CH-NH-C(O)-O-; X 2 , X 4 , and X 6 each independently represents absent, —O—, —NH—, —C(O)—, —C(O)—NH—, —NH—C(O) -, -NH-C(O)-NH-, -OC(O)-NH-, or -NH-C(O)-O-; x1 and each x5 are independently 0 or 1; each x2 is independently an integer from 0 to 50 (e.g., from 1 to 40 or from 1 to 30); each x3 is independently an integer from 1 to 11; x4 is 0, 1, or 2; and Each x6 is independently an integer between 0 and 10 (e.g., 1 and 6), provided that the sum of both x6s is 12. The following is the result.

[0456] In still further embodiments, link A is [ka] and where: Q A1 is an arbitrarily substituted C 2-12 Heteroalkylene (e.g., -C(O)-N(H)-, -N(H)-C(O)- , -S(O)2-N(H)-, or -N(H)-S(O)2- containing heteroalkylene), optionally substituted TaC 1-12 Thioheterocyclylenes (e.g., [ka] ), optionally substituted C 1-12 Heterocyclylenes (e.g., 1,2,3-triazole-1,4-diyl) Or [ka] ), cyclobut-3-ene-1,2-dione-3,4-diyl or pyrid-2-ylhydrazone), any C replaced by 6-16 Triazoloheterocyclylenes (e.g., [ka] ), optionally substituted C 8-16 Triazolocycloalkenylene (e.g., [ka] ), or a dihydropyridazine group (e.g., [ka] ) and; Each R M1 are independently H or an auxiliary moiety; R T is the bond to the targeting moiety; R P is an internucleoside bridging group, a nucleobase, a capping group, or an abasic spacer It is a combination with; Q T is -CO-, -NH-, -NH-CH2-, or -CO-CH2-; Q P is -C(O)-N(H)-, -N(H)-C(O)-, -S(O)-N(H)-, or -N(H)-S(O)-; Each Q S are independently optionally substituted C 2-12 Alkylene, optionally substituted C 2-12 Al kenylene, optionally substituted C 2-12 Alkynylene, or optionally substituted (C 6-10 aryl) -C 1-6 - alkylene; Each of q1, q3, and q7 is independently 0 or 1; Each of q2 and q8 is an integer of 0 to 50 (e.g., 1 to 40 or 1 to 30); q4 is an integer from 0 to 10; Each of q5 and q6 is independently an integer from 1 to 10 (e.g., 1 to 6); and q9 is an integer from 1 to 10.

[0457] In still further embodiments, link A is [ka] and where: In each structural formula, one [ka] represents a single bond, and the other, [ka] represents a double bond; Each R M1 are independently H or an auxiliary moiety; R T is the bond to the targeting moiety; R Pis an internucleoside bridging group, a nucleobase, a capping group, or an abasic spacer It is a combination with; Q T is -CO-, -CO-CH2-, -NH-, or -NH-CH2-; Q P is -C(O)-N(H)-, -N(H)-C(O)-, -S(O)-N(H)-, or -N(H)-S(O)-; Each Q S are independently optionally substituted C 2-12 Alkylene, optionally substituted C 2-12 Al kenylene, optionally substituted C 2-12 Alkynylene, or optionally substituted (C 6-10 aryl) -C 1-6 - alkylene; Each of q1, q3, and q7 is independently 0 or 1; Each of q2 and q8 is an integer of 0 to 50 (e.g., 1 to 40 or 1 to 30); q4 is an integer from 0 to 10; Each of q5 and q6 is independently an integer from 1 to 10 (e.g., 1 to 6); and q9 is an integer from 1 to 10.

[0458] In some embodiments, q5 is 0. In other embodiments, q5 is an integer from 2 to 6. It's a number.

[0459] In certain embodiments, the conjugate group is: [ka] and where: Q A1 are independently optionally substituted C 2-12 Heteroalkylene (e.g., -C(O)-N(H)-, -N(H )-C(O)-, -S(O)2-N(H)-, or -N(H)-S(O)2- containing heteroalkylene), optionally substituted Replaced C 1-12 Thioheterocyclylenes (e.g., [ka] ), optionally substituted C 1-12 Heterocyclylenes (e.g., 1,2,3-triazole-1,4-diyl) Or [ka] ), cyclobut-3-ene-1,2-dione-3,4-diyl, pyrid-2-ylhydrazone, optionally substituted C 6-16 Triazoloheterocyclylenes (e.g., [ka] ), optionally substituted C 8-16 Triazolocycloalkenylene (e.g., [ka] ), or a dihydropyridazine group (e.g., [ka] ) and; Q A2 is an arbitrarily substituted C 2-12 Alkynyl, optionally substituted N-protected amino, azido, N-maleimide, S-protected thiol, [ka] or N-protected versions of these, [ka] , optionally substituted C containing an endocyclic carbon-carbon triple bond 6-16 Heterocyclyl (e.g., [ka] ), 1,2,4,5-tetrazine groups (e.g., [ka] ), or optionally substituted C 8-16 Cycloalkynyl (e.g., [ka] ), -NHR N1 , optionally substituted C 4-8 Strained cycloalkenyl (e.g., trans-cyclooctenyl) norbornenyl or norbornenyl, or -COOR 12 or an optionally substituted C containing -CHO 1-1 6 alkyl; R N1 is H, an N-protecting group, or an optionally substituted C 1-6 is alkyl; Each R 12 are independently H or optionally substituted C 1-6 is alkyl; R 13 is a halogen (e.g., F); R P is an internucleoside bridging group, a nucleobase, a capping group, or an abasic spacer It is a combination with; Each Q S are independently optionally substituted C 2-12 Alkylene, optionally substituted C 2-12 Al kenylene, optionally substituted C 2-12 Alkynylene, or optionally substituted (C 6-10 aryl) -C 1-6 - alkylene; Each R M are independently H, ancillary moieties, -(CH2) q7 -CO-N(R M1)2, or -C[-CH2O-(CH2) q7 -CO- N(R M1 )2]3, wherein each q7 is independently an integer from 1 to 5, and each R M1 teeth, independently, H or an auxiliary moiety; X 3 and X 5 each independently represents absent, —O—, —NH—, —CH—NH—, —C(O)—, —C(O)—NH—, —NH— C(O)-, -NH-C(O)-NH-, -OC(O)-NH-, -NH-C(O)-O-, -CH2-NH-C(O)-NH-, -CH2-OC(O)-NH- or —CH—NH—C(O)—O—; X 7 represents absence, -O-, -OP(O)(OH)-O-, -OP(S)(OH)-O-, -NH-, -CH2-NH-, -C(O)-, -C(O )-NH-, -NH-C(O)-, -NH-C(O)-NH-, -OC(O)-NH-, -NH-C(O)-O-, -CH2-NH-C(O)-NH-, -CH2 -OC(O)-NH-, or -CH-NH-C(O)-O-; X 2 , X 4 , and X 6 each independently represents absent, —O—, —NH—, —O—, —C(O)—, —C(O)—NH—, —NH -C(O)-, -NH-C(O)-NH-, -OC(O)-NH-, or -NH-C(O)-O-; x1 and each x5 are independently 0 or 1; each x2 is independently an integer from 0 to 50 (e.g., from 1 to 40 or from 1 to 30); each x3 is independently an integer from 1 to 11; x4 is 0, 1, or 2; and Each x6 is independently an integer between 0 and 10 (e.g., 1 and 6), provided that the sum of both x6s is 12. The following is the result.

[0460] In some embodiments, the conjugate group is: [ka] and where: Q A1 is an arbitrarily substituted C 2-12 Alkynyl, optionally substituted N-protected amino, azido, N-maleimide, S-protected thiol, [ka] or N-protected versions of these, [ka] , optionally substituted C containing an endocyclic carbon-carbon triple bond 6-16 Heterocyclyl (e.g., [ka] ), 1,2,4,5-tetrazine groups (e.g., [ka] ), or optionally substituted C 8-16 Cycloalkynyl (e.g., [ka] ), -NHR N1 , optionally substituted C 4-8 Strained cycloalkenyl (e.g., trans-cyclooctenyl) norbornenyl or norbornenyl, or -COOR 12 or an optionally substituted C containing -CHO 1-1 6 alkyl; R N1 is H, an N-protecting group, or an optionally substituted C 1-6 is alkyl; Each R 12 are independently H or optionally substituted C1-6 is alkyl; R 13 is a halogen (e.g., F); R P is an internucleoside bridging group, a nucleobase, a capping group, or an abasic spacer It is a combination with; Each Q S are independently optionally substituted C 2-12 Alkylene, optionally substituted C 2-12 Al kenylene, optionally substituted C 2-12 Alkynylene, or optionally substituted (C 6-10 aryl) -C 1-6 - alkylene; X 7 represents absence, -O-, -NH-, -OP(O)(OH)-O-, -OP(S)(OH)-O-, -CH2-NH-, -C(O)-, -C( O)-NH-, -NH-C(O)-, -NH-C(O)-NH-, -OC(O)-NH-, -NH-C(O)-O-, -CH2-NH-C(O)-NH-, -CH 2-OC(O)-NH-, or -CH-NH-C(O)-O-; X 6 is absent, -O-, -NH-, -O-, -C(O)-, -C(O)-NH-, -NH-C(O)-, -NH-C(O)-NH-, -OC (O)-NH-, or -NH-C(O)-O-; x1 is independently 0 or 1; each x2 is independently an integer from 0 to 50 (e.g., from 1 to 40 or from 1 to 30); each x3 is independently an integer from 1 to 11; and x4 is 0, 1, or 2.

[0461] In some embodiments, the conjugate group is: [ka] and where: Q A1 is an arbitrarily substituted C 2-12 Alkynyl, optionally substituted N-protected amino, azido, N-maleimide, S-protected thiol, [ka] or N-protected versions of these, [ka] , optionally substituted C containing an endocyclic carbon-carbon triple bond 6-16 Heterocyclyl (e.g., [ka] ), 1,2,4,5-tetrazine groups (e.g., [ka] ), or optionally substituted C 8-16 Cycloalkynyl (e.g., [ka] ), -NHR N1 , optionally substituted C 4-8 Strained cycloalkenyl (e.g., trans-cyclooctenyl) norbornenyl or norbornenyl, or -COOR 12 or an optionally substituted C containing -CHO 1-1 6 alkyl; R N1 is H, an N-protecting group, or an optionally substituted C 1-6 is alkyl; Each R 12 are independently H or optionally substituted C 1-6 is alkyl; R 13 is a halogen (e.g., F); R P is an internucleoside bridging group, a nucleobase, a capping group, or an abasic spacer It is a combination with; Q P is -C(O)-N(H)-, -N(H)-C(O)-, -S(O)-N(H)-, or -N(H)-S(O)-; Each Q S are independently optionally substituted C 2-12 Alkylene, optionally substituted C 2-12 Al kenylene, optionally substituted C 2-12 Alkynylene, or optionally substituted (C 6-10 aryl) -C 1-6 - alkylene; Each of q1 and q3 is independently 0 or 1; q2 is an integer of 0 to 50 (e.g., 1 to 40 or 1 to 30); q4 is an integer from 0 to 10; and q5 is an integer of 1 to 10 (for example, 1 to 6).

[0462] In still further embodiments, the conjugated group is: [ka] and where: R P is an internucleoside bridging group, a nucleobase, a capping group, or an abasic spacer It is a combination with; Q P is -C(O)-N(H)-, -N(H)-C(O)-, -S(O)-N(H)-, or -N(H)-S(O)-; Each Q S are independently optionally substituted C 2-12 Alkylene, optionally substituted C 2-12 Al kenylene, optionally substituted C 2-12 Alkynylene, or optionally substituted (C 6-10 aryl) -C 1-6 - alkylene; Each of q1 and q3 is independently 0 or 1; q2 is an integer of 0 to 50 (e.g., 1 to 40 or 1 to 30); q4 is an integer from 0 to 10; and q5 is an integer of 1 to 10 (for example, 1 to 6).

[0463] In certain exemplary embodiments, the conjugated group is: [ka] TIFF2024167198000074.tif214170TIFF2024167198000075.tif231170TIFF2024167198000076.tif72170, Here, q2 is an integer of 1 to 50 (for example, an integer of 1 to 24 or 1 to 8 (for example, 2 or 3)), q4 is an integer from 0 to 10 (for example, 0, 1, 2, 3, 4, 5, 6, 7, or 8), and q10 is an integer from 0 to 8 (for example, q is an integer such as 1, 2, 3, 4, 5, or 6, q is 0 or 1, Z is O or S, and Each R M are independently H, ancillary moieties, -(CH2) q7 -CO-N(R M1 )2, or -C[-CH2O-(CH2) q7 -CO-N( R M1 )2]3, wherein each q7 is independently an integer from 1 to 5, and each R M1 is German In other words, it is an H or auxiliary part.

[0464] The following exemplary conjugate groups are suitable for conjugation with targeting moieties via metal-catalyzed cycloaddition: Can be used for: [ka] (wherein q2 is an integer of 1 to 50 (e.g., an integer of 1 to 24 or 1 to 8 (e.g., 2 or 3)), and q 4 is an integer from 0 to 10 (for example, 0, 1, 2, 3, 4, 5, 6, 7, or 8), and q10 is an integer from 0 to 8 (for example, For example, 1, 2, 3, 4, 5, or 6, where q11 is 0 or 1, and Z is O or S.

[0465] The following exemplary conjugate groups are suitable for conjugation with targeting moieties via metal-free cycloaddition: Can be used to: [ka] TIFF2024167198000079.tif216170TIFF2024167198000080.tif223170TIFF2024167198000081.tif34170 (wherein q2 is an integer of 1 to 50 (for example, an integer of 1 to 24 or 1 to 8 (for example, 2 or 3))), and q 4 is an integer from 0 to 10 (for example, 0, 1, 2, 3, 4, 5, 6, 7, or 8), and q10 is an integer from 0 to 8 (for example, q is an integer such as 1, 2, 3, 4, 5, or 6, q is 0 or 1, Z is O or S, and Each R M are independently H, ancillary moieties, -(CH2) q7 -CO-N(R M1 )2, or -C[-CH2O-(CH2) q7 -CO-N( R M1 )2]3, wherein each q7 is independently an integer from 1 to 5, and each R M1 is German In other words, H or auxiliary part).

[0466] The following exemplary conjugate groups are used for conjugation to targeting moieties via amide formation: Can be used: [ka] (wherein q2 is an integer of 0 to 50 (for example, an integer of 1 to 8 (for example, 2 or 3)), and q12 is , an integer from 1 to 11 (for example, an integer from 1 to 5 (for example, an integer of 1, 2, 3, 4, or 5)).

[0467] (bioreversible group) The bioreversible group may be 135 Da to 10 kDa (e.g., 135 Da to 5 kDa, 200 Da to 5 kDa, or 200 Da to 2 kDa). ) and is a monovalent substituent containing disulfide (-SS-). In the case of , the shortest chain of atoms covalently bonding the disulfide and valence of the bioreversible group is 2 to 10 atoms (e.g., 2 to 6 atoms or 4 to 6 atoms (e.g., 4 or 5 atoms)) Bioreversible groups are cleavable intracellularly under physiological conditions.

[0468] Bioreversible groups can be included in phosphoesters to allow, for example, the immunomodulatory polynucleotides of the invention to be synthesized. The overall negative charge of the immunomodulatory polynucleotide can be reduced. , which may enhance cellular uptake of the immunomodulatory polynucleotides and / or conjugates of the invention. The immunomodulatory polynucleotides of the invention may contain phosphoester and / or abasic spacers. In some embodiments, the immunomodulatory polymers of the present invention may contain one or more bioreversible groups. A nucleotide may contain one to six bioreversible groups (e.g., one to four bioreversible groups (e.g., one, two)). , or three bioreversible groups).

[0469] The bioreversible group can be of formula (XXII): R 5 -SS-(LinkB)-, (XXII) (In the formula, Link B is linked to a phosphate, phosphorothioate, or phosphorodithioate. Combined SP 3 is a divalent group containing a hybridized carbon atom and a carbon atom bonded to -SS-, and R5 teeth , optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 Aryl or -linked C( -R M ) r or link B is a phosphate, phosphorothioate, or phosphoro sp bound to dithioate 3 Trivalent lysine containing a hybridized carbon atom and a carbon atom bonded to -SS- linker, where the third valence of link B is -SS- and R 5 In combination with C replaced by 3-9 forming a heterocyclylene; Link C is a polyvalent group; Each R M are independently H, an auxiliary moiety, or -Q G [(-Q B -Q C -Q D ) s2 -R M1 ] p1 and where: Each R M1 are independently H or an auxiliary moiety; Each Q B and each Q D are independently absent, -CO-, -NH-, -O-, -S-, -SO2-, -OC(O)-, -COO-, -NHC(O)-, -C(O)NH-, -CH-, -CHNH-, -NHCH-, -CHO-, or -OCH-; Each Q C are independently absent, optionally substituted C 1-12 Alkylene, optionally substituted C 2-12 Alkenylene, optionally substituted C 2-12 Alkynylene, optionally substituted C 2-12 Hetero Alkylene, or optionally substituted C 1-9 is heterocyclylene, Each Q G are independently optionally substituted C 1-6 Alkane-triyl, optionally substituted C 1- 6-Alkane-tetrayl, optionally substituted C 2-6 heteroalkane-triyl, or optionally substituted Replaced C 2-6 heteroalkane-tetrayl, each s2 is independently an integer from 0 to 10; and p1 is 2 or 3; and r is an integer from 1 to 6 (e.g., 1, 2, or 3).

[0470] In some embodiments, links B and / or R 5 contains a bulky group bonded to -SS-. The inclusion of bulky groups attached to S- bonds may be beneficial, for example, for stabilizing sulfur-sulfur bonds during polynucleotide synthesis. This can enhance quality.

[0471] In further embodiments, link B consists of 1, 2, or 3 groups, each of which is independently, optionally substituted C 1-12 Alkylene, optionally substituted C 2-12 Alkenylene, any C replaced by 2-12 Alkynylene, optionally substituted C 6-10 Arylene, optionally substituted C 2-12 Heteroalkylene and optionally substituted C 1-9 Heterocyclylene It is selected.

[0472] In certain embodiments, the link B and -SS- in combination are: [ka] (where, Each R 6 are independently, C 2-7Alkanoyl; C 1-6 Alkyl; C 2-6 Alkenyl; C 2-6 Archi Nil; C 1-6 Alkylsulfinyl; C 6-10 Aryl; Amino; (C 6-10 Aryl)-C 1-4 -Arki Le; C 3-8 Cycloalkyl; (C 3-8 Cycloalkyl)-C 1-4 -Alkyl; C 3-8 cycloalkenyl; (C 3-8 Cycloalkenyl)-C 1-4 -Alkyl;Halo;C 1-9 Heterocyclyl; C 1-9 Heteroary Le;(C 1-9 heterocyclyl)oxy; (C 1-9 Heterocyclyl)aza;hydroxy; C 1-6 Thioal Coxy; -(CH2) q CO2R A (where q is an integer from 0 to 4, and R A is C 1-6 Alkyl, C 6-1 0 aryl, and (C 6-10 Aryl)-C 1-4 -(CH2) q CON R B R C (where q is an integer from 0 to 4, and R B and R C is hydrogen, C 1-6 Alkyl, C 6-10 a Reel, and (C 6-10 Aryl)-C 1-4 -(CH2) q SO2R D (where q is an integer from 0 to 4, and R D is C 1-6Alkyl, C 6-10 aryl, and (C 6-10 Aryl)-C 1-4 -(CH2) q SO2NR E R F (where q is an integer from 0 to 4, and R E and R F each independently represents hydrogen, alkyl, aryl, and Bi(C 6-10 Aryl)-C 1-4 -alkyl); thiol; aryloxy ;Cycloalkoxy;Arylalkoxy;(C 1-9 Heterocyclyl)-C 1-4 -Alkyl; (C 1-9 F Tetraaryl)-C 1-4 -Alkyl; C 3-12 Silyl; Cyano; or -S(O)R H (where R H is water C1-C6 alkyl, C 6-10 Aryl, and (C 6-10 Aryl)-C 1-4 -alkyl or two adjacent R 6 The R 6 The atom to which each group is attached Together, in combination, C6 aryl, C 2-5 Heterocyclyl, or C 2-5 Heteroary and forming a cyclic group selected from the group consisting of C 2-7 Alkanoyl; C 1-6 Alkyl; C 2-6 Alkenyl; C 2-6 Alkynyl; C 1-6 Alkylsulfinyl; C 6-10 a Reel; Amino; (C 6-10 Aryl)-C 1-4-Alkyl; C 3-8 Cycloalkyl; (C 3-8 Cycloal Kill)-C 1-4 -Alkyl; C 3-8 Cycloalkenyl; (C 3-8 Cycloalkenyl)-C 1-4 - alkyl; Halo; C 1-9 Heterocyclyl; C 1-9 Heteroaryl; (C 1-9 heterocyclyl)oxy; (C 1-9 F Tetracyclyl)aza;hydroxy; C 1-6 Thioalkoxy;-(CH2) q CO2R A (where q is 0 to 4 is an integer in R A is C 1-6 Alkyl, C 6-10 Aryl, and (C 6-10 Aryl)-C 1-4 -a -(CH2) q CONR B R C (where q is an integer from 0 to 4, TsuR B and R C is hydrogen, C 1-6 Alkyl, C 6-10 Aryl, and (C 6-10 Aryl)-C 1-4 -Arki independently selected from the group consisting of -(CH2) q SO2R D (where q is an integer from 0 to 4, TsuR D is C 1-6 Alkyl, C 6-10 Aryl, and (C 6-10 Aryl)-C 1-4 -alkyl selected from);-(CH2) q SO2NR E R F (where q is an integer from 0 to 4, and RE and R F Each each independently represents hydrogen, alkyl, aryl, and (C 6-10 Aryl)-C 1-4 -From alkyl thiol; aryloxy; cycloalkoxy; arylalkoxy; (C 1-9 Heterocyclyl)-C 1-4 -Alkyl; (C 1-9 Heteroaryl)-C 1-4 -Alkyl; C 3-12 Siri -S(O)R; Cyano; and -S(O)R H (where R H is hydrogen, C1-C6 alkyl, C 6-10 Aryl, and (C 6-10 Aryl)-C 1-4 -alkyl) or optionally substituted with 3 substituents; m1 is 0, 1, or 2; and m2 is 0, 1, 2, 3, or 4); or link B, -SS-, and R form a structure selected from the group consisting of 5 is a combination Wasa, [ka] to form a group containing

[0473] In still further embodiments, link C is 0 to 3 polyvalent monomers (e.g., optionally substituted). Replaced C 1-6 Alkane-triyl, optionally substituted C 1-6 Alkane-tetrayl, or trivalent nitrogen atom) and one or more divalent monomers (e.g., 1 to 40), where each The divalent monomers of 1-6 Alkylene; optionally substituted C2-6 a Alkenylene; optionally substituted C 2-6 Alkynylene; optionally substituted C 3-8 Cycloalkylene ; optionally substituted C 3-8 Cycloalkenylene; optionally substituted C 6-14 Arylene; N, O, and optionally substituted C having 1 to 4 heteroatoms selected from S 1-9 Heteroaryl optionally substituted C having 1 to 4 heteroatoms selected from N, O, and S; 1-9 Haitai Iromycin; imino; optionally substituted N; O; or S(O) m (where m is 0, 1, or 2 In some embodiments, each monomer is independently optionally substituted. C 1-6 Alkylene; optionally substituted C 3-8 Cycloalkylene; optionally substituted C 3-8 Shik Optionally substituted C 6-14 Arylene; 1 to 4 selected from N, O, and S Optionally substituted C with heteroatoms 1-9 heteroarylene; selected from N, O, and S Optionally substituted C with 1 to 4 heteroatoms 1-9 Heterocyclylene; imino; optionally Substituted N; O; or S(O) m (where m is 0, 1, or 2 (e.g., m is 2)) In some embodiments, each monomer independently comprises an optionally substituted C 1-6 Alkylene; Optionally substituted C 3-8 Cycloalkylene; optionally substituted C 3-8 Cycloalkenylene; any C replaced by 6-14Arylene; having 1 to 4 heteroatoms selected from N, O, and S Optionally substituted C 1-9 Heteroarylene; one to four heteroatoms selected from N, O, and S. Optionally substituted C with children 1-9 Heterocyclylene; optionally substituted N; O; or S(O) m (child where m is 0, 1, or 2. The non-bioreversible linker connected to the reaction product may be 2 to 500 (e.g., 2 to 300, 2 to 200) The link C can contain one or more such monomers. The polyethylene glycol may contain the above polyethylene glycol (for example, the polyethylene glycol may be 88 Da to 1 It may have a molecular weight of 100 kDa (e.g., 88 Da to 500 Da).

[0474] The group -linking C(-R M ) r The compounds that can be used in the preparation of 2015 / 188197. -Link C(-R M ) r Non-limiting examples include: [ka] are listed, where: R 14 is a bond with -SS-, R M is the auxiliary part or -Q G [(-Q B -Q C -Q D ) s2 -R M1 ] p1 and where: Each R M1 are independently H or an auxiliary moiety; Each Q B and each Q D are independently absent, -CO-, -NH-, -O-, -S-, -SO2-, -OC(O)-, -COO-, -NHC(O)-, -C(O)NH-, -CH-, -CHNH-, -NHCH-, -CHO-, or -OCH-; Each Q C are independently absent, optionally substituted C 1-12 Alkylene, optionally substituted C 2-12 Alkenylene, optionally substituted C 2-12 Alkynylene, optionally substituted C 2-12 Hetero Alkylene, or optionally substituted C 1-9 is a heterocyclylene; Each Q G are independently optionally substituted C 1-6 Alkane-triyl, optionally substituted C 1- 6-Alkane-tetrayl, optionally substituted C 2-6 heteroalkane-triyl, or optionally substituted Replaced C 2-6 heteroalkane-tetrayl, each s2 is independently an integer from 0 to 10; and p1 is 2 or 3; each r4 is independently an integer from 1 to 6; and Each r5 is independently an integer from 0 to 10.

[0475] In some embodiments, R M is an auxiliary moiety. Together with R M1 is the auxiliary part.

[0476] In certain embodiments, the bioreversible linker group is [ka] wherein one end of the group is connected to a polynucleotide and the other One end is connected to a targeting moiety (in one embodiment, an antibody).

[0477] (non-bioreversible group) Non-bioreversible groups are groups that have bonds (e.g., cleavable bonds) that are cleavable under physiological conditions, in serum, or in endosomes. A non-naturally occurring univalent substituent is one that does not contain a substituent group (e.g., an ester, a thioester, or a disulfide). The isomerizable group is an optionally substituted C 2-16 Alkyl; optionally substituted C 3-16 Alkenyl; any C replaced by 3-16 Alkynyl; optionally substituted C 3-8 Cycloalkyl; optionally substituted C 3-8 Cycloalkenyl; optionally substituted (C 3-8 Cycloalkyl)-C 1-4 -Alkyl; optionally substituted Replaced (C 3-8 Cycloalkenyl)-C 1-4 -alkyl; optionally substituted C 6-14 Aryl; any was replaced by (C 6-14 Aryl)-C 1-4 -alkyl; 1 to 4 hetero atoms selected from N, O, and S Optionally substituted C with a C atom 1-9 Heteroaryl; 1 to 4 selected from N, O, and S Optionally substituted (C 1-9 Heteroaryl)-C 1-4 -Alkyl; N, O, and optionally substituted C having 1 to 4 heteroatoms selected from S 2-9 Heterocyclyl( wherein the heterocyclyl does not contain an S-S bond; 1 to 4 selected from N, O, and S Optionally substituted (C 2-9 Heterocyclyl)-C 1-4- alkyl (where the heterocyclyl does not contain a S-S bond); or a group of formula (XXIII): [ka] may be During the ceremony, L 3 is C 2-6 is alkylene; R 7 is an arbitrarily substituted C 2-6 Alkyl; optionally substituted C 6-14 aryl; optionally substituted (C 6-14 Aryl)-C 1-4 -alkyl; optionally substituted C 3-8 Cycloalkyl; optionally substituted (C 3-8 Cycloalkyl)-C 1-4 -alkyl; one to one selected from the group consisting of N, O, and S Optionally substituted C with four heteroatoms 1-9 Heteroaryl; the group consisting of N, O, and S optionally substituted (C 1-9 Heteroaryl)-C 1- 4-alkyl; optionally having 1 to 4 heteroatoms selected from the group consisting of N, O, and S Substituted C 2-9 heterocyclyl (wherein the heterocyclyl does not contain a S-S bond); N, Optionally substituted (C) having 1 to 4 heteroatoms selected from O, and S 2-9 Heterothymic Lil)-C 1-4 -alkyl (wherein the heterocyclyl does not contain a S-S bond); and -OH, C -6 alkoxy or -COOH terminated poly(ethylene glycol); and R 8 is H or C 1-6 It is alkyl.

[0478] Non-bioreversible phosphotriesters are substituted with a conjugated group, C 2-16 Alkyl, [ka] or [ka] A substituted phosphatase, which is the group formed by the cycloaddition reaction of phosphatase with an azide-containing substrate. may be phosphate or phosphorothioate, where: n is an integer from 1 to 6; R 9 is an optionally substituted C6 aryl; a six-membered ring containing one or two nitrogen atoms Optionally substituted C 4-5 heteroaryl; or a six-membered ring containing one or two nitrogen atoms Any substituted C 4-5 is heterocyclyl; R 10 is H or C 1-6 is alkyl; R 11 is halogen, -COOR 11A , or -CON(R 11B )2, where R 11A and R 11B Each of , independently, H, optionally substituted C 1-6 Alkyl, optionally substituted C 6-14 aryl, optionally Substituted C 1-9 Heteroaryl or optionally substituted C 2-9 is heterocyclyl; and The azide-containing substrate is [ka] is.

[0479] In some embodiments, the non-bioreversible group is a -linked D(-R M1 ) r1 where: Link D is a multivalent linker, and each R M1 are independently H or an auxiliary moiety, and r is an integer from 1 to 6.

[0480] In some cases, -Link D(-R M1 ) r1 is of formula (XXIV): -Q R -Q 3 ([-Q 4 -Q 5 -Q 6 ] r2 -Q 7 -R M1 ) r1 , (XXIV) (In the formula, r1 is an integer from 1 to 6; Each r2 is independently an integer from 0 to 50 (e.g., 0 to 30), where the repeating units are the same is or is different from; Q R is [-Q 4 -Q 5 -Q 6 ] r2 -Q L -, where Q L is an arbitrarily substituted C 2-12 Heteroarchitecture olefins (e.g., containing -C(O)-N(H)-, -N(H)-C(O)-, -S(O)-N(H)-, or -N(H)-S(O)-) heteroalkylene), optionally substituted C 1-12 Thioheterocyclylenes (e.g., [ka] ), optionally substituted C 1-12 Heterocyclylenes (e.g., 1,2,3-triazole-1,4-diyl) Or [ka] ), cyclobut-3-ene-1,2-dione-3,4-diyl, pyrid-2-ylhydrazone, optionally substituted C 6-16 Triazoloheterocyclylenes (e.g., [ka] ), optionally substituted C 8-16 Triazolocycloalkenylene (e.g., [ka] ), or a dihydropyridazine group (e.g., [ka] ) and; Q 3 When r1 is 1, a linear group (e.g., [-Q 4 -Q 5 -Q 6 ] r2 -), or r1 is an integer from 2 to 6 If the number is a branched group (e.g., [-Q 4 -Q 5 -Q 6 ] s -Q 8 ([-Q 4 -Q 5 -Q 6 ] r2 -(Q 8 ) r3 ) r4 (where r3 is 0 or 1, and r4 is 0, 1, 2, or 3); each r2 is independently 0 is an integer between 0 and 50 (e.g., 0 and 30), where the repeating units are the same or different. and; Each Q 4 and each Q 6 are independently absent, -CO-, -NH-, -O-, -S-, -SO2-, -OC(O)-, -COO-, -NHC(O)-, -C(O)NH-, -CH2-, -CH2NH-, -NHCH2-, -CH2O-, or -OCH2-; Each Q 5 are independently absent, optionally substituted C 1-12 Alkylene, optionally substituted C 2-12 Alkenylene, optionally substituted C 2-12 Alkynylene, optionally substituted C 2-12 Hetero Alkylene, or optionally substituted C 1-9 is a heterocyclylene; Each Q 7 are independently absent, -CO-, -NH-, -O-, -S-, -SO2-, -CH2-, -C(O)O-, -OC(O )-, -C(O)NH-, -NH-C(O)-, -NH-CH(R a )-C(O)-, or -C(O)-CH(R a )-NH-; Each Q 8 are independently optionally substituted C 1-6 Alkane-triyl, optionally substituted C 1- 6-Alkane-tetrayl, optionally substituted C 2-6 heteroalkane-triyl, or optionally substituted Replaced C 2-6 Heteroalkane-tetrayl; and Each R a is independently H or an amino acid side chain; and Each R M1 are independently H or an auxiliary moiety).

[0481] In formula (XXIV), Q 4 , Q 5 , and Q 6 In formula (XXIV), at least one of the following is present: may contain a single branch point if each r3 is 0, or at least one r3 is 1 In the case where Q is a substituted or unsubstituted alkyl group, it may contain multiple branching points. R-Q 5 -Q 4 -Q L - where Q 5 teeth , optionally substituted C 2-12 Heteroalkylene or optionally substituted C 1-12 is alkylene , and Q 4 In formula (XXIV), Q is —CO—, —NH—, or —O—. L teeth: [ka] It could be.

[0482] In formula (XXIV), Q 3 is the formula [-Q 4 -Q 5 -Q 6 ] r2 -, where Q 4 , Q 5 , and Q 6 is as defined for formula (XXIV). 3 is a branched group [-Q 4 -Q 5 -Q 6 ] r 2-Q 8 ([-Q 4 -Q 5 -Q 6 ] r2 -(Q 8 ) r3 ) r4 where each Q 8 are independently and arbitrarily placed Replaced C 1-6 Alkane-triyl, optionally substituted C 1-6 Alkane-tetrayl, optionally substituted Replaced C 2-6 Heteroalkane-triyl or optionally substituted C 2-6 Heteroalkane-tetrate Lyle is; where: Each r2 is independently an integer from 0 to 50 (e.g., 0 to 30), where the repeating units are the same be one or different; r3 is 0 or 1; r4 is 0, 1, 2, or 3; where: When r3 is 0, the link D is a trivalent or tetravalent group; and When r3 is 1, the link D is a tetravalent, pentavalent, or hexavalent group.

[0483] In some embodiments, r3 is 0.

[0484] In some embodiments, Q 8 teeth: [ka] is.

[0485] The group -link D(-R M1 ) p The compounds that can be used in the preparation of WO 2 It is described in No. 015 / 188197.

[0486] In certain embodiments, the non-bioreversible linker group is [ka] wherein one end of the group is connected to a polynucleotide and the other One end is connected to a targeting moiety (in one embodiment, an antibody).

[0487] (auxiliary part) The auxiliary moiety may be a dye or a hydrophilic group or a combination thereof (e.g., a hydrophilic polymer (e.g., For example, poly(ethylene glycol) (PEG), positively charged polymers (e.g., poly(ethyleneimine)), or a monovalent group containing a sugar alcohol (e.g., glucitol). , 100 Da to 2.5 kDa (e.g., 350 Da to 2.5 kDa, 100 Da to 1,200 Da, or 1 kDa to 2.5 kDa) The molecular weight of the compound may be 100 to 2000.

[0488] The dyes can be conjugated to the conjugates of the invention within cells (e.g., using Fluorescence Recovery After Photobleaching (FRAP)). Phosphate groups may be included to visualize uptake or monitor translocation of the compound. Dyes known in the art include 5'- or 3'-terminal phosphate or phosphonates. via a thiolate or a phosphate or may be included as an auxiliary moiety linked to the polynucleotide via a phosphorothioate. Non-limiting examples of useful structures that can be used as dyes include FITC , RD1, allophycocyanin (APC), aCF™ dye (Biotium, Hayward, CA), BODIPY (Life Technologies) Invitrogen™ 10 (Life Technologies, Carlsbad, CA), AlexaFluor® (Life Technologies), Biosciences Invitrogen™, Carlsbad, CA), DyLight Fluor (Thermo Scientific Pierce P rotein Biology Products, Rockford, IL), ATTO (ATTO-TEC GmbH, Siegen, Germany), Fl uoProbe (Interchim SA, Motlucon, France) and Abberior Probes (Abberior GmbH, Gott ingen, Germany).

[0489] As auxiliary moieties in the immunomodulatory polynucleotides of the invention and in the conjugates of the invention Hydrophilic polymers and positively charged polymers that can be used are known in the art. A non-limiting example of a positively charged polymer is poly(ethylene glycol). A good example is poly(ethyleneimine).

[0490] Sugar alcohol-based adjunct moieties include, for example, amino-terminal glucitol or glucitol The amino-terminal glucitol auxiliary moiety may be a cluster of: [ka] Non-limiting examples of glucitol clusters are: [ka] is.

[0491] In one embodiment, provided herein is a compound of Formula (B): or a stereoisomer, 2 a mixture of the above diastereomers, tautomers, or a mixture of two or more tautomers; or or a pharmaceutically acceptable salt, solvate, or hydrate thereof; R X -L N -(Q) e (B) (In the formula: R x is a conjugated group; L N is a linker; each Q is independently a phosphotriester-containing oligonucleotide; and and e is an integer of 1, 2, 3, or 4.

[0492] In some embodiments, in formula (B), R x teeth, [ka] is.

[0493] In one embodiment, in formula (B), L N is a linker containing polyethylene glycol do.

[0494] In one embodiment, in formula (B), L N teeth, [ka] where d is an integer ranging from about 0 to about 50. In some embodiments, d is an integer ranging from about 0 to about In some embodiments, d is an integer ranging from about 0 to about 5. In this embodiment, d is an integer of about 0, about 1, or about 3.

[0495] In certain embodiments, in Formula (B), e is an integer of 1. In certain embodiments, in Formula (B), each Q independently has the structure of Formula (D): [ka] .

[0496] In the formula, X N , X 3' , X 5' , Y P , b, and c are each as defined herein.

[0497] (targeting part) The targeting moieties used in the conjugates of the present invention can be used to Targeting specific cells and tissues in the body for targeted delivery of selected payload polynucleotides. The cells targeted by the conjugates of the present invention can be The targeting moiety is an antigen-binding target. a moiety (e.g., an antibody or antigen-binding fragment thereof), a polypeptide, an aptamer, or one or more In the conjugates of the present invention, the group may be a group containing a small molecule (e.g., mannose). The targeting moiety addresses the problem of uneven distribution of immunomodulatory polynucleotides in vivo. It can be effective in

[0498] (antigen binding part) The antigen-binding moiety in the conjugate of the invention may be an antibody or an antigen-binding fragment thereof (e.g., F(a b) 2 or Fab) or modified derivatives thereof (e.g., Fcab or fusion proteins (e.g., Human or chimeric (e.g., humanized) antibodies can be used in the context of the present invention. It can be used as the antibody in the conjugate.

[0499] The antigen-binding portion targets cells bearing the surface antigen recognized by the antigen-binding portion. In particular, APCs can be targeted by the antigen-binding moiety in the conjugate of the present invention. The cells may be immunolabeled with anti-CD38, anti-CD79b, anti-CD30, anti-CD22, or anti-CD20, anti-CD19 antibodies, or any of these. or modified derivatives thereof. Dendritic cells (pDCs) were stained with anti-DEC205, anti-CD304, anti-CD303, anti-CD40, anti-CD74, anti-BDCA2, or anti- Targeted by CD123 antibodies, or antigen-binding fragments thereof, or modified derivatives thereof Macrophages can be immunolabeled with ...

Claims

1. Oligonucleotides of formula (A): or stereoisomers thereof, mixtures of two or more diastereomers , tautomers, or mixtures of two or more tautomers; or pharmaceutically acceptable salts thereof. salts, solvates, or hydrates thereof; X 5' -(X N ) b -Y P -(X N ) c -X 3' (A) (In the formula: Each X N are independently nucleotides; X 3' is the 3' terminal nucleotide; X 5' is the 5' terminal nucleotide; Y P is an internucleoside phosphotriester; and b and c are each an integer ranging from about 0 to about 25; provided that their sum is 5 or greater; wherein the oligonucleotide comprises nucleotides having modified nucleobases).

2. 2. The oligonucleotide of claim 1, wherein b is an integer ranging from about 1 to about 15.

3. 2. The oligonucleotide of claim 1, wherein b is an integer of about 3, about 4, about 11, or about 14.

4. 2. The oligonucleotide of claim 1, wherein b is an integer of about 3.

5. 2. The oligonucleotide of claim 1, wherein b is an integer of about 4.

6. 2. The oligonucleotide of claim 1, wherein b is an integer of about 11.

7. 2. The oligonucleotide of claim 1, wherein b is an integer of about 14.

8. The oligonucleotide of any one of claims 1 to 7, wherein c is an integer ranging from about 0 to about 10. Do.

9. 8. The oligonucleotide of any one of claims 1 to 7, wherein c is an integer of about 0 or about 8.

10. The oligonucleotide of any one of claims 1 to 7, wherein c is an integer of about 0.

11. 8. The oligonucleotide of any one of claims 1 to 7, wherein c is an integer of about 8.

12. The oligonucleotide of any one of claims 1 to 11, wherein the sum of b and c is in the range of about 5 to about 20. Chid.

13. The oligonucleotide of any one of claims 1 to 11, wherein the sum of b and c is in the range of about 5 to about 15. Chid.

14. The sum of b and c is about 8, about 9, about 10, about 11, about 12, about 13, or about 14. The oligonucleotide according to any one of claims 1 to 4.

15. The oligonucleotide of any one of claims 1 to 11, wherein the sum of b and c is about 11 or about 14. Do.

16. The oligonucleotide of any one of claims 1 to 11, wherein the sum of b and c is about 11.

17. The oligonucleotide of any one of claims 1 to 11, wherein the sum of b and c is about 14.

18. Each X N are independently 2'-deoxyribonucleotides. The oligonucleotide according to paragraph .

19. Each X N are independently 2'-deoxyadenosine, 2'-deoxyguanosine, and 2'-deoxy Cytidine, 5-halo-2'-deoxycytidine, 2'-deoxythymidine, 2'-deoxyuridine, or 5-halo-2'-deoxyuridine. Reotide.

20. Each X N are independently 2'-deoxyadenosine, 2'-deoxyguanosine, and 2'-deoxy Cytidine, 2'-deoxythymidine, 5-bromo-2'-deoxyuridine, or 5-iodo-2'-deoxyuridine 18. The oligonucleotide of any one of claims 1 to 17, which is oxyuridine.

21. X 3' is a 2'-deoxyribonucleotide, nucleotide.

22. X 3' However, 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, 5- 2'-deoxycytidine, 2'-deoxythymidine, 2'-deoxyuridine, or 5-halo-2'- 21. The oligonucleotide of any one of claims 1 to 20, which is deoxyuridine.

23. X 3' is 2'-deoxythymidine, Chid.

24. X 3' is a 2'-modified ribonucleotide, Reotide.

25. X 3' is 2'-methoxyribonucleotide or 2'-ethoxymethoxyribonucleotide 21. The oligonucleotide of any one of claims 1 to 20.

26. X 5' is a 2'-deoxyribonucleotide, nucleotide.

27. X 5' However, 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, 5- 2'-deoxycytidine, 2'-deoxythymidine, 2'-deoxyuridine, or 5-halo-2'- 26. The oligonucleotide of any one of claims 1 to 25, which is deoxyuridine.

28. X 5' is a 2'-deoxyribonucleotide having a substituted pyrimidine base, The oligonucleotide according to any one of the preceding claims.

29. X 5' is a 2'-deoxyribonucleotide having a 5-substituted pyrimidine base, 6. The oligonucleotide of any one of 5.

30. X 5' 2'-deoxythymidine, 5-halo-2'-deoxycytidine, or 5-halo-2'-deoxy 26. The oligonucleotide of any one of claims 1 to 25, which is uridine.

31. X 5' The oligonucleotide of any one of claims 1 to 25, wherein Cleotide.

32. X 5' The oligonucleotide of any one of claims 1 to 25, wherein Cleotide.

33. X 5' However, 2'-deoxythymidine, 5-bromo-2'-deoxycytidine, and 5-iodo-2'-deoxy cytidine, 5-bromo-2'-deoxyuridine, or 5-iodo-2'-deoxyuridine; 26. The oligonucleotide of any one of claims 1 to 25.

34. X 5' 2'-deoxythymidine, 5-bromo-2'-deoxyuridine, or 5-iodo-2'-deoxyuridine 26. The oligonucleotide of any one of claims 1 to 25, which is xyluridine.

35. X 5' The oligonucleotide of any one of claims 1 to 34, wherein Cleotide.

36. 36. The oligonucleotide of claim 35, wherein the 3'-phosphorothioate is chiral.

37. The oligonucleotide of claim 35, wherein the 3'-phosphorothioate has the chirality of Rp. Reotide.

38. 36. The oligonucleotide of claim 35, wherein the 3'-phosphorothioate has a chirality of Sp. Reotide.

39. X 5' has a 3'-phosphorothioate group with chirality Rp, and X 3' 2'-Methoxy Any of claims 1 to 34, which is a ribonucleotide or a 2'-ethoxymethoxyribonucleotide. The oligonucleotide according to any one of claims 1 to 4.

40. X 5' has a 3'-phosphorothioate group with chirality Sp, and X 3' 2'-Methoxy Any of claims 1 to 34, which is a ribonucleotide or a 2'-ethoxymethoxyribonucleotide. The oligonucleotide according to any one of claims 1 to 4.

41. Y P but: 【Chemical 1】 wherein Z is O or S; and d is an integer ranging from about 0 to about 50. The oligonucleotide according to any one of the preceding claims.

42. Y P but: 【Chemistry 2】 wherein Z is O or S; and d is an integer ranging from about 0 to about 50. The oligonucleotide according to any one of the preceding claims.

43. 43. The oligonucleotide of claim 41 or 42, wherein Z is O.

44. 43. The oligonucleotide of claim 41 or 42, wherein Z is S.

45. The oligonucleotide of any one of claims 41 to 44, wherein d is an integer ranging from about 0 to about 10. Chid.

46. 46. ​​The oligonucleotide of claim 45, wherein d is an integer ranging from about 0 to about 5.

47. 46. ​​The oligonucleotide of claim 45, wherein d is an integer of about 0, about 1, or about 3.

48. 48. The method of claim 1, further comprising administering to said patient a further internucleoside phosphotriester. oligonucleotides.

49. the further internucleoside phosphotriester is an alkyl phosphotriester 49. The oligonucleotide of claim 48.

50. the further internucleoside phosphotriester is an ethyl phosphotriester; 49. The oligonucleotide of claim 48.

51. The oligonucleotide of any one of claims 1 to 50, comprising one 5-halo-2'-deoxyuridine. Cleotide.

52. The 5-halo-2'-deoxyuridine is 5-bromo-2'-deoxyuridine or 5-iodo-2'-deoxyuridine.

52. The oligonucleotide of claim 51, which is oxyuridine.

53. The oligonucleotide of any one of claims 1 to 52, comprising three or more 2'-deoxycytidines. Punch.

54. The oligonucleotide of any one of claims 1 to 53, comprising three 2'-deoxycytidines. Chid.

55. The oligonucleotide of any one of claims 1 to 54, comprising three or more 2'-deoxyguanosines. Reotide.

56. The oligonucleotide of any one of claims 1 to 55, comprising four 2'-deoxyguanosines. Punch.

57. Any of claims 1 to 56, comprising three 2'-deoxycytidines and three 2'-deoxyguanosines. The oligonucleotide according to any one of claims 1 to 4.

58. Any of claims 1 to 57, comprising three 2'-deoxycytidines and four 2'-deoxyguanosines. The oligonucleotide according to any one of claims 1 to 4.

59. The oligonucleotide of any one of claims 1 to 58, comprising three or more 2'-deoxythymidines. Punch.

60. 60. The oligonucleotide of claim 59, comprising 3, 4, 5, 6, 7, or 8 2'-deoxythymidines. Punch.

61. 60. The oligonucleotide of claim 59, comprising 3, 4, 5, or 8 2'-deoxythymidines. Punch.

62. 62. The method of claim 1, comprising 0, 1, or 2 2'-deoxyadenosines. oligonucleotides.

63. 63. The method of claim 1, comprising one or more internucleoside phosphorothioates. Oligonucleotides.

64. at least one of the internucleoside phosphorothioates is chiral.

64. The oligonucleotide according to item 63.

65. Compounds of formula (B): or stereoisomers, mixtures of two or more diastereomers, tautomers, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, or or hydrate; R X -L N -(Q) e (B) (In the formula: R x is a conjugated group; L N is a linker; each Q is independently a phosphotriester-containing oligonucleotide; and and e is an integer of 1, 2, 3, or 4.

66. R x but 【Chemistry 3】 66. The compound of claim 65, wherein:

67. R x Ga-NH 2 66. The compound of claim 65, wherein:

68. A compound of formula (C): or a stereoisomer, a mixture of two or more diastereomers, or a tautomer thereof or a mixture of two or more tautomers; or a pharmaceutically acceptable salt or solvate thereof product, or hydrate; 【Chemistry 4】 (In the formula: Ab is antibody; Each L N are independently linkers; each Q is independently a phosphotriester-containing oligonucleotide; each e is independently an integer of 1, 2, 3, or 4; and and f is an integer of 1, 2, 3, or 4.

69. 69. The compound of claim 68, wherein f is an integer of 1 or 2.

70. 69. The compound of claim 68, wherein f is an integer equal to 1.

71. L N is a linker comprising polyethylene glycol Compound.

72. L N but, 【Chemistry 5】 wherein d is an integer ranging from about 0 to about 50. compound.

73. L N but, 【Chemistry 6】 wherein d is an integer ranging from about 0 to about 50. compound.

74. 74. The compound of claim 72 or 73, wherein d is an integer ranging from about 0 to about 10.

75. 75. The compound of claim 74, wherein d is an integer ranging from about 0 to about 5.

76. 75. The compound of claim 74, wherein d is an integer of about 0, about 1, or about 3.

77. 77. The compound of any one of claims 65-76, wherein e is an integer equal to 1.

78. 78. The compound of any one of claims 65-77, wherein each Q independently has the structure of formula (D): : 【Chemistry 7】 (In the formula: Each X N are independently nucleotides; X 3' is the 3' terminal nucleotide; X 5' is the 5' terminal nucleotide; Y P is the residue of an internucleoside phosphotriester; and b and c are each an integer ranging from about 0 to about 25; provided that their sum is 5 or greater; wherein the oligonucleotide comprises nucleotides having modified nucleobases).

79. 79. The compound of claim 78, wherein b is an integer ranging from about 1 to about 15.

80. 79. The compound of claim 78, wherein b is an integer of about 3, about 4, about 11, or about 14.

81. 79. The compound of claim 78, wherein b is an integer of about 3.

82. 79. The compound of claim 78, wherein b is an integer of about 4.

83. 79. The compound of claim 78, wherein b is an integer of about 11.

84. 79. The compound of claim 78, wherein b is an integer of about 14.

85. 85. The compound of any one of claims 78-84, wherein c is an integer ranging from about 0 to about 10.

86. 85. The compound of any one of claims 78-84, wherein c is an integer of about 0 or about 8.

87. 85. The compound of any one of claims 78-84, wherein c is an integer of about 0.

88. 85. The compound of any one of claims 78-84, wherein c is an integer of about 8.

89. 89. The compound of any one of claims 78-88, wherein the sum of b and c ranges from about 5 to about 20.

90. 89. The compound of any one of claims 78-88, wherein the sum of b and c is in the range of about 5 to about 15.

91. Any of claims 78 to 88, wherein the sum of b and c is about 8, about 9, about 10, about 11, about 12, about 13, or about 14. The compound according to any one of claims 1 to 4.

92. Each X N is independently a 2'-deoxyribonucleotide. The compound according to claim 1.

93. Each X N are independently 2'-deoxyadenosine, 2'-deoxyguanosine, and 2'-deoxy Cytidine, 5-halo-2'-deoxycytidine, 2'-deoxythymidine, 2'-deoxyuridine, or 5-halo-2'-deoxyuridine.

94. Each X N are independently 2'-deoxyadenosine, 2'-deoxyguanosine, and 2'-deoxy Cytidine, 2'-deoxythymidine, 5-bromo-2'-deoxyuridine, or 5-iodo-2'-deoxyuridine 92. The compound of any one of claims 78-91, which is oxyuridine.

95. X 3' is a 2'-deoxyribonucleotide 。

96. X 3' However, 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, 5- 2'-deoxycytidine, 2'-deoxythymidine, 2'-deoxyuridine, or 5-halo-2'- 92. The compound of any one of claims 78-91, which is deoxyuridine.

97. X 3' 92. The compound of any one of claims 78-91, wherein is 2'-deoxythymidine.

98. X 3' is a 2'-modified ribonucleotide.

99. X 3' is 2'-methoxyribonucleotide or 2'-ethoxymethoxyribonucleotide 95. The compound of any one of claims 78 to 94.

100. X 5' is a 2'-deoxyribonucleotide 。

101. X 5' However, 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, 5- 2'-deoxycytidine, 2'-deoxythymidine, 2'-deoxyuridine, or 5-halo-2'- 101. The compound of claim 100 which is deoxyuridine.

102. X 5' is a 2'-deoxyribonucleotide having a substituted pyrimidine base. The compounds listed above.

103. X 5' is a 2'-deoxyribonucleotide having a 5-substituted pyrimidine base, The compound described.

104. X 5' 2'-deoxythymidine, 5-halo-2'-deoxycytidine, or 5-halo-2'-deoxy 103. The compound of claim 102, which is uridine.

105. X 5' However, 2'-deoxythymidine, 5-bromo-2'-deoxycytidine, and 5-iodo-2'-deoxy cytidine, 5-bromo-2'-deoxyuridine, or 5-iodo-2'-deoxyuridine; 103. The compound of claim 102.

106. X 5' 2'-deoxythymidine, 5-bromo-2'-deoxyuridine, or 5-iodo-2'-deoxyuridine 103. The compound of claim 102, which is xylidine.

107. X 5' has a 3'-phosphorothioate group. 。

108. 108. The compound of claim 107, wherein the 3'-phosphorothioate is chiral.

109. 108. The compound of claim 107, wherein the 3'-phosphorothioate has chirality Rp.

110. 108. The compound of claim 107, wherein the 3'-phosphorothioate has a chirality of Sp.

111. X 5' has a 3'-phosphorothioate group with chirality Rp, and X 3' 2'-Methoxy 78 to 107, which is a ribonucleotide or a 2'-ethoxymethoxyribonucleotide The compound according to any one of claims 1 to 4.

112. X 5' has a 3'-phosphorothioate group with chirality Sp, and X 3' 2'-Methoxy 78 to 107, which is a ribonucleotide or a 2'-ethoxymethoxyribonucleotide The compound according to any one of claims 1 to 4.

113. 113. Any one of claims 78 to 112, comprising an additional internucleoside phosphotriester. The compounds listed above.

114. the further internucleoside phosphotriester is an alkyl phosphotriester 114. The compound of claim 113.

115. the further internucleoside phosphotriester is an ethyl phosphotriester; 114. The compound of claim 113.

116. The compound of any one of claims 78 to 115, comprising one 5-halo-2'-deoxyuridine. 。

117. The 5-halo-2'-deoxyuridine is 5-bromo-2'-deoxyuridine or 5-iodo-2'-deoxyuridine.

117. The compound of claim 116 which is oxyuridine.

118. 118. The compound of any one of claims 78-117, comprising three or more 2'-deoxycytidines.

119. 119. The compound of claim 118, comprising three 2'-deoxycytidines.

120. 120. The compound of any one of claims 78-119, comprising four or more 2'-deoxyguanosines.

121. 121. The compound of claim 120, comprising four 2'-deoxyguanosines.

122. Any of claims 78 to 121, comprising three 2'-deoxycytidines and four 2'-deoxycytidines. The compound according to any one of claims 1 to 4.

123. 123. The compound of any one of claims 78-122, comprising three or more 2'-deoxythymidines.

124. 124. The compound of claim 123, comprising 3, 4, 5, 6, 7, or 8 2'-deoxythymidines.

125. 124. The compound of claim 123, comprising 3, 4, 5, or 8 2'-deoxythymidines.

126. Any one of claims 78 to 125, comprising 0, 1, or 2 2'-deoxyadenosines. The compounds listed above.

127. Any one of claims 74 to 126, comprising one or more internucleoside phosphorothioates. Compound.

128. at least one of the internucleoside phosphorothioates is chiral. Item 127. The compound according to item 127.

129. N 1 N 2 CGN 3 CG(T) x GN 4 CGN 5 An oligonucleotide with the sequence T (where: x is an integer ranging from 1 to 4; N 1 is absent or 2'-deoxythymidine; N 2 is a 2'-deoxyribonucleotide having a modified nucleobase; N 3 is 2'-deoxyadenosine or 2'-deoxyadenosine, each optionally containing a 3'-phosphotriester. is oxythymidine; N 4 is 2'-deoxyadenosine or 2'-deoxythymidine; and N 5 is 2'-deoxythymidine optionally containing a 3'-phosphotriester).

130. 130. The oligonucleotide of claim 129, wherein x is an integer of 1 or 4.

140. 131. The oligonucleotide of claim 129 or 130, wherein x is an integer equal to 1.

141. N 1 141. The oligonucleotide of any one of claims 129-140, wherein:

142. N 1 is 2'-deoxythymidine Punch.

143. N 2 is a 2'-deoxyribonucleotide having a substituted pyrimidine base, 2. The oligonucleotide according to any one of claims 1 to 11.

144. N 2 is a 2'-deoxyribonucleotide having a 5-substituted pyrimidine base. The oligonucleotides listed.

145. N 2 is 5-halo-2'-deoxycytidine or 5-halo-2'-deoxyuridine, The described oligonucleotide.

146. N 2 is 5-bromo-2'-deoxyuridine or 5-iodo-2'-deoxyuridine.

143. The oligonucleotide according to claim 143.

147. N 3 is 2'-deoxyadenosine containing a 3'-phosphotriester, The oligonucleotide according to any one of claims 1 to 4.

148. N 3 is 2'-deoxythymidine Punch.

149. N 3 is 2'-deoxythymidine containing a 3'-phosphotriester. The oligonucleotide according to any one of claims 1 to 4.

150. N 4 is 2'-deoxyadenosine, Reotide.

151. N 4 is 2'-deoxythymidine Punch.

152. N 5 is 2'-deoxythymidine Punch.

153. N 5 is 2'-deoxythymidine containing a 3'-phosphotriester, The oligonucleotide according to any one of claims 1 to 4.

154. Any one of claims 129 to 153, comprising one or more internucleoside phosphorothioates The oligonucleotides listed.

155. at least one of the internucleoside phosphorothioates is chiral.

155. The oligonucleotide according to paragraph 154.

156. SEQ ID NOs: p236, p238, p243, p246, p275, p276, p308, p313, p347, p361, p362, p42 5, p433, p434, p435, p436, p437, p438, p477, p478, p479, p480, p481, p482, p483 130. The oligonucleotide of claim 129, having the sequence of p481, p482, p483, p484, p485, p486, p487, p488, or p489. Cleotide.

157. Immunomodulatory polynucleotides containing one or more abasic spacers or internucleoside phosphotriesters nucleotide.

158. The immunomodulatory polynucleotide of claim 157, wherein said immunomodulatory polynucleotide comprises 5-halouridine. Ligands.

159. the 5-halouridine is at least one of the two 5'-terminal nucleosides; or The immunomodulatory polynucleotide of claim 158, wherein the immunomodulatory polynucleotide is present in an immunostimulatory sequence (ISS). Regulatory polynucleotides.

160. 160. The immunomodulatory polynucleotide of claim 158 or 159, wherein said 5-halouridine is 5-bromouridine. nucleotide.

161. 160. The immunomodulatory polynucleotide of claim 158 or 159, wherein the 5-halouridine is 5-iodouridine. nucleotide.

162. The 5-halouridine is attached to the 3'-position of the internucleoside phosphodiester phosphate.

162. The immunomodulatory polynucleotide of any one of claims 158-161, comprising:

163. The 5-halouridine is linked to an internucleoside phosphodiester phosphorothioate 162. The immunomodulatory polynucleotide of any one of claims 158-161, comprising the 3'-position.

164. An immunomodulatory polynucleotide comprising a 5'-terminal 5-bromouridine.

165. the immunomodulatory polynucleotide comprises one or more internucleoside phosphotriesters; The immunomodulatory polynucleotide of any one of claims 157-164.

166. The one or more internucleoside phosphotriesters may be 1 to 5 internucleoside phosphotriesters.

166. The immunomodulatory polynucleotide of claim 165, which is an ester.

167. at least one of said internucleoside phosphotriesters comprises a conjugate group.

167. The immunomodulatory polynucleotide of paragraph 165 or 166.

168. At least one of the internucleoside phosphotriesters comprises a phosphotriester containing a conjugate group.

167. The immunomodulatory polynucleotide of claim 165 or 166, which is a thiotriester.

169. The immunomodulatory polynucleotide of any one of claims 157 to 168, further comprising a terminal phosphate ester. nucleotide.

170. 170. The immunomodulatory polymer of claim 169, wherein said terminal phosphate is a 5'-terminal phosphate. Ligands.

171. 170. The immunomodulatory polymer of claim 169, wherein said terminal phosphate is a 3'-terminal phosphate. Ligands.

172. The immunomodulator of any one of claims 169 to 171, wherein the terminal phosphate ester comprises a conjugate group. Nodal polynucleotides.

173. 173. The method of claim 172, wherein the terminal phosphate ester is a phosphothiotriester containing a conjugated group. The immunomodulatory polynucleotides described above.

174. The immunomodulatory polypeptide of any one of claims 157 to 173, comprising a 5'-cap or a 3'-cap. Ligands.

175. Claim 174, wherein said immunomodulatory polynucleotide comprises a 5'-cap that is a 5'-5' cap. The immunomodulatory polynucleotide described.

176. The 5'-5' cap may be an internucleoside phosphate, an internucleoside phosphorothioate, or 17. The method of claim 17, further comprising covalently linking a conjugate group to an internucleoside phosphorodithioate or an internucleoside phosphorodithioate.

6. The immunomodulatory polynucleotide according to 5.

177. The immunomodulatory polynucleotide may comprise an internucleoside phosphate, an internucleoside phosphate, or Contains a conjugate group covalently linked to a phosphorothioate or internucleoside phosphorodithioate 175. The immunomodulatory polynucleotide of claim 174, comprising a 3'-cap.

178. Any of claims 157-177, wherein the immunomodulatory polynucleotide comprises a 5'-terminal immunostimulatory sequence. The immunomodulatory polynucleotide of any one of claims 1 to 4.

179. at least one of said internucleoside phosphotriesters is a 5'-terminal immunostimulatory sequence is bonded to the 3'-carbon atom of a nucleoside having a 5'-carbon atom bonded to 178. The immunomodulatory polynucleotide according to claim 178.

180. 179. The immunomodulatory polynucleotide of claims 157-179, wherein the immunomodulatory polynucleotide comprises one or more abasic spacers. The immunomodulatory polynucleotide of any one of claims 1 to 4.

181. Claims 157-180, wherein the one or more abasic spacers are one or two abasic spacers. The immunomodulatory polynucleotide of any one of claims 1 to 4.

182. wherein at least one of the abasic spacers is an internucleoside abasic spacer. The immunomodulatory polynucleotide of any one of claims 157 to 181.

183. 157. At least one of said abasic spacers is a 3'-terminal abasic spacer. The immunomodulatory polynucleotide of any one of claims 1 to 182.

184. Any one of claims 157 to 183, wherein at least one of the abasic spacers comprises a conjugate group.

2. The immunomodulatory polynucleotide according to claim 1.

185. 185. The immunomodulatory polynucleotide of claims 157-184, wherein the immunomodulatory polynucleotide comprises a total of 6 to 16 nucleotides. The immunomodulatory polynucleotide of any one of claims 1 to 4.

186. At least 50% of the internucleoside bridging groups in said immunomodulatory polynucleotide are phosphoro 186. The immunomodulatory polynucleotide of any one of claims 157-185, comprising a thioate.

187. At least 80% of the internucleoside bridging groups in said immunomodulatory polynucleotide are phosphoro 187. The immunomodulatory polynucleotide of claim 186, wherein said polynucleotide comprises a thioate.

188. further comprising conjugate groups covalently attached to the nucleobases in said immunomodulatory polynucleotide. The immunomodulatory polynucleotide of any one of claims 157-187.

189. the immunomodulatory polynucleotide comprises a cytidine and a guanosine at the second and third nucleotide positions; The immunomodulatory polynucleotide of claim 157 or 188, comprising as a side.

190. the immunomodulatory polynucleotide comprises a cytidine and a guanosine at the third and fourth nucleotides; 190. The immunomodulatory polynucleotide of claim 157 or 189, comprising as a side

191. The immunomodulatory polynucleotide of any one of claims 157-190, further comprising one or more auxiliary moieties. Cleotide.

192. the immunomodulatory polynucleotide comprises a conjugate moiety, and 192. The immunomodulatory polynucleoside of claim 191, wherein said moiety comprises at least one of said auxiliary moieties. Chid.

193. one of the auxiliary moieties is poly(ethylene glycol) (PEG) having a molecular weight of 100 Da to 2,500 Da; 193. The immunomodulatory polynucleotide of claim 191 or 192, comprising:

194. each PEG independently comprises a total of at least 3 ethylene glycol repeat units.

193. The immunomodulatory polynucleotide according to claim 193.

195. each PEG independently comprises a total of at least 20 ethylene glycol repeat units.

195. The immunomodulatory polynucleotide of paragraph 193 or 194.

196. Claim 193 - Each PEG independently contains a total of 50 or less ethylene glycol repeat units.

195. The immunomodulatory polynucleotide of any one of claims 195.

197. Any of claims 191-196, wherein the immunomodulatory polynucleotide comprises 1 to 8 PEG. The immunomodulatory polynucleotide described.

198. Monophosphate, diphosphate, triphosphate, auxiliary moiety, terminal phosphodiester 5'-5' cap, and a group -OR' selected from the group consisting of a terminal phosphotriester, a terminal phosphotriester, a 5'-5' cap, and a group -OR' '-capping groups, where R' is a bioreversible group, a non-bioreversible group, and an O-protecting group. The immunomodulatory polynucleoside of any one of claims 157 to 197 is selected from the group consisting of: Chid.

199. The 5'-capping group is a phosphate, phosphorothioate, or phosphorodithioate. Optionally substituted C bonded to ate 1-6 Alkyl-containing monophosphate or terminal phosphate 199. The immunomodulatory polynucleotide of claim 198, which is a diester.

200. Monophosphate, diphosphate, triphosphate, auxiliary moiety, terminal phosphodiester 3'-capping group selected from the group consisting of a terminal ester, a terminal phosphotriester, and a group -OR' group, wherein R' is selected from the group consisting of bioreversible groups, non-bioreversible groups, and O-protecting groups. The immunomodulatory polynucleotide of any one of claims 157-199, selected.

201. The 3'-capping group is a phosphate, phosphorothioate, or phosphorodithioate. Optionally substituted C bonded to ate 1-6 Alkyl-containing monophosphate or terminal phosphate 201. The immunomodulatory polynucleotide of claim 200, which is a diester.

202. Any one of claims 157 to 201, comprising a nucleobase attached to a conjugate moiety The immunomodulatory polynucleotides described above.

203. The immunogen of any one of claims 157 to 202 hybridized to a complementary polynucleotide. Hybridized immunomodulatory polynucleotides, including immunomodulatory polynucleotides.

204. The immunomodulatory polynucleotide comprises at least one sterically condensed nucleoside. The immunomodulatory polynucleotide of any one of claims 157 to 203, comprising an inter-domain phosphorothioate. A composition comprising leotide.

205. At least one stereochemically enriched internucleoside phosphorothioate is present in said immunoglobulin. Between the 5'-terminal nucleoside in the immunoregulatory polynucleotide and the cytidine of the CpG of the immunostimulatory sequence 205. The composition of claim 204, wherein the

206. The stereochemically enriched internucleoside phosphorothioate is S-stereogenic.

206. The composition of claim 204 or 205.

207. The stereochemically enriched internucleoside phosphorothioate is R-stereogenic.

206. The composition of claim 204 or 205.

208. At least one stereochemically enriched internucleoside phosphorothioate is present in said immunoglobulin. Binding to the 5'-carbon atom of the cytidine of CpG in the immunostimulatory sequence of the immunomodulatory polynucleotide The composition of any one of claims 204 to 207.

209. The stereochemically enriched internucleoside phosphorothioate is S-stereogenic. The composition of claim 208,

210. The stereochemically enriched internucleoside phosphorothioate is R-stereogenic. The composition of claim 208,

211. One stereochemically enriched internucleoside phosphorothioate is included in the immunomodulatory polynucleotide. Claims 204-2 connecting the first nucleoside and the second nucleoside in a nucleotide 11. The composition of any one of claims 10.

212. The stereochemically enriched internucleoside phosphorothioate is S-stereogenic. The composition of claim 211,

213. The stereochemically enriched internucleoside phosphorothioate is R-stereogenic. The composition of claim 211,

214. One stereochemically enriched internucleoside phosphorothioate is included in the immunomodulatory polynucleotide. Claims 204-2 connecting the fourth nucleoside and the fifth nucleoside in a nucleotide 14. The composition of any one of claims 13.

215. The stereochemically enriched internucleoside phosphorothioate is S-stereogenic. The composition of claim 214.

216. The stereochemically enriched internucleoside phosphorothioate is R-stereogenic. The composition of claim 214.

217. A conjugate comprising an antibody or antibody fragment and one or more immunomodulatory polynucleotides. wherein the antibody or antibody fragment comprises an al Q-tag and each of the immunomodulatory polynucleotides independently comprise a linker covalently attached to said Q-tag.

218. 218. The conjugate of claim 217, wherein said Q-tag is an N-terminal Q-tag.

219. 218. The conjugate of claim 217, wherein said Q-tag is a C-terminal Q-tag.

220. 220. The method of claim 217, wherein the Q-tag is located in the heavy chain of the antibody or antibody fragment. The conjugate according to any one of claims 1 to 4.

221. 220. The method of claim 217, wherein the Q-tag is located in the light chain of the antibody or antibody fragment. The conjugate according to any one of claims 1 to 4.

222. At least one of the immunomodulatory polynucleotides contains a 5-modified uridine or a 5-modified cytidine.

222. The conjugate of any one of claims 217-221, comprising:

223. A conjugate comprising a targeting moiety and one or more immunomodulatory polynucleotides, Each of the immunomodulatory polynucleotides independently comprises a linker, wherein the targeting moiety covalently linked to said linker, wherein at least one of said immunomodulatory polynucleotides comprises a 5-modified uridine or a 5-modified cytidine.

224. 222 or 223, wherein at least one of said immunomodulatory polynucleotides comprises a 5-modified uridine.

223. The conjugate according to claim 223.

225. The 5-modified uridine is a 5-halouridine, a 5-alkynyluridine, or a 5-heterocyclyluridine.

225. The conjugate of claim 224, which is ururidine.

226. 226. The conjugate of claim 225, wherein said 5-modified uridine is a 5-halouridine.

227. The conjugate of claim 225 or 226, wherein said 5-halouridine is 5-bromouridine. to.

228. The conjugate of claim 225 or 226, wherein said 5-halouridine is 5-iodouridine. to.

229. The 5-modified uridine is present at the two 5'-ends of at least one of the immunomodulatory polynucleotides. The conjugate of any one of claims 222 to 228, which is one of the nucleotides 。

230. The 5-modified uridine is attached to the 3'-position of the internucleoside phosphate 230. The conjugate of any one of claims 222-229, comprising

231. The 5-modified uridine is linked to a 3' internucleoside phosphate phosphorothioate The conjugate of any one of claims 222-229, comprising a -position.

232. At least one of said immunomodulatory polynucleotides has a cytidine and a guanosine at the second and third positions The conjugate of any one of claims 217 to 231, comprising as a third nucleoside 。

233. At least one of said immunomodulatory polynucleotides has a cytidine and a guanosine at the third and The conjugate of any one of claims 217 to 231, comprising as a fourth nucleoside 。

234. wherein at least one of said immunomodulatory polynucleotides comprises a total of 6 to 16 nucleotides. The conjugate of any one of claims 217 to 233.

235. A conjugate comprising a targeting moiety and one or more immunomodulatory polynucleotides, Each of the immunomodulatory polynucleotides independently comprises a linker, wherein the targeting moiety covalently attached to the linker, and at least one of the immunomodulatory polynucleotides has a total of 6 to 10 The conjugate comprises 16 nucleotides.

236. At least one of the immunomodulatory polynucleotides contains one or more abasic spacers or nucleotides The conjugate of any one of claims 217 to 235, comprising an interosidic phosphotriester. to.

237. A conjugate comprising a targeting moiety and one or more immunomodulatory polynucleotides, Each of the immunomodulatory polynucleotides independently comprises a linker, wherein the targeting moiety covalently attached to the linker, wherein at least one of the immunomodulatory polynucleotides is one or more The conjugate comprises an abasic spacer or an internucleoside phosphotriester.

238. At least one abasic spacer or at least one phosphotriester is attached to the phosphorus The conjugate of claim 237, comprising a CAR.

239. wherein at least one of said immunomodulatory polynucleotides comprises one or more abasic spacers. The conjugate of any one of claims 217 to 238.

240. the one or more internucleoside abasic spacers are one or two abasic spacers; 240. The conjugate of claim 239.

241. wherein at least one of the abasic spacers is an internucleoside abasic spacer. The conjugate of any one of claims 235 to 240.

242. Claim 235, wherein at least one of said abasic spacers is a 3'-terminal abasic spacer.

241. The conjugate of any one of claims 1 to 241.

243. At least one of the immunomodulatory polynucleotides contains one or more internucleoside phosphotriesters The conjugate of any one of claims 217-242, comprising a sterol.

244. The one or more internucleoside phosphotriesters may be 1 to 5 internucleoside phosphotriesters.

244. The conjugate of claim 243, which is an ester.

245. 2. The method of claim 1, wherein the conjugate further comprises one or more auxiliary moieties attached to the linker. The conjugate of any one of claims 17 to 244.

246. A conjugate comprising a targeting moiety, one or more auxiliary moieties, and one or more immunomodulatory polynucleotides. a gate, wherein each of said immunomodulatory polynucleotides independently binds to said targeting moiety; The conjugate, comprising a linker.

247. At least one of the auxiliary moieties is a poly(ethylene glycol) having a molecular weight of 100 Da to 2,500 Da.

247. The conjugate of claim 245 or 246, comprising a PEG (PEG-10 alkyl ether).

248. each PEG independently comprises a total of at least 3 ethylene glycol repeat units.

247. The conjugate according to claim 247.

249. each PEG independently comprises a total of at least 20 ethylene glycol repeat units.

249. A conjugate according to item 247 or 248.

250. Claim 247 - each PEG independently contains a total of 50 or less ethylene glycol repeat units 249. The conjugate of any one of claims 249.

251. The conjugate of any one of claims 247-250, wherein the conjugate comprises 1 to 8 PEG. Jugate.

252. The targeting moiety may comprise an antigen-binding moiety, a polypeptide, an aptamer, or one or more small molecules. The conjugate of any one of claims 217-251, wherein the group comprises

253. 253. The conjugate of claim 252, wherein said targeting moiety is an antigen-binding moiety.

254. 253. The conjugate of claim 252, wherein said targeting moiety is an antibody or an antigen-binding fragment thereof. 。

255. The 5'-capping group in at least one of the immunomodulatory polynucleotides is a monovalent phosphate, diphosphate, triphosphate, auxiliary moiety, terminal phosphodiester, terminal terminal phosphotriesters, and groups -OR', wherein R' is a bioreversible Any of claims 217 to 254, wherein the O-protecting group is selected from the group consisting of a non-bioreversible group, a non-bioreversible group, and an O-protecting group. The conjugate according to any one of claims 1 to 4.

256. The 5'-capping group is a phosphate, phosphorothioate, or phosphorodithioate. Optionally substituted C bonded to ate 1-6 Alkyl-containing monophosphate or terminal phosphate 256. The conjugate of claim 255, which is a diester.

257. The 3'-capping group in at least one of the immunomodulatory polynucleotides is a monovalent phosphate, diphosphate, triphosphate, auxiliary moiety, terminal phosphodiester, terminal terminal phosphotriesters, and groups -OR', where R' is a bioreversible Any of claims 217 to 256, wherein the O-protecting group is selected from the group consisting of a non-bioreversible group, an O-protecting group, and an O-protecting group. The conjugate according to any one of claims 1 to 4.

258. The 3'-capping group is a phosphate, phosphorothioate, or phosphorodithioate. Optionally substituted C bonded to ate 1-6 Alkyl-containing monophosphate or terminal phosphate The conjugate of claim 257, which is a diester.

259. At least one of the immunomodulatory polynucleotides has a nucleobase attached to the linker. The conjugate of any one of claims 217-258, comprising

260. Any of claims 217-259, wherein the conjugate comprises 1 to 6 immunomodulatory polynucleotides. The conjugate according to any one of claims 1 to 4.

261. The conjugate of claim 260, wherein the conjugate comprises 1 to 4 immunomodulatory polynucleotides. Indugegate.

262. 262. The method of claim 261, wherein said conjugate comprises only one immunomodulatory polynucleotide. Conjugates.

263. 263. The method of claim 262, wherein said conjugate comprises no more than two immunomodulatory polynucleotides. Conjugates.

264. The conjugate of any one of claims 217-263, wherein the conjugate comprises one targeting moiety. Conjugates.

265. the immunomodulatory polynucleotide comprises a human immunostimulatory sequence within the 5'-terminal 4 nucleotides 262. The conjugate of any one of claims 217 to 261.

266. a human immunostimulatory sequence within the 5'-terminal 4 nucleotides of the immunomodulatory polynucleotide Nucleosides containing cytidines with a 5'-carbon atom linked to a substituted phosphate ester 266. The conjugate of claim 265.

267. At least one of the immunomodulatory polynucleotides contains a 5-modified uridine or a 5-modified cytidine.

267. The conjugate of any one of claims 217-266, comprising:

268. At least one of the immunomodulatory polynucleotides hybridizes to its complement. The conjugate of any one of claims 217-267.

269. At least one of the immunomodulatory polynucleotides is at least one stereochemically enriched. The nucleic acid of any one of claims 217 to 268, comprising an internucleoside phosphorothioate. A composition comprising a conjugate.

270. Compositions Comprising Conjugates Comprising a Targeting Moiety and One or More Immunomodulatory Polynucleotides wherein each of the immunomodulatory polynucleotides independently comprises a linker, a targeting moiety covalently attached to the linker, and one containing at least one stereochemically condensed internucleoside phosphorothioate , the composition.

271. At least one stereochemically enriched internucleoside phosphorothioate is present in said immunoglobulin. Between the 5'-terminal nucleoside and the cytidine of CpG in the immunostimulatory sequence of an immunoregulatory polynucleotide 271. The composition of claim 269 or 270, wherein the composition is disposed on

272. The stereochemically enriched internucleoside phosphorothioate is S-stereogenic. The composition of any one of claims 269-271.

273. The stereochemically enriched internucleoside phosphorothioate is R-stereogenic. The composition of any one of claims 269-272.

274. At least one stereochemically enriched internucleoside phosphorothioate is present in said immunoglobulin. Binding to the 5'-carbon atom of the cytidine of CpG in the immunostimulatory sequence of the immunomodulatory polynucleotide The composition of any one of claims 269-273.

275. The stereochemically enriched internucleoside phosphorothioate is S-stereogenic. The composition of claim 274.

276. The stereochemically enriched internucleoside phosphorothioate is R-stereogenic. The composition of claim 274.

277. At least one stereochemically enriched internucleoside phosphorothioate is present in said immunoglobulin. A compound that connects the first nucleoside and the second nucleoside in an immunomodulatory polynucleotide. The composition of any one of claims 269 to 276.

278. The stereochemically enriched internucleoside phosphorothioate is S-stereogenic. The composition of claim 277.

279. The stereochemically enriched internucleoside phosphorothioate is R-stereogenic. The composition of claim 277.

280. At least one stereochemically enriched internucleoside phosphorothioate is present in said immunoglobulin. A compound that connects the fourth and fifth nucleosides in an immunomodulatory polynucleotide. The composition of any one of claims 269 to 279.

281. The stereochemically enriched internucleoside phosphorothioate is S-stereogenic. The composition of claim 280,

282. The stereochemically enriched internucleoside phosphorothioate is R-stereogenic. The composition of claim 280,

283. A pharmaceutically acceptable carrier and an immunomodulatory polynucleotide according to any one of claims 157 to 203. leotide, the composition of any one of claims 204 to 216, any one of claims 217 to 268 or a composition according to any one of claims 269 to 282. Finished product.

284. Methods for modulating endosomal toll-like receptors in cells containing the endosomal toll-like receptors 204. A method of treating said cells with an immunomodulatory polynucleotide according to any one of claims 157 to 203. , the composition of any one of claims 204 to 216, the composition of any one of claims 217 to 268 a conjugate, a composition according to any one of claims 269 to 282, or a medicament according to claim 283 composition and conditions that allow the immunomodulatory polynucleotide to be transported into the cell. wherein after said contacting, activity of said endosomal toll-like receptor is The method, wherein the

285. the immunomodulatory polynucleotide is an immunostimulatory polynucleotide, and the method The method of claim 284, wherein the method is for stimulating a somatic toll-like receptor.

286. the immunomodulatory polynucleotide is an immunosuppressive polynucleotide, and the method The method of claim 283, wherein the method is for inhibiting a somatic toll-like receptor.

287. Induction of one or more cytokines in antigen-presenting cells containing endosomal toll-like receptors 204. A method for the treatment of an inflammatory bowel disease, comprising administering to an animal or animal animal the antigen-presenting cells of claim 157. leotide, the composition of any one of claims 204 to 216, any one of claims 217 to 268 a conjugate according to any one of claims 269 to 282, a composition according to claim 283, The pharmaceutical composition and the one or more immunomodulatory polynucleotides are capable of being delivered into the cells. and contacting the cells under conditions that enable the cells to express at least one of the nucleotides of the present invention, wherein after the contacting, The level of one cytokine is increased, and the targeting moiety targets the antigen-presenting cells. 、 wherein the immunomodulatory polynucleotide is an immunostimulatory polynucleotide. The method.

288. The method of claim 287, wherein said antigen-presenting cell is a B cell.

289. 10. The method of claim 1 , wherein at least one of the one or more cytokines is a proinflammatory cytokine. 287 or 288.

290. the antigen-presenting cells are plasmacytoid dendritic cells, and wherein the targeting moiety binds to the plasma cells. The method of claim 287, wherein the antibody recognizes dendritic cells-like.

291. The method of claim 287, wherein said antigen-presenting cell is a macrophage.

292. 287. The method of claim 287, wherein at least one of said cytokines is a type I interferon. How to post.

293. The method of any one of claims 284-292, wherein said toll-like receptor is TLR9.

294. 46. ​​A method of treating a liquid tumor in a patient, comprising administering to said patient a compound according to any one of claims 1 to 45. the composition of any one of claims 157 to 203; claim 204 The composition of any one of claims 217 to 268, the conjugate of any one of claims 217 to 268 The composition of any one of claims 269 to 282 or the pharmaceutical composition of claim 283. administering an effective amount of the targeting moiety to a subject, wherein the targeting moiety targets B cells and inhibits the immune response. the method, wherein the polynucleotide is an immunostimulatory polynucleotide that is a TLR9 agonist. 。

295. 295. The method of claim 294, wherein the liquid tumor is a hematological tumor.

296. 296. The method of claim 295, wherein the hematological tumor is lymphoma.

297. 297. The method of claim 296, wherein said lymphoma is non-Hodgkin's B-cell lymphoma.

298. The lymphoma is selected from the group consisting of mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and the like.

298. The method of claim 297, wherein the cancer is lymphoma, chronic lymphocytic leukemia, or multiple myeloma.

299. 204. A method of treating a solid tumor in a patient, comprising administering to said patient a compound according to any one of claims 157 to 203. the immunomodulatory polynucleotide of any one of claims 204 to 216, the composition of claim 21 The conjugate of any one of claims 7 to 268, or the composition of any one of claims 269 to 282. or the pharmaceutical composition of claim 283, wherein the targeting moiety is in the form Targets plasmocytoid dendritic cells and the immunomodulatory polynucleotide is a TLR9 agonist The method, wherein the polynucleotide is an immunostimulatory polynucleotide.

300. 204. The method of claim 157, wherein the immunomodulatory polynucleotide is an immunostimulatory polynucleotide. The immunomodulatory polynucleotide of any one of claims 1 to 4.

301. 269. The method of claim 217, wherein the immunomodulatory polynucleotide is an immunostimulatory polynucleotide. The conjugate according to any one of claims 1 to 4.

302. Claims 204-216 and 204-216, wherein the immunomodulatory polynucleotide is an immunostimulatory polynucleotide. and the composition described in any one of 269 to 282.

303. The method of claim 283, wherein said immunomodulatory polynucleotide is an immunostimulatory polynucleotide. Pharmaceutical compositions.

304. 46. ​​The method of claim 1, wherein the immunomodulatory polynucleotide is an immunosuppressive polynucleotide. The immunomodulatory polynucleotide of any one of claims 1 to 4.

305. The immunomodulatory polynucleotide of claims 217 to 268 is an immunosuppressive polynucleotide. The conjugate according to any one of claims 1 to 4.

306. Claims 204 to 216, and wherein the immunomodulatory polynucleotide is an immunosuppressive polynucleotide. and the composition described in any one of 269 to 282.

307. The method of claim 283, wherein said immunomodulatory polynucleotide is an immunosuppressive polynucleotide. Pharmaceutical compositions.

308. A method of treating cancer in a subject having cancer, comprising administering to said subject a compound of any one of claims 157 to 203. the immunomodulatory polynucleotide of any one of claims 204 to 216, the composition of claim 21 The conjugate of any one of claims 7 to 268, or the composition of any one of claims 269 to 282.

284. The method of claim 283, further comprising administering to the subject a therapeutically effective amount of the compound of claim 283. method.

309. The method of claim 308, wherein the cancer is a liquid tumor.

310. The method of claim 309, wherein the liquid tumor is a hematological tumor.

311. 311. The method of claim 310, wherein the hematological tumor is lymphoma.

312. The lymphoma is non-Hodgkin's B-cell lymphoma, mantle cell lymphoma, diffuse large cell lymphoma, B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, or multiple myeloma, The method of claim 311.

313. The method of claim 308, wherein the cancer is a solid tumor.

314. 314. The method of claim 313, wherein the solid tumor is colon cancer, melanoma, or head and neck cancer.

315. 309. The method of claim 308, wherein said targeting moiety is an antibody or an antibody fragment.

316. Any of claims 308-315, wherein the targeting moiety binds to an antigen on an antigen-presenting cell (APC). The method described in claim 1.

317. Claim 316, wherein the APC is a B cell, a plasmacytoid dendritic cell (pDC), or a macrophage. The method described.

318. The antigen is CD19, CD20, CD22, CD30, CD38, CD79 or CD79b, CD205, BDCA2, BDC A4, or PD-L1.

319. The method of any one of claims 308-318, wherein the conjugate is administered systemically.

320. 320. The method of claim 319, wherein said conjugate is administered by intravenous injection (iv).

321. Any one of claims 308-320, wherein the immunomodulatory polynucleotide is a TLR9 agonist. The method described in section.

322. Any of claims 308-321, wherein said amount is effective to elicit an adaptive immune response against said cancer. The method according to any one of claims 1 to 4.

323. The method of claim 322, wherein said amount is effective to increase cell-mediated immunity.

324. 323. The method of claim 322, wherein said amount is effective to increase T cell tumor infiltration in a solid tumor. How to do it.

325. The method of claim 324, wherein the T cells are CD4+ or CD8+ T cells.

326. Claim 322, wherein said amount is effective to elicit durable anti-tumor immunity in said patient. The method described.

327. said amount being effective to inhibit tumor growth or reduce tumor size in said subject The method of any one of claims 308-326, wherein

328. Administration of the conjugate is in the form of an unconjugated form of the immunomodulatory polynucleotide. administration of methicillin-resistant Staphylococcus aureus resulted in a lesser increase in inflammatory cytokines in the subject compared to administration of methicillin-resistant Staphylococcus aureus The method of any one of claims 308 to 327.

329. The method of claim 328, wherein the inflammatory cytokine is IL-6, IL-10, or TNFγ.

330. 329. The method of claim 308, wherein the amount is not effective to activate the complement pathway in the subject. The method described in any one of claims 1 to 4.

331. The method of claim 330, wherein said amount is not effective to activate complement C3 in said subject. Law.

332. The method of any one of claims 308 to 331, wherein the cancer is a checkpoint inhibitor relapsed or refractory cancer. The method described in any one of claims 1 to 4.

333. The checkpoint inhibitor is a PD-1 inhibitor, a PD-L1 inhibitor, or a C The method of claim 332, which is a TLA-4 inhibitor.

334. any of claims 308-333, comprising administering to said subject a checkpoint inhibitor. The method according to any one of claims 1 to 4.

335. The checkpoint inhibitor is a PD-1 inhibitor, a PD-L1 inhibitor, or a C The method of claim 334, which is a TLA-4 inhibitor.

336. The checkpoint inhibitor is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody. The method of claim 334.

337. 337. The method of claim 308, comprising administering to said subject a T cell agonist. How to post.

338. 338. The method of claim 337, wherein said T cell agonist is an OX-40, ICOS, or 4-1 BB agonist. How to do it.

339. 46. ​​A method of treating non-B cell tumors in a subject with cancer, comprising administering to a subject a method of treating a non-B cell tumor in a subject having cancer, the method ... the immunomodulatory polynucleotide of any one of claims 46 to 58, the composition of any one of claims 46 to 58, The conjugate according to any one of claims 157 to 203, the conjugate according to any one of claims 204 to 216 A composition, a conjugate according to any one of claims 217 to 268, a compound according to any one of claims 269 to 282 administering to the subject a therapeutically effective amount of the composition of any one of claims 281 to 283 or the pharmaceutical composition of claim 283. wherein the targeting moiety binds to a B cell antigen.

340. 204. A method of treating a solid tumor in a subject with cancer comprising the steps of: the immunomodulatory polynucleotide of any one of claims 204 to 216, the composition of any one of claims 204 to 216, The conjugate of any one of claims 217 to 268, any one of claims 269 to 282 or a pharmaceutical composition of claim 283, wherein wherein the targeting moiety binds to a B cell antigen.

341. 204. A method of treating a liquid tumor in a subject with cancer comprising the steps of: the immunomodulatory polynucleotide of any one of claims 204 to 216, the composition of any one of claims 204 to 216, The conjugate of any one of claims 217 to 268, any one of claims 269 to 282 or a pharmaceutical composition of claim 283. wherein the targeting moiety binds to an APC antigen.

342. The method of claim 341, wherein the APC antigen is a pDC or macrophage antigen.

343. A method of treating cancer in a subject having cancer, comprising administering to said subject a compound of any one of claims 157 to 203. the immunomodulatory polynucleotide of any one of claims 204 to 216, the composition of claim 21 The conjugate of any one of claims 7 to 268, or the composition of any one of claims 269 to 282. or a therapeutically effective amount of the pharmaceutical composition of claim 283 and a checkpoint inhibitor. administering to said subject.

344. The checkpoint inhibitor is a PD-1 inhibitor, a PD-L1 inhibitor, or a C The method of claim 343, which is a TLA-4 inhibitor.

345. The checkpoint inhibitor is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody. The method of claim 344.

346. A method of treating cancer in a subject having cancer, comprising administering to said subject a compound of any one of claims 157 to 203. the immunomodulatory polynucleotide of any one of claims 204 to 216, the composition of claim 21 The conjugate of any one of claims 7 to 268, or the composition of any one of claims 269 to 282. or a therapeutically effective amount of the pharmaceutical composition of claim 283 and a T cell agonist. The method comprising:

347. 347. The method of claim 346, wherein said T cell agonist is an OX-40, ICOS, or 4-1 BB agonist. How to do it.

348. The immunomodulatory polynucleotide of any one of claims 157 to 203, any one of claims 204 to 216 A composition according to any one of claims 217 to 268, a conjugate according to any one of claims 217 to 268, A composition according to any one of claims 269 to 282, or a pharmaceutical composition according to claim 283, or A pharmaceutical composition comprising the pharmaceutical composition of item 125 and a checkpoint inhibitor.

349. 349. The pharmaceutical composition of claim 348, further comprising a pharmaceutically acceptable excipient or solvent.

350. The immunomodulatory polynucleotide of any one of claims 157 to 203, any one of claims 204 to 216 A composition according to any one of claims 217 to 268, a conjugate according to any one of claims 217 to 268, A composition according to any one of claims 269 to 282, or a pharmaceutical composition according to claim 283 and a T-cell agonist. A pharmaceutical composition comprising:

351. 351. The pharmaceutical composition of claim 350, further comprising a pharmaceutically acceptable excipient or solvent.

352. the targeting moiety binds to an APC antigen, and the conjugate targets a liquid tumor in the subject. or the immunogen according to any one of claims 157 to 203, which is capable of suppressing the growth of a solid tumor. A regulatory polynucleotide, a composition of any one of claims 204-216, a composition of any one of claims 217-268 A conjugate according to any one of claims 269 to 282, a composition according to any one of claims 269 to 282, or The pharmaceutical composition of claim 283.

353. the targeting moiety binds to a B cell antigen, and the conjugate induces B cell tumors in the subject. The immunomodulatory polypeptide of any one of claims 157 to 203, which is capable of inhibiting tumor growth. Nucleotides, the composition of any one of claims 204 to 216, any one of claims 217 to 268 a conjugate according to any one of claims 269 to 282, a composition according to any one of claims 269 to 282, or claim 283 The pharmaceutical composition described.

354. the targeting moiety binds to a B cell antigen, and the conjugate binds to a non-B cell antigen in the subject The immunomodulatory polynucleotide of any one of claims 157 to 203, which is capable of inhibiting tumor growth. A nucleotide, a composition of any one of claims 204-216, or any one of claims 217-268 The conjugate of claim 1, the composition of any one of claims 269 to 282, or claim 28 3. The pharmaceutical composition described in 3.

355. the targeting moiety binds to a B cell antigen and the conjugate targets a solid tumor in the subject. The immunomodulatory polypeptide of any one of claims 157 to 203, which is capable of inhibiting tumor growth. Nucleotides, the composition of any one of claims 204 to 216, any one of claims 217 to 268 a conjugate according to any one of claims 269 to 282, a composition according to any one of claims 269 to 282, or claim 283 The pharmaceutical composition described.

356. The targeting moiety binds to a pDC or macrophage antigen, and the conjugate Any one of claims 157 to 203, capable of inhibiting the growth of liquid tumors in elephants the composition of any one of claims 204-216; claim 217 The conjugate of any one of claims 268 to 269, or the composition of any one of claims 269 to 282.

284. The method of claim 283, wherein the compound is a compound of formula (I) or a pharmaceutical composition according to claim 283.

357. The targeting moiety binds to a pDC or macrophage antigen, and the conjugate Any one of claims 157 to 203, capable of inhibiting the growth of solid tumors in elephants the composition of any one of claims 204-216; claim 217 The conjugate of any one of claims 268 to 269, or the composition of any one of claims 269 to 282.

284. The method of claim 283, wherein the compound is a compound of formula (I) or a pharmaceutical composition according to claim 283.

358. Any of claims 157 to 203, wherein the conjugate is capable of increasing cell-mediated immunity. the immunomodulatory polynucleotide of any one of claims 204 to 216; the composition of any one of claims 204 to 216; The conjugate of any one of claims 217 to 268, any one of claims 269 to 282 284. The composition of claim 283, or the pharmaceutical composition of claim 283.

359. 10. The method of claim 1, wherein the conjugate is capable of increasing T cell tumor infiltration in a subject. The immunomodulatory polynucleotide of any one of claims 57 to 203, any one of claims 204 to 216 The composition according to any one of claims 217 to 268, the conjugate according to any one of claims 269 to 282 284. The composition of any one of claims 283, or the pharmaceutical composition of claim 283.

360. The immunomodulatory agent of any one of claims 157 to 203, wherein the T cells are CD4+ or CD8+ T cells. The polynucleotide of any one of claims 204 to 216, the composition of any one of claims 217 to 268 The conjugate of any one of claims 269 to 282, the composition of any one of claims 269 to 282, or the composition of any one of claims 269 to 282. The pharmaceutical composition of claim 283.

361. 10. The method of claim 9, wherein the conjugate is capable of eliciting adaptive anti-tumor immunity in a subject. The immunomodulatory polynucleotide of any one of claims 157 to 203, any one of claims 204 to 216 The composition according to any one of claims 217 to 268, the conjugate according to any one of claims 269 to 282 284. The composition of any one of claims 283, or the pharmaceutical composition of claim 283.

362. wherein the conjugate is capable of stimulating IFNγ secretion or expression in a subject. The immunomodulatory polynucleotide of any one of paragraphs 157 to 203, any one of claims 204 to 216 The composition of any one of claims 217 to 268, the conjugate of any one of claims 269 to 270, 82, or the pharmaceutical composition of claim 283.

363. Any of claims 157-203, wherein the conjugate does not activate the complement pathway in a subject. the immunomodulatory polynucleotide of any one of claims 204 to 216; the composition of any one of claims 204 to 216; The conjugate of any one of claims 217 to 268, any one of claims 269 to 282 284. The composition of claim 283, or the pharmaceutical composition of claim 283.

364. Any of claims 157-203, wherein the conjugate does not activate complement C3 in a subject. the immunomodulatory polynucleotide of any one of claims 204 to 216, the composition of any one of claims 204 to 216, The conjugate of any one of claims 217 to 268, any one of claims 269 to 282 or the pharmaceutical composition of claim 283.

365. A method of treating cancer in a subject having cancer, comprising administering a CpG-Ab immunoconjugate administering to the subject an effective amount of the CpG-Ab immunoconjugate to a tumor-associated The method, wherein the antibody does not bind to the antigen (TAA).

366. The CpG-Ab immunoconjugate is directed against normal immune cells expressing at least one toll-like receptor. The method of claim 365, which specifically binds to a target antigen associated with the cell.

367. The method of claim 366, wherein said normal immune cells express TLR9.

368. The method of claim 366 or 367, wherein said normal immune cell is an antigen-presenting cell (APC).

369. The method of claim 368, wherein the APC is a B cell, a dendritic cell, or a macrophage.

370. The target antigen may be an MHC molecule, a T cell costimulatory molecule, an immune checkpoint molecule, a B cell-specific a dendritic cell-specific antigen, a dendritic cell-specific antigen, and a macrophage-specific antigen. The method of claim 369.

371. The method of claim 370, wherein said MHC molecule is selected from an MHC class I and an MHC class II molecule. 。

372. The T cell costimulatory molecules include OX40, CD2, CD27, CDS, ICAM-1, LFA-1 / CD11a / CD18, ICOS / CD 278, 4-1BB / CD137, GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp8 0, CD160, B7-H3, and CD83. Law.

373. The immune checkpoint molecule is PD-1, PD-L1, PD-L2, TIM-3, LAG-3, CEACAM-1, CE ACAM-5, CLTA-4, VISTA, BTLA, TIGIT, LAIR1, CD47, CD160, 2B4, CD172a, and TGFR The method of any one of claims 370-372, wherein said method is selected from the list consisting of:

374. The target antigen is CD1, CD2, CD5, CD6, CD9, CD11, CD17, CD18, CD19, CD20, CD21, C D22, CD23, CD24, CD25, CD26, CD27, CD30, CD38, CD40, CD44, CD45R(B220), CD49, CD 52, CD56, CD74, CD79b, CD93, CD123, CD138, CD163, CD205, CD206, CD274, CD303, and and CD304.

375. the CpG-Ab immunoconjugate comprises an immunostimulatory polynucleotide selected from Table 2 The method of any one of claims 365 to 374.

376. The CpG-Ab immunoconjugate is selected from the group consisting of p236, p238, p243, p246, p275, p276, p308, p313 , p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479, Selected from the group consisting of p480, p481, p482, p483, p484, p485, p486, p487, p488, and p489 376. The method of claim 375, comprising an immunostimulatory polynucleotide that is

377. 3. The method of claim 2, wherein the CpG-Ab immunoconjugate is not conjugated to a T cell epitope. A method described in any one of claims 65 to 376.

378. Any of claims 365-376, wherein the T cell epitope is an epitope of ovalbumin (OVA). The method according to any one of claims 1 to 4.

379. A method of treating cancer in a subject having cancer, comprising administering a CpG-Ab immunoconjugate administering to the subject an effective amount of the CpG-Ab immunoconjugate to a tumor-associated specifically binds to an antigen (TAA), wherein the TAA is a target of a specific antigen, such as CD19, CD20, CD22, STAT3, or exporter. an antigen selected from the group consisting of tyrosine kinase 7, Her2, Src, EGFR, CD52, CXCR-4, Muc-1, and DNA Not the above method.

380. Binding of the CpG-Ab immunoconjugate to the TAA induces the CpG-Ab immunoconjugate into cancer cells expressing the TAA. The method of claim 379, wherein the method promotes internalization of the G-Ab immunoconjugate.

381. Binding of the CpG-Ab immunoconjugate to the TAA induces endosomal differentiation of cancer cells expressing the TAA.

381. The method of claim 379 or 380, wherein said method promotes transport of said CpG-Ab immunoconjugate into a tumor.

382. Binding of the CpG-Ab immunoconjugate to the TAA induces TL in cancer cells expressing the TAA. The method of any one of claims 379-381, wherein the method promotes activation of the R9 signaling pathway.

383. Claim 382, ​​wherein said TAA and said TLR9 are located on the same cell membrane of a cancer cell expressing said TAA. The method described.

384. Claim 383, wherein both said TAA and said TLR9 are located on the cell membrane of a cancer cell that expresses said TAA. The method described.

385. Both the TAA and the TLR9 are located on the endosomal membrane of cancer cells expressing the TAA. The method of claim 383.

386. Binding of the CpG-Ab immunoconjugate to the TAA induces apoptosis in cancer cells expressing the TAA. The method of any one of claims 379-385, wherein cis is induced.

387. The method of any one of claims 379-386, wherein said TAA is not expressed by normal immune cells. method.

388. The method of any one of claims 379-386, wherein said TAA is expressed by normal immune cells. Law.

389. The method of claim 388, wherein said normal immune cell is an antigen-presenting cell (APC).

390. The TAA is selected from the group consisting of CD8, CD11b, CD11c, CD14, CD33, CD40, CD123, CD157, CD168, CD169, CD 172a, CD200, CD204, CD205, CD301, CD302, CD303, CD304, CD205, and CD206 The method of any one of claims 379-389 selected from the group:

391. The CpG-Ab immunoconjugate may also be administered to the TAA or any other antigen-binding protein expressed by the cancer cells. The method of any one of claims 379-390, wherein said TAA is not conjugated to a TAA of

392. the CpG-Ab immunoconjugate comprises an immunostimulatory polynucleotide selected from Table 2 The method of any one of claims 379 to 392.

393. The CpG-Ab immunoconjugate is selected from the group consisting of p236, p238, p243, p246, p275, p276, p308, p313 , p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479, Selected from the group consisting of p480, p481, p482, p483, p484, p485, p486, p487, p488, and p489 393. The method of claim 392, comprising an immunostimulatory polynucleotide.

394. 3. The method of claim 2, wherein the CpG-Ab immunoconjugate is not conjugated to a T cell epitope. A method described in any one of claims 79 to 393.

395. The method of claim 394, wherein said T cell epitope is ovalbumin (OVA).

396. Treating immunotherapy-resistant or refractory cancer in a subject with immunotherapy-resistant or refractory cancer 20. A method for administering to a subject a therapeutically effective amount of a CpG-Ab immunoconjugate. Hmm, the above method.

397. The method of claim 396, wherein said CpG-Ab immunoconjugate does not bind to a tumor-associated antigen.

398. The CpG-Ab immunoconjugate is directed against normal immune cells expressing at least one toll-like receptor. The method of claim 397, wherein the antibody specifically binds to a target antigen associated with the cell.

399. 397. The method of claim 396, wherein said CpG-Ab immunoconjugate specifically binds to a tumor-associated antigen. method.

400. Claim 396, wherein said cancer is resistant to treatment with an immune checkpoint modulator. The method of any one of claims 1 to 399.

401. further comprising co-administering said immune checkpoint modulator to said subject.

401. The method of claim 400.

402. the CpG-Ab immunoconjugate comprises an immunostimulatory polynucleotide selected from Table 2 The method of any one of claims 396 to 401.

403. The CpG-Ab immunoconjugate is selected from the group consisting of p236, p238, p243, p246, p275, p276, p308, p313 , p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479, Selected from the group consisting of p480, p481, p482, p483, p484, p485, p486, p487, p488, and p489 The method of claim 402, comprising an immunostimulatory polynucleotide.

404. 1. A method of preventing cancer in a subject in need thereof, comprising administering a CpG-Ab immunoconjugate administering to the subject a therapeutically effective amount of the CpG-Ab immunoconjugate specifically target antigens associated with normal immune cells that express at least one toll-like receptor. The method of claim 1, wherein

405. 2. The method of claim 1 , further comprising co-administering a tumor-associated antigen with said CpG-Ab immunoconjugate.

404. The method described in

406. 10. The method of claim 1, wherein the CpG-Ab immunoconjugate is not conjugated to the tumor-associated antigen.

405. The method described in

407. The method of any one of claims 404-406, wherein said normal immune cells express TLR9.

408. The method of any one of claims 404 or 407, wherein said normal immune cell is an antigen-presenting cell (APC). How to do it.

409. the CpG-Ab immunoconjugate comprises an immunostimulatory polynucleotide selected from Table 2 The method of any one of claims 404 to 408.

410. The CpG-Ab immunoconjugate is selected from the group consisting of p236, p238, p243, p246, p275, p276, p308, p313 , p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479, Selected from the group consisting of p480, p481, p482, p483, p484, p485, p486, p487, p488, and p489 The method of claim 409, comprising an immunostimulatory polynucleotide.

411. 1. A method of preventing cancer in a subject in need thereof, comprising administering a CpG-Ab immunoconjugate co-administering a therapeutically effective amount of said CpG-Ab immunoconjugate with a cancer vaccine, wherein said CpG-Ab immunoconjugate The gate is specific to a target antigen associated with normal immune cells that express at least one toll-like receptor. The method of heterologously binding.

412. the CpG-Ab immunoconjugate is formulated as an adjuvant for the cancer vaccine; The method of claim 411.

413. Method for inducing an adaptive immune response in a subject, comprising treating with a CpG-Ab immunoconjugate administering to the subject an effective amount of the CpG-Ab immunoconjugate specifically bind to a target antigen associated with normal immune cells that express another toll-like receptor, The method.

414. The method of claim 413, wherein the subject has cancer.

415. The method of claim 414, wherein said target antigen is not a TAA.

416. The target antigen is CD19, CD20, CD22, STAT3, exportin 7, Her2, Src, EGFR, CD5 41. A TAA that is not an antigen selected from the group consisting of: CXCR-4, Muc-1, and DNA.

4. The method described in claim 4.

417. The method of claim 414, wherein the subject has an infectious disease.

418. The method of any one of claims 413-417, wherein said normal immune cells express TLR9.

419. The method of any one of claims 413-418, wherein said normal immune cell is an antigen-presenting cell (APC). method.

420. The method of any of claims 413-419, wherein the adaptive immune response is CD8+ T cell dependent. Law.

421. the CpG-Ab immunoconjugate comprises an immunostimulatory polynucleotide selected from Table 2 The method of any one of claims 413 to 420.

422. The CpG-Ab immunoconjugate is selected from the group consisting of p236, p238, p243, p246, p275, p276, p308, p313 , p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479, Selected from the group consisting of p480, p481, p482, p483, p484, p485, p486, p487, p488, and p489 The method of claim 421, comprising an immunostimulatory polynucleotide that is

423. 1. A method of treating cancer in a subject having cancer, comprising administering to the subject a compound selected from Tables 6-A and 6-B. The method comprises administering a therapeutically effective amount of a CpG-Ab immunoconjugate to said patient.

424. The method of claim 423, wherein said CpG-Ab immunoconjugate binds to a tumor-associated antigen (TAA). 。

425. Claim 423 or 42, wherein said CpG-Ab immunoconjugate binds to a target antigen other than said TAA.

4. The method described in claim 4.

426. The CpG-Ab immunoconjugates target antibodies associated with normal immune cells that express TLR receptors. The method of any one of claims 423-425, wherein the antigen is bound to the antigen.

427. The CpG-Ab immunoconjugate is selected from the group consisting of p236, p238, p243, p246, p275, p276, p308, p313 , p347, p361, p362, p425, p433, p434, p435, p436, p437, p438, p477, p478, p479, CpG-Ab immunoconjugates containing p480, p481, p482, p483, p484, p485, p486, p487, p488, and p489 The method of any one of claims 423-426, wherein the compound is selected from the group consisting of: a conjugate.

428. further comprising co-administering a therapeutically effective amount of at least one additional cancer therapeutic agent.

8. The method of any one of paragraphs 365 to 427.

429. The at least one additional cancer therapeutic agent is selected from the group consisting of a second TAA, a T cell costimulatory molecule, and an immune thrombin gene. The method of claim 428, wherein the agonist is selected from a checkpoint modulator.

430. The method of claim 429, wherein said second TAA is the same as said TAA.

431. The method of claim 429, wherein said second TAA is different from said TAA.

432. The T cell costimulatory molecules include OX40, CD2, CD27, CDS, ICAM-1, LFA-1 / CD11a / CD18, ICOS / CD 278, 4-1BB / CD137, GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp8 0, CD160, B7-H3, and CD83, or their ligands. The method of any one of claims 429 to 431.

433. The T cell costimulatory molecule is an anti-OX40 antibody, an anti-ICOS / CD278 antibody, or an anti-4-1BB / CD137 antibody. or an antigen-binding fragment thereof.

434. The immune checkpoint modulator is selected from the group consisting of PD-1, PD-L1, PD-L2, TIM-3, LAG-3, and CE ACAM-1, CEACAM-5, CLTA-4, VISTA, BTLA, TIGIT, LAIR1, CD47, CD160, 2B4, CD172a, and TGFR. The method of any one of claims 429 to 433.

435. The immune checkpoint modulator is an anti-CD47 antibody, an anti-PD-1 antibody, or an anti-PD-L1 antibody. or an antigen-binding fragment thereof.

436. The method of any one of claims 365-435, wherein the cancer is a solid tumor.

437. The method of any one of claims 365-435, wherein the cancer is a liquid tumor.

438. The method of any one of claims 365-437, wherein the cancer is a recurrent cancer.

439. Any one of claims 365-438, wherein the administering or co-administering is by systemic administration. How to do it.

440. A therapeutically effective amount of said CpG-Ab immunoconjugate activates the complement pathway in said subject. The method of any one of claims 365-439, wherein the method is not effective to

441. The method of claim 440, wherein said amount is not effective to activate complement C3 in said subject. Law.

442. Any of claims 365-441, wherein the CpG-Ab immunoconjugate is the compound of claim 68. The method described in claim 1.

443. Claim 365: wherein said CpG-Ab immunoconjugate comprises the oligonucleotide of claim 1. The method of any one of claims 1 to 442.

444. Any of claims 365 to 443, wherein the CpG-Ab immunoconjugate comprises the compound of claim 65. The method according to any one of claims 1 to 5.

445. Any of claims 365 to 444, wherein the CpG-Ab immunoconjugate comprises the compound of claim 78. The method according to any one of claims 1 to 5.

446. The CpG-Ab immunoconjugate is selected from the group consisting of SB-342, SB-343, SB-341, SB-340, SB-179, and SB-181. , SB-186, SB-189, SB-228, SB-229, SB-242, SB-263, SB-337, SB-267, SB-284, SB-312 , SB-313, SB-347, SB-373, SB-382, SB-388, SB-389, SB-408, SB-416, SB-419, SB-421 SB-423, SB-426, SB-427, SB-428, SB-429, and SB-430.

45. The method of any one of claims 45.

Citation Information

Patent Citations

  • Human application of engineered chimeric antigen receptor (car) T cells

    JP2016525881A

  • Polynucleotide constructs with disulfide groups

    JP2016537027A

  • Immunomodulatory polynucleotides, their antibody conjugates, and methods of using them

    JP7712765B2

  • RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)

    US20050032733A1